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considering both irritation and cancer hazards
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Abstract
Formaldehyde is a well-studied chemical and effects from inhalation exposures have been extensively characterized 
in numerous controlled studies with human volunteers, including asthmatics and other sensitive individuals, which 
provide a rich database on exposure concentrations that can reliably produce the symptoms of sensory irritation. 
Although individuals can differ in their sensitivity to odor and eye irritation, the majority of authoritative reviews of 
the formaldehyde literature have concluded that an air concentration of 0.3 ppm will provide protection from eye 
irritation for virtually everyone. A weight of evidence–based formaldehyde exposure limit of 0.1 ppm (100 ppb) is 
recommended as an indoor air level for all individuals for odor detection and sensory irritation. It has recently been 
suggested by the International Agency for Research on Cancer (IARC), the National Toxicology Program (NTP), and 
the US Environmental Protection Agency (US EPA) that formaldehyde is causally associated with nasopharyngeal 
cancer (NPC) and leukemia. This has led US EPA to conclude that irritation is not the most sensitive toxic endpoint 
and that carcinogenicity should dictate how to establish exposure limits for formaldehyde. In this review, a number 
of lines of reasoning and substantial scientific evidence are described and discussed, which leads to a conclusion 
that neither point of contact nor systemic effects of any type, including NPC or leukemia, are causally associated 
with exposure to formaldehyde. This conclusion supports the view that the equivocal epidemiology studies that 
suggest otherwise are almost certainly flawed by identified or yet to be unidentified confounding variables. Thus, this 
assessment concludes that a formaldehyde indoor air limit of 0.1 ppm should protect even particularly susceptible 
individuals from both irritation effects and any potential cancer hazard.
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I.Introduction
Over the past four decades, formaldehyde has been the 
subject of extensive scientific study due to (1) its long rec-
ognized irritant properties, (2) the discovery that inhaled 
formaldehyde could induce nasal tumors in rodents, and 
(3) some findings from epidemiology studies suggesting 
that formaldehyde might be capable of increasing the risk 
of certain cancers in humans as well. Numerous compre-
hensive reviews addressing all aspects of formaldehyde 
toxicity and potential for adverse health effects have been 
conducted  by  regulatory  and  other  authoritative  bod-
ies from around the world, including the International 
Agency for Research on Cancer (IARC, 2003, 2009), the 
National Toxicology Program (NTP, 2009), the Agency for 
Toxic Substances and Disease Registry (ATSDR, 1999), the 
US Environmental Protection Agency (US EPA, 2010a), the 
National Academy of Sciences (NAS, 2007), Health Canada 
(2005), Germany’s Federal Institute for Risk Assessment 
(BfR)  (2006),  Australia’s  National  Industrial  Chemicals 
Notification  and  Assessment  Scheme  (NICNAS) 
(2005),  the  European  Union’s  Scientific  Committee  for 
Occupational Exposure Limits (SCOEL), and the World 
Health Organization (WHO, 2002, 2010). The number of 
published scientific papers on various aspects of formal-
dehyde-related issues is now in the thousands.
Formaldehyde continues to receive substantial pub-
licity due, at least in part, to its presence in the indoor 
air of Federal Emergency Management Agency (FEMA) 
trailers (i.e., temporary housing units supplied to the vic-
tims of Hurricanes Katrina and Rita in New Orleans and 
Mississippi) (ATSDR, 2007a, 2007b). This publicity has 
involved both non-cancer effects such as sensory irrita-
tion of the eyes, nose, and throat as well as allegations 674  R. Golden
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of increased risk of cancer, particularly nasopharyngeal 
and  leukemia,  including  the  concept  that  there  is  no 
safe  level  of  exposure  for  these  endpoints.  Seemingly 
lost in the debate is the fact that formaldehyde is one of 
the most studied chemicals in use today (NAS, 2007). 
The biochemistry and kinetics of formaldehyde are well 
understood and extensively characterized, due largely to 
the fact that it is an endogenous compound found in all 
living organisms and plays a well-established role in nor-
mal metabolic processes. With respect to the relationship 
between formaldehyde exposure and sensory irritation, 
there  is  an  abundance  of  high-quality  empirical  data 
derived from numerous controlled human exposure stud-
ies from which to draw weight of evidence–based conclu-
sions (e.g., NAS, 2007, 2008; US EPA, 2005; SCOEL, 2008; 
WHO, 2010). These data are relied upon in this review as 
the basis for deriving an acceptable residential indoor 
air exposure limit for formaldehyde (i.e., 24 hours/day, 
7 days/week). Also considered are sensory irritation in 
children and other potentially sensitive individuals and 
asthmatics, since these issues have also received consid-
erable attention.
Inhaled  formaldehyde  at  sufficient  concentrations 
has been established as a carcinogen for nasal tumors in 
rodents, with numerous studies documenting this phe-
nomenon.  In  addition,  the  biochemistry  and  kinetics, 
including adducts and non-linear tissue accumulation, 
are  well  examined.  With  respect  to  formaldehyde-in-
duced nasal tumors in rodents and their likely relevance 
to humans, there are abundant mode-of-action (MOA) 
data  now  available,  including  chronic  toxicogenomic 
data  as  specifically  called  for  in  the  NAS  (2007a) 
report  Applications  of  Toxicogenomic  Technologies  to 
Predictive  Toxicology  and  Risk  Assessment  that  now 
bring an unprecedented ability to assess this endpoint for 
purposes of risk assessment. These data will be discussed 
in the context of whether it is necessary, in a regulatory 
context, to continue to treat formaldehyde with various 
precautionary approaches, which embrace considerable 
uncertainty and require that substantial empirical data 
be ignored.
Other non-cancer endpoints have also been reported 
to  be  associated  with  exposure  to  formaldehyde  (e.g., 
reproductive/developmental, neurological, and immune 
effects).  Although  some  of  the  studies  reporting  such 
effects relied on unconventional routes of administration 
such as intraperitoneal or intravascular injection, others 
do not. However, the recent demonstration that inhaled 
formaldehyde does not move past the nasal epithelium to 
reach distant sites (Lu et al., 2010a, 2010b; Moeller et al., 
2010; Swenberg et al., 2010) raises questions about how 
distant site effects might occur. Consequently, these end-
points are not addressed in this review. However, because 
of the intense interest surrounding leukemia (unequivo-
cally also a distant site disease), both the abundant epide-
miology data, which are the principal basis for the claimed 
association, as well as the data pertaining to biological 
plausibility are discussed in considerable detail.
The purpose of this paper is to provide the logic and 
rationale  for  deriving  a  residential  indoor  air  concen-
tration for formaldehyde using the most defensible sci-
entific data related to exposures and/or effects reliably 
associated with this chemical, including both cancer and 
non-cancer effects. Although the number derived is not 
meant to imply that the present occupational exposure 
values are not protective of worker health, it should be 
noted that such values have been developed for 40 hours/
week exposures, whereas a residential values must be 
for 24/7 exposures and be protective for a lifetime for all 
individuals, including infants, children, and the elderly. 
However, as discussed in this review, formaldehyde is 
an exception to Haber’s Law, which states that the inci-
dence and/or severity of a toxic effect depends on the 
both the exposure and duration, i.e., exposure concen-
tration (c) rate times the duration time (t) of exposure 
(c × t). Consequently, for formaldehyde-induced sensory 
irritation,  once  symptoms  are  produced  at  a  certain 
concentration, they are not exacerbated with additional 
duration of exposure. This has substantial implications 
for establishing exposure limits for this endpoint. With 
respect to the main non-cancer effect considered, i.e., 
sensory irritation (with the eyes as the most sensitive tar-
get organ), the discussion and analysis that follow can be 
considered a de facto weight-of-evidence review of this 
topic because the primary data relied upon—controlled 
human exposure studies—have been reviewed and ana-
lyzed multiple times by numerous regulatory and other 
authoritative bodies from around the world, with the con-
clusions reached reflecting a consensus (e.g., NAS, 2007, 
2008; US EPA, 2005; Nielson and Wolkoff, 2010; Wolkoff 
and Nielson, 2010; SCOEL, 2008; BfR, 2006; WHO, 2010).
For  the  two  cancer  endpoints  of  potential  concern 
(i.e., nasopharyngeal cancer [NPC] and leukemia), more 
controversial  conclusions  have  recently  been  reached 
regarding these issues. Based primarily on several large 
epidemiology studies conducted by the National Cancer 
Institute  (NCI)  (e.g.,  Hauptmann  et  al.,  2003,  2004, 
2009;  Beane  Freeman  et  al.,  2009),  the  International 
Agency  for  Research  on  Cancer  (IARC,  2009),  the 
National Toxicology Program (NTP, 2010), and the US 
Environmental Protection Agency (US EPA, 2010a) have 
interpreted these data as demonstrating causal associa-
tions between formaldehyde exposure and NPC as well 
as a number of lymphohematopoietic cancers (mainly 
leukemia).  However,  several  critical  reanalyses  of  the 
epidemiology data have raised concerns as to whether 
the reported associations are causally related to formal-
dehyde exposure (Marsh et al., 2004, 2005, 2007, 2010). 
Although there is abundant mode of action (MOA) data 
for  formaldehyde-induced  nasal  tumors  in  rodents 
(e.g., McGregor et al., 2006; Conolly et al., 2003, 2004; 
Andersen et al., 2008, 2010), the same cannot be said for 
lymphohematopoieitc cancers. Instead, for this grouping 
of cancers, despite a number of unproven hypotheses 
that attempt to explain how formaldehyde might lead 
to  the  development  of  lymphohematopoietic  cancers Indoor air exposure limit for formaldehyde  675
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(e.g., Zhang et al, 2009; DeVoney et al., 2006a, 2006b) 
none  are  supported  by  any  empirical  data  (Heck  and 
Casanova, 2004; Golden et al., 2006; Pyatt et al., 2008; 
IARC,  2006).  Recent  toxicokinetic  and  toxicogenomic 
data demonstrating clear dose-dependent transitions for 
formaldehyde-induced toxicity further call into question 
whether either NPC or leukemia might be a consequence 
of exposure to formaldehyde.
Although IARC, NTP, and US EPA have all concluded 
that  exposure  to  formaldehyde  is  associated  with 
increased risk of NPC and leukemia, as discussed in this 
review, the scientific evidence for these conclusions is 
equivocal at best. Particularly in conjunction with some 
of the most recent data that call into question whether 
formaldehyde exposure is capable of causing either NPC 
or leukemia, it raises the issue if these collective regula-
tory  or  authoritative  conclusions  are  driven  solely  by 
science or if policy considerations and a precautionary 
approach might play a contributory role. The abundant 
data  suggesting  that  such  approaches  are  not  neces-
sary for evaluation formaldehyde-induced toxicity and 
potential effects in humans are described and discussed. 
A related issue concerns the role that uncertainty might 
play in the regulatory decision-making process. Although 
uncertainty is clearly justified in reaching decisions con-
cerning  chemicals  for  which  there  are  little  data,  this 
is  hardly  the  situation  with  formaldehyde,  a  naturally 
occurring endogenous compound, which is one of the 
most widely studied chemicals in existence. In fact, for 
potential formaldehyde-induced adverse effects, as dis-
cussed in this review, because there appears to be an 
unprecedented dichotomy between certainty and uncer-
tainty,  the  resolution  of  this  dilemma  hinges  on  how 
the abundant data are interpreted. Ultimately, however, 
after contemplating the complex and interrelated issues 
addressed in this review, readers must judge for them-
selves whether the totality of the data are supportive of 
demonstrating  causal  associations  between  formalde-
hyde and either NPC or leukemia.
II.Disposition of inhaled formaldehdye
A.Formaldehyde as an endogenous compound
Formaldehyde is naturally produced as a metabolic by-
product by all living organisms and serves as a source of 
methyl units, which are transferred via tetrahydrofolate 
into the one-carbon pool for incorporation into various 
macromolecules  (IARC,  2006;  Dhareshwar  and  Stella, 
2007). Due to its natural presence, there are predictable 
and fairly constant levels (i.e., 1–2 μM or ≈2.5 ppm) in the 
blood. Because of its high enzymatic activity, the ability 
of formaldehyde dehydrogenase (FDH; also designated 
aldehyde dehydrogenase, ADH3) to metabolize gaseous 
formaldehyde in the upper respiratory tract is so efficient 
that when humans, monkeys, or rats are exposed by inha-
lation to formaldehyde, no change in normal endogenous 
blood levels can be detected at the end of exposure. Heck 
et al. (1985) determined the effect of inhalation exposure 
to  formaldehyde  on  blood  concentrations  in  rats  and 
humans. Following exposure of F344 rats to 14.4 ppm for 
2 hours, formaldehyde concentrations of 2.24 ± 0.07 and 
2.25 ± 0.07 μg/g were measured in the blood in exposed 
rats and controls, respectively. Formaldehyde concentra-
tions in human venous blood from four males and two 
females  were  determined  by  analyzing  blood  samples 
collected  before  and  after  exposure  to  1.9 ppm  form-
aldehyde for 40 minutes. Average formaldehyde blood 
concentrations before and after exposure were 2.61 and 
2.77 μg/g blood, respectively. In neither rats nor humans 
was  there  a  statistically  significant  effect  of  formalde-
hyde exposure on average concentrations in the blood. 
In a similar study, Casanova et al. (1988) exposed three 
rhesus monkeys to formaldehyde at 6 ppm, 6 hours/day, 
5 days/week for 4 weeks. The formaldehyde concentra-
tion in the blood immediately after the final exposure in 
the  three  exposed  and  three  unexposed  animals  were 
1.84 and 2.42 μg/g blood, respectively. The inability of 
inhaled formaldehyde to alter normal endogenous blood 
concentrations suggests that this metabolic feature most 
likely protects internal organs from effects of low levels 
of  formaldehyde,  such  as  the  concentrations  typically 
found in an indoor environment, and also suggests that 
no adverse internal effects from formaldehyde would be 
expected from such levels (ATSDR, 1999). Because of this 
extensive metabolic capability as well as the recent con-
firmatory discovery that no inhaled formaldehyde gets 
past the nasal epithelium into the systemic circulation, 
formaldehyde should be more properly characterized as 
a chemical with adverse effects (i.e., sensory irritation) 
occurring only at the point of contact after a concentra-
tion is achieved in excess of endogenous levels and that 
exceeds the body’s ability to maintain homeostasis. This 
“threshold” level is reached and primarily at the point of 
contact, i.e., eyes, nose, or throat.
Additionally, in aqueous systems formaldehyde exists 
primarily (>99.9%) in its hydrated form of methanediol, 
with only a small amount (<0.1%) as free formaldehyde. 
Because free formaldehyde can diffuse from tissues in the 
upper respiratory tract into exhaled air, small, but mea-
surable, amounts can be detected in the breath. These 
levels are the result of the naturally occurring formalde-
hyde present in all tissues as a part of normal metabolic 
processes.  Although  there  are  analytical  challenges  in 
accurately determining formaldehyde concentrations in 
human breath (Moser et al., 2005; Kushch et al., 2008), 
the levels detected using a chemical-specific methodol-
ogy fall into the low-ppb (parts-per-billion) range (i.e., 
<0.5–1.7 ppb) (Riess et al., 2010). These data clearly chal-
lenge the current regulatory presumption that there is 
no safe level of exposure to formaldehyde as well as the 
risk assessment methodology based on the default no-
threshold assumption.
B.Potential for distant site toxicity
An obvious requirement for any formaldehyde-induced 
inhalation  effects  other  than  those  that  result  from 676  R. Golden
  Critical Reviews in Toxicology
direct contact with the eyes or upper respiratory tract 
is the necessity for absorption and transport to distant 
sites. This issue has substantial implications for assess-
ing whether inhaled formaldehyde would be capable of 
causing leukemia, which requires, at a minimum, that it 
reaches the blood or bone marrow to initiate this disease. 
Although there is no detectable increase in endogenous 
formaldehyde blood concentrations following inhalation 
exposure to formaldehyde, recent evaluations by both 
IARC (2009) and NTP (2009) have raised questions con-
cerning this issue as it might pertain to distant site toxic-
ity. Particularly with respect to explaining the biological 
basis for formaldehyde-induced leukemia, the potential 
for distant site toxicity (which would be obligatory for this 
disease) is based on a few publications (i.e., Zhang et al., 
2009, 2010) hypothesizing that inhaled formaldehyde can 
increase endogenous free formaldehyde (i.e., gaseous) 
levels in the blood, with subsequent distant site toxic-
ity. As a consequence, it is postulated that increased free 
formaldehyde can lead to adverse effects, either directly 
on the bone marrow or on circulating hematopoietic pro-
genitor cells (HPCs) or stem cells, leading to myelotoxic-
ity, decreased circulating red and white blood cells (i.e., 
pancytopenia), and ultimately leukemia. In conjunction 
with the epidemiology data, the conclusion that inhaled 
formaldehyde can raise endogenous levels with deleteri-
ous consequences to the hematopoietic system played 
a role in the decisions by both IARC and NTP to elevate 
formaldehyde from a probable or reasonably anticipated 
carcinogen to a known human carcinogen.
Following inhalation exposure to formaldehyde, the 
key hypothesis pertaining to formaldehyde-induced leu-
kemia involves absorption and transport of exogenous 
formaldehyde  to  the  bone  marrow,  with  subsequent 
myelotoxicity,  and/or  direct  interaction  (i.e.,  muta-
tion) in the circulation with susceptible stem cells, with 
the  “transformed”  cells  traveling  to  the  bone  marrow 
to initiate the leukemogenic process. In support of this 
hypotheses, Zhang et al. (2009, 2010) describe how gas-
eous formaldehyde in the presence of water (from the 
blood) dissolves and is converted to its hydrated form, 
methanediol [CH2(OH)2] (also known as methylene gly-
col) and therefore could potentially reach the bone mar-
row in this form, i.e., “…methandiol…which can readily 
penetrate into tissues, may travel to the marrow through 
the blood where it is in equilibrium with reactive form-
aldehyde.  The  formaldehyde,  once  generated,  can  react 
with cellular macromolecules producing toxic injury.” An 
almost identical statement appears in the IARC’s (2009) 
recent deliberations, “In aqueous solution, formaldehyde 
is rapidly converted to its diol form, methanediol (form-
aldehyde hydrate, CH2(OH)2 or methylene glycol), and a 
dynamic equiblirium with formaldehyde is formed. The 
concentration  of  the  diol  versus  that  of  formaldehyde 
depends  on  the  precise  conditions  (temperature,  pH, 
formaldehyde  concentration)  under  which  the  reaction 
occurs....  Importantly,  methanediol,  with  a  molecular 
weight of only 48, can readily penetrate into tissues (Fox, 
1985). Thus, formaldehyde may reach the marrow through 
the blood as methanediol, where it equilibrates again to 
reactive formaldehyde. The formaldehyde, once regener-
ated, can react with cellular macromolecules producing 
toxic injury.” In addition, NTP (2009) also describes a 
similar logic involving methanediol to help explain how 
a reactive chemical such as formaldehyde can be distrib-
uted and undergo metabolism throughout the body, also 
citing Fox et al. (1985) as well as Matubayasi et al. (2007). 
The cited basis for methanediol as a way for formalde-
hyde to be distributed to distant sites is a publication by 
Fox et al. (1985) on the use of 4% formaldehyde solutions 
for tissue fixation. At this concentration, formaldehyde 
rapidly penetrates dead tissues to denature and cross-link 
proteins, thereby also arresting enzymatic degradation. 
However, such a comparison, primarily extrapolating an 
event in non-living tissue at a high concentration of form-
aldehyde to living tissue, in vivo, at low concentration is 
suspect. Hypothesizing about the biological activity of 
formaldehyde based on tissue fixing concentrations of 
4% (i.e., 40,000 ppm) to normal endogenous concentra-
tions of 2–3 ppm, which are at least 10,000 times lower, is 
questionable. The paper by Matubayasi et al. (2007) also 
has no relevance to biological systems, since it is about 
the  formaldehyde/methanediol  equilibrium  at  varying 
temperatures and concludes that in hot water (≈200°C), 
the  equilibrium  is  shifted  toward  free  formaldehyde. 
Because formaldehyde in its hydrated form (i.e., meth-
anediol) is already present in the blood, it has penetrated 
every tissue in the body due to its ubiquitous presence.
1.Formaldehyde kinetics
The hypothesis implying that the formaldehyde-meth-
anediol equilibrium is inexplicably disrupted at distant 
sites,  thereby  leading  to  release  of  free  formaldehyde, 
which then causes adverse effects illustrates a fundamen-
tal misunderstanding of the well-established kinetics of 
formaldehyde. Gaseous formaldehyde, as a non-hydrated 
aldehyde, predominates only in the air phase. Whether in 
the extracellular spaces or within cells, free formaldehyde 
will be present at extremely low concentrations, since it 
first reacts reversibly with water to form an acetal (i.e., 
a more chemically correct designation of the hydrated 
form than methanediol) and then interacts with glutathi-
one (GSH) to form a thioacetal. The equilibrium constant 
for the acetal versus free formaldehyde strongly favors 
the  acetal  by  a  factor  of  approximately  7000.  In  other 
words,  at  physiological  temperature  and  pH,  >99.9% 
of formaldehyde is present as methanediol, with <0.1% 
as free formaldehyde. Consequently, the assertions by 
Zhang et al. (2010) and IARC (2009) are not consistent 
with formaldehyde kinetics, as neither the acetal (meth-
anediol)  nor  the  thioacetal  represents  ways  in  which 
inhaled gaseous formaldehyde could travel through the 
circulation and reach distant tissues. Consequently, it is 
unknown (and not explained by Zhang et al., 2009, 2010; 
IARC, 2009; or NTP, 2009) how this equilibrium would 
be disrupted either in the circulation or at distant sites Indoor air exposure limit for formaldehyde  677
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to release free formaldehyde to adversely affect blood 
cells or the bone marrow. Because explanations about 
how this might occur conflicts with the well-established 
biological and chemical behavior of formaldehyde, the 
hypothesized leukemogenic events appear to be unlikely 
in biological systems.
There is also another practical aspect of this issue that 
needs to be addressed. Any explanation of how inhaled 
formaldehyde might increase endogenous concentrations 
(e.g., methanediol releasing free formaldehyde at distant 
sites) would have to overcome a large body of data dem-
onstrating that due to the prodigious metabolic capacity 
of animals and humans, exogenous formaldehyde quite 
simply cannot raise endogenous levels. As explained by 
Heck and Casanova (2004), “An adult man…would absorb 
30 μg formaldehyde per minute if the formaldehyde con-
centration were 2 ppm. Assuming that 93% of the inhaled 
formaldehyde is eliminated by saturable metabolism in the 
respiratory tract as calculated for both rats and monkeys…
the  maximum  amount  of  residual  formaldehyde  that 
would be available for distribution to other tissues would 
be 7%.... If the residual formaldehyde were unmetabolized 
and distributed to total body water (41 L), its maximum 
concentration after 8 h would be less than 0.001 mM, which 
is well below the concentration of endogenous formalde-
hyde in human blood (≈0.1 mM). Of course, metabolism in 
the blood and tissues would greatly reduce the actual con-
centration of residual formaldehyde in total body water. 
Therefore, inhaled formaldehyde would not be expected 
to increase the formaldehyde concentration in the blood 
in accordance with the empirical results.” The empirical 
results referenced refer to studies in rats, monkeys, and 
humans demonstrating that inhaled formaldehyde does 
not change endogenous concentrations (Casanova et al., 
1988; Heck et al., 1985. The above description was con-
firmed by Franks (2004) who developed a mathematical 
model for the absorption and metabolism of formalde-
hyde vapor by humans. This model, which accounted for 
numerous physiological parameters, including interfac-
ing  between  air/mucus,  mucous/epithelial  tissues  and 
blood, the calculations indicated that inhalation of form-
aldehyde at 1.9 ppm would lead to a predicted increase 
of 0.00044 mg/L in blood concentrations, which is well 
below measured endogenous levels. Consequently, based 
on measurement as well as dosimetry modeling, there is 
no evidence that inhaled formaldehyde can increase the 
endogenous levels found in the blood.
A  tissue-based  pharmacokinetic  (PK)  model  esti-
mated  various  forms  of  tissue  formaldehyde  (i.e.,  free 
and  formaldehyde  acetal  [i.e.,  methanediol])  and  tis-
sue  glutathione  (GSH)  in  conjunction  with  a  13-week 
toxicogenomic  study  in  rats  exposed  to  formaldehyde 
at 0, 0.7, 2, 6, 10, or 15 ppm for 6 hours/day for 1, 4, or 
13 weeks (Andersen et al., 2010). The pharmacokinetic 
analysis showed that the lower two inhaled formalde-
hyde concentrations (0.7 and 2 ppm) would result in only 
minor changes in cellular GSH and formaldehyde acetal. 
However, at exposures above 4 ppm, formaldehyde acetal 
increased with a much steeper dose-response, whereas 
free GSH was significantly reduced. The model was also 
used  to  estimate  the  dose-response  of  formaldehyde 
acetal in relation to inhaled formaldehyde accounting for 
endogenous formaldehyde and showed that exposures 
in the range of 1–2 ppm would not be sufficient to cause 
significant increases in tissue formaldehyde compared 
to background in the normal tissues of the nose. This 
model is the first to describe background production of 
formaldehyde  by  normal  physiological  processes,  the 
associated GSH status, and increases in tissue formal-
dehyde acetal that would be expected following inhala-
tion of various formaldehyde concentrations. As noted 
by Andersen et al. (2010), “Research on [formaldehyde] 
histopathology, gene expression, and now with PK mod-
eling of endogenous [formaldehyde] is consistent with a 
threshold for carcinogenicity and tissue responses to this 
endogenous aldehyde.” This PK tissue model further dem-
onstrates the substantial degree to which the kinetics and 
dose-response characteristics of inhaled formaldehyde 
can be modeled and understood in biological systems.
2.Stable isotope studies with inhaled 13CD2-formaldehyde
The unlikelihood of exogenous formaldehyde entering 
the blood with transport to distant sites is now further 
supported by a recent study by Lu et al. (2010a) in which 
male F344 rats were exposed to 10 ppm of the stable iso-
tope 13CD2-formaldehyde for 1 or 5 days (6 hours/day). 
Following the 1- or 5-day exposures, blood was collected 
for lymphocyte isolation as well as tissue samples from 
nasal respiratory epithelium, spleen, thymus, lung, and 
liver; bone marrow was collected from both femurs. DNA 
adducts from all tissues were subsequently prepared for 
analysis. Because of the slight mass differences between 
DNA  adducts  derived  from  exogenous  (i.e.,  13CD2-
formaldehyde) compared to DNA adducts derived from 
endogenous (i.e., 12C-formaldehyde), the source of form-
aldehyde-DNA  adducts  detected  in  each  tissue  could 
be  determined.  Whereas  formaldehyde-DNA  adducts 
from  both  endogenous  and  exogenous  formaldehyde 
were  detected  in  nasal  epithelium  after  either  1  or  5 
days of exposure, no 13CD2-formaldehyde-DNA adducts 
were detected in any tissue distal to the nasal epithe-
lium,  including  the  lung,  spleen,  liver,  thymus,  bone 
marrow, or lymphocytes. As described by the authors, 
“The  absence  of  exogenous  formaldehyde-induced  DNA 
adducts and crosslinks in other tissues supports the con-
clusion that genotoxic effects of inhaled formaldehyde are 
implausible at sites remote to the portal-of-entry.” In addi-
tion, with respect to the issue concerning methanediol as 
an  explanation  for  transport  of  inhaled  formaldehyde 
to distant sites, Lu et al. (2010a) addressed this as well, 
“Furthermore, by monitoring the transitions that would 
occur if there was any hydrogen-deuterium exchange, we 
have  demonstrated  that  neither  inhaled  formaldehyde, 
nor  methanediol  derived  from  inhaled  formaldehyde 
reaches sites distant to the portal of entry.” These findings, 
particularly the inability to detect  13CD2-formaldehyde-678  R. Golden
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DNA adducts in white blood cells or bone marrow, have 
substantial implications with respect to the likelihood of 
formaldehyde-induced  leukemia  as  a  consequence  of 
either effects on circulating stem or hematopoietic pro-
genitor cells or distant site toxicity.
The above findings have now been extended to non-hu-
man primates. A study by Moeller et al. (2010) determined 
the presence of endogenous and exogenous formaldehyde 
in  DNA  from  bone  marrow  of  cynomolgus  macaques 
exposed to 1.9 and 6.1 ppm of  13CD2-formaldehyde for 6 
hours a day for 2 consecutive days. In bone marrow, no 
exogenous adducts were detected, even though ~10-fold 
larger  amounts  of  DNA  were  analyzed  to  intentionally 
bias the results toward detecting such adducts. However, 
endogenous N2-hydroxymethyl-dG adducts were present 
at  17.48 ± 2.61  and  12.43 ± 3.63  adducts/107  dG  in  bone 
marrow DNA from the 1.9 and 6.1 ppm exposures, respec-
tively. This study confirms the findings by Lu et al. (2010a) 
in a non-human primate and further demonstrates that 
inhaled formaldehyde is not delivered to tissue sites dis-
tal to the nasal epithelium. Since additional tissues from 
numerous sites distant to the point of contact were col-
lected at necropsy, these will be analyzed in a future paper 
to better characterize the distribution of exogenous and 
endogenous formaldehyde-DNA adducts in non-human 
primates following formaldehyde inhalation exposure.
The  substantial  understanding  of  formaldehyde 
kinetics  and  toxicogenomics  in  the  upper  respiratory 
tract plays an important supporting role in subsequent 
discussions of sensory irritation as well as both nasopha-
ryngeal cancer and leukemia. This body of data informs 
both local effects in nasal epithelial tissues as well as the 
likelihood of formaldehyde delivery to distant sites.
III.Sensory irritation
A.Fundamental aspects of odor detection and sensory 
irritation
The most common effects from exposure to formalde-
hyde vapor involve sensory irritation of the eyes, nose, 
and throat when sufficient concentrations are reached, 
with eye irritation generally accepted as the most sensi-
tive endpoint. Although the ability of formaldehyde to 
cause or exacerbate asthma symptoms is also of con-
cern, this is addressed separately as an important related 
issue of whether children might be more sensitive than 
adults to formaldehyde-related sensory irritation. With 
respect to formaldehyde-induced sensory irritation, this 
phenomenon  involves  a  dose-response  continuum  in 
which low levels begin to trigger the sensory nerves, but 
the rate of removal (i.e., detoxification) of formaldehyde 
from tissues in the nose and upper airways is sufficient to 
limit accumulation and prevent tissue damage. As expo-
sure concentrations increase, compensation and repair 
mechanisms will be progressively overwhelmed with an 
increasing likelihood of adverse effects. The continuum 
of effects due to increasing formaldehyde concentrations 
can be broken down into those associated first with odor 
detection, followed by sensory irritation and associated 
upper respiratory tract endpoints when progressing to 
higher concentrations and effects such as frank tissue 
damage and nasal tumors, which are discussed later in 
this review. Consequently, it is important to determine 
the concentration(s) of formaldehyde that can reliably 
be  associated  with  causing  the  symptoms  of  sensory 
irritation  as  distinct  from  (i.e.,  unconfounded)  odor 
detection.
Although there is a large database in rodent studies 
characterizing  the  sensory  irritation  effects  of  formal-
dehyde (e.g., Nielsen et al., 1999; Alarie and Anderson, 
1979; Anderson et al., 1979; Kane and Alarie, 1977), these 
data are not reviewed or relied upon in this evaluation. 
Although such data provide valuable insights on formal-
dehyde and potential interactive effects with other irri-
tant chemicals, the documented respiratory differences 
between  rats  (obligatory  nose  breathers)  and  humans 
(oronasal breathing) render the findings from such stud-
ies of limited relevance. Furthermore, the availability of 
numerous controlled human studies makes reliance on 
animal data unnecessary for evaluating this endpoint.
Formaldehyde can be a strongly irritating gas at spe-
cific  concentrations  and  also  has  a  distinct,  pungent 
smell. However, odor perception and the threshold for 
sensory irritation are sometimes not clearly differenti-
ated  and  generally  exist  on  a  concentration  gradient, 
but may overlap, i.e., some individuals may detect the 
odor  before  perceiving  eye  irritation  or  vice  versa.  In 
the case of formaldehyde, however, the progression of 
responses is clear, with human studies showing that for 
most  individuals,  odor  perception  generally  precedes 
sensory  irritation.  Importantly,  sensory  irritation  and 
odor perception are different and distinct physiological 
phenomena. Odor is the sensation of smell carried by 
the olfactory nerve (first cranial nerve). Sensory irrita-
tion involves stimulation of the trigeminal nerve (fifth 
cranial  nerve),  and  near  triggering  concentrations  is 
generally considered to be a physiological and not a toxic 
response in that no tissue damage or cellular injury is 
involved (Gaffney and Paustenbach, 2007; Paustenbach 
and Gaffney, 2006; Dalton, 2002, 2003). This is particu-
larly the case for formaldehyde-induced sensory irrita-
tion as discussed in this review and does not imply that 
formaldehyde-induced  cytotoxicity  does  not  occur  at 
concentrations in excess of those necessary to trigger the 
symptoms of sensory irritation (i.e., ≥2 ppm). Sensory 
irritation  encompasses  a  graded  series  of  responses 
generally categorized as ranging from slight to moderate 
to severe. For formaldehyde, eye irritation is generally 
the most sensitive indicator of exposure and represents 
the threshold response for sensory irritation. At higher 
exposure levels, stimulation of the trigeminal nerves in 
the nasal passages and the upper respiratory tract rep-
resents the next step of sensory irritation (i.e., nose and 
throat irritation) (Paustenbach et al., 1997). This would 
be followed by frank tissue damage (i.e., cytotoxicity) at 
sufficient concentrations.Indoor air exposure limit for formaldehyde  679
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There are various reports of different odor thresholds 
(i.e., the minimum level that can be detected), with a typ-
ical range of 0.5 to 1 ppm (ATSDR, 1999; US EPA, 2006c). 
Although some documents list odor thresholds at lower 
levels, these are likely to be obfuscated by the same accu-
racy issues (i.e., false positives) as for sensory irritation. 
For  example,  a  guidance  document  (US  Coast  Guard, 
2001) notes that the odor threshold for formaldehyde is 
0.8 ppm, but also states that persons with sensitive noses 
can detect it at levels as low as 0.1 ppm. Although it is 
likely that some highly sensitive individuals can detect 
the odor of formaldehyde at levels below 0.5 ppm, there 
are no empirical data (e.g., human volunteer chamber 
studies) documenting that humans can reliably detect 
formaldehyde at levels of 0.1 ppm or less. However, it is 
possible that people with a diminished ability to detect 
odors  could  still  have  symptoms  of  sensory  irritation 
without  detecting  the  pungent  odor  of  formaldehyde. 
Finally, it is important to note that olfaction of formal-
dehyde does not imply that any adverse effects are trig-
gered, including the onset of sensory irritation (Gaffney 
and Paustenbach, 2007; Paustenbach and Gaffney, 2006; 
Dalton, 2002, 2003).
Most of the early studies that investigated the irritant 
properties  of  formaldehyde  did  not  properly  account 
for the characteristic acrid or pungent odor. The ability 
of most individuals to detect the odor of formaldehyde 
is  typically  more  sensitive  than  the  lowest  exposure 
level that produces the symptoms of sensory irritation. 
Therefore,  studies  designed  to  evaluate  the  irritation 
threshold must account for the odor of formaldehyde by 
masking it with an odoriferous but non-irritating sub-
stance, such as methylmercaptan, in order for the study 
results to be valid. Failure to do so raises the likelihood 
that subjects will confuse the odor with symptoms of 
sensory irritation (Lang et al., 2008). Without account-
ing  for  the  confounding  effects  of  odor,  some  early, 
largely  uncontrolled,  studies  suggested  that  sensory 
irritation from formaldehyde was on the order of less 
than 0.01 ppm (10 ppb). Those studies did not control 
for the misinterpretation of odor detection as sensory 
irritation (Abraham, 2001) or for behavioral sensitiza-
tion  to  the  odor  of  formaldehyde  (and  other  highly 
odoriferous compounds), which confounds the study 
of other properties of these compounds such as sensory 
irritation (Shusterman et al., 1988). Properly conducted 
studies,  using  appropriate  controls,  have  more  accu-
rately determined the ability of humans to detect the 
odor of formaldehyde. These studies have failed to con-
firm the ability of even the most sensitive individual to 
detect exceedingly low concentrations of formaldehyde. 
For example, ATSDR (2008) lists the lower level of odor 
detection as 0.5 ppm. This level has been confirmed by 
a number of human volunteer chamber studies, which 
have placed significant emphasis on removing the odor 
bias associated with formaldehyde exposure (Iwasaki 
and Ishiguro, 1978; Leonardos et al., 1969; Hellman and 
Small, 1974).
Like  the  majority  of  other  odoriferous  compounds, 
formaldehyde has an odor threshold that is typically less 
than its irritant threshold. This has been confirmed by a 
number of studies that have examined the ability of sev-
eral groups to detect irritation (e.g., Arts et al., 2008). The 
conjunctiva is the most sensitive structure in the upper 
airway, so it is generally used as the test organ. In those 
studies in which both the detection and irritant levels 
were evaluated, the detection (odor) was always lower 
than the irritant level. For example, Noisel et al. (2007) 
reported  an  odor  detection  level  of  0.75 ppm,  with  a 
minimum irritant level of 1.0 ppm, whereas an US EPA 
(2005) study reported an odor detection level of 0.5 ppm 
(consistent with ASTDR), with a minimum irritant level 
of 1.5 ppm.
B.Formaldehyde-induced tissue damage in the upper 
respiratory tract
Although there is a rich literature of rodent studies that 
have investigated sensory irritation, the numerous con-
trolled human exposure chamber studies on formalde-
hyde-induced sensory irritation renders the animal data 
of limited importance. However, it is important to distin-
guish the documented differences between the sensory 
irritation  caused  by  formaldehyde  from  its  potential 
adverse or pathological effects on tissues. Unlike form-
aldehyde, some chemicals (e.g., acrolein) can produce 
corrosive  effects  or  physically  damage  respiratory  tis-
sues, even under short-term exposure conditions, at air 
concentrations that are not greatly above their irritation 
thresholds (ACGIH, 1992). In contrast, the scientific lit-
erature demonstrates that sensory irritation of the eyes 
and upper respiratory tract caused by formaldehyde does 
not result in any histopathological evidence of adverse 
cellular effects. Rather, it is a physiological adaptation to 
trigeminal nerve stimulation, along with reduced breath-
ing rate, bradycardia, and vasoconstriction (Alarie and 
Luo, 1986; Barrow et al., 1986; Paustenbach et al., 1997).
Controlled studies in humans report that short-term 
exposure  (i.e.,  less  than  1  hour)  to  formaldehyde  air 
concentrations below 2 ppm produces no toxicological 
effects on the eyes or on tissues in the upper respira-
tory tract (ATSDR, 1999; Paustenbach et al., 1997). This 
finding has been extensively confirmed in studies with 
rats and monkeys, which show that even with long-term 
exposure,  formaldehyde  does  not  cause  pathological 
lesions or changes in respiratory tract tissues at air con-
centrations below 3 ppm (Paustenbach et al., 1997). For 
example, F344 rats exposed to formaldehyde at 0, 0.7, 
2, 6, 10, and 15 ppm for 6 hours/day, 5 days/week for 6 
months showed no metaplasia in any region of the nasal 
cavity at 0, 0.7, or 2 ppm (Kimbell et al., 1997); in another 
study F344 rats were exposed to the same formaldehyde 
concentrations  for  6  hours/day,  5  days/week  for  24 
months with no formaldehyde-induced nasal histopa-
thology observed in the 0.7 or 2 ppm groups (Monticello 
et  al.,  1996).  Similarly,  12  male  cynomolgus  monkeys 
were exposed to 0, 0.2, 0.98, or 2.95 ppm formaldehyde 680  R. Golden
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for 22 hours/day, 7 days/week for 26 weeks, followed by 
histological examination of the lungs, trachea, and nasal 
turbinates.  There  was  no  incidence  of  monkeys  with 
squamous  metaplasia/hyperplasia  in  nasal  turbinate 
epithelium at 0.98 ppm (Rusch et al. (1983).
Due  to  differences  in  airway  anatomy  and  airflow 
between rats and humans (e.g., rats are obligate nose 
breathers),  tissue  damage  in  humans  requires  form-
aldehyde  air  concentrations  even  higher  than  those 
associated  with  tissue  damage  in  rats  (Kimbell  et  al., 
2001; Conolly et al., 2004). As discussed below, the data 
documenting the lack of chronic formaldehyde-induced 
nasal histopathology at concentrations of 1 ppm or less 
challenge the derivation of Chronic Reference Exposure 
levels (RELs) or other regulatory guidance levels based 
on reports of nasal lesions (i.e., rhinitis, squamous meta-
plasia  or  dysplasia)  in  occupationally  exposed  work-
ers. Although these types of nasal lesions undoubtedly 
occurred as reported, the compelling lack of such lesions 
in both rats and monkeys following chronic exposure to 
formaldehyde alone (at concentrations far greater than 
would be achieved in an occupational setting) suggests 
that other co-exposures or levels of formaldehyde much 
higher than reported likely played contributory roles in 
such reports.
C.Short- versus long-term exposure for formaldehyde-
induced sensory irritation
For  formaldehyde-induced  sensory  irritation,  there 
are  essentially  no  meaningful  differences  between 
short-term and longer-term exposure (US EPA, 2004; 
NAS, 2007; Shusterman et al., 2006). As concluded by 
NAS (2007), “Formaldehyde irritation does not appear 
to follow Haber’s law (concentration [c] × exposure time 
[t] = response  [k]  for  extrapolating  between  short-term 
and long-term toxicity levels. Generally, concentrations 
that do not produce short-term sensory irritation also do 
not produce sensory irritation after repeated exposure.” 
Also noted by NAS (2007) was that “The degree of sensory 
and irritant effects at lower exposure levels depends on 
concentration rather than duration.”  This  conclusion 
is based on test results derived from human chamber 
studies  (and  now  confirmed  by  genomics  data)  that 
show that once symptoms are produced at a certain 
concentration, they are not enhanced with additional 
exposure time. It should be emphasized that this phe-
nomenon (i.e., lack of time as a component) applies 
only to sensory irritation and not to tissue-damaging 
events such as cytotoxicity following exposure to higher 
concentrations. In addition, even for sensitive individ-
uals, as concluded by Paustenbach et al. (1997), “The 
data indicated that below 1.0 ppm, if irritation occurs in 
some persons, the effects rapidly subside due to ‘accom-
modation.’” This conclusion is essentially echoed by a 
more recent review, “Accommodation to low concentra-
tions that cause short-term irritation has been reported; 
in such cases, irritation subsides with exposure dura-
tion” (NAS, 2007).
D.Exposure-response characterization of 
formaldehyde-induced sensory irritation
It has long been appreciated that workplace exposure 
to  sufficient  levels  of  formaldehyde  was  associated 
with  sensory  irritation.  However,  with  regulations 
in place to protect against such effects, the focus on 
non-occupational  exposures  has  been  more  recent. 
Part of the initial rationale for the study of the possible 
adverse health effects of formaldehyde from exposure 
in the indoor residential environment began in the late 
1960s and early 1970s as a result of the increased use of 
urea-formaldehyde foam insulation in homes and the 
use of formaldehyde-containing glues and adhesives 
in composite wood panels and particle board used in 
manufactured housing. This change in practice led to 
numerous studies all directed at determining the con-
centrations of formaldehyde at which the symptoms 
of  sensory  irritation  occurred,  with  the  goal  of  first 
understanding  exposure-response  relationships  and 
then using such data to establish exposure levels that 
would  be  protective  for  the  most  sensitive  members 
of the population. These studies fall into several broad 
categories, including workplace, community (i.e., resi-
dential), and controlled chamber studies.
1.Occupational and residential exposure studies
With  respect  to  workplace  studies,  many  (and  quite 
possibly  most  or  all)  are  confounded  to  varying 
degrees by mixed exposures to wood dust, terpenes, 
and  other  airborne  substances  (e.g.,  Alexandersson 
and Hedenstierna, 1989);  furniture  lacquers,  textiles, 
paint, plywood, polyethylene, and chipboard that con-
tained formaldehyde (e.g., Nordman  et  al.,  1985);  or 
particulates,  phenol,  sodium  hydroxide,  and  carbon 
monoxide (e.g., Horvath et al., 1988). Similarly, stud-
ies investigating pulmonary function or nasal epithelial 
lesions (i.e., cytotoxicity such as squamous metaplasia 
or  dysplasia)  are  also  often  confounded  by  simulta-
neous  exposure  to  particulates  (and  typically  other 
chemicals as well), which may change the dynamics 
of detoxification and respiratory tract penetration due 
to  surface  adsorption/desorption.  For  example,  as 
noted by ATSDR (1999), “Effect levels associated with 
formaldehyde-induced changes in pulmonary function 
variables in workers exposed to airborne formaldehyde 
concentrations generally less than 1 ppm…are not of suf-
ficient magnitude to be of obvious clinical significance, 
have not been observed consistently across studies, and 
may be confounded, in some cases, by the presence of 
wood dust particulates which may facilitate transport 
of adsorbed formaldehyde to deeper regions of the respi-
ratory tract compared with low-level exposure to form-
aldehyde alone.”
Even in the studies in which mild nasal epithelial lesions 
have been observed in formaldehyde-exposed workers, 
there  are  questions  concerning  potential  confounders 
that make it difficult to attribute reported effects to form-
aldehyde alone. Examples of such confounded studies Indoor air exposure limit for formaldehyde  681
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include Ballarin et al. (1992)—wood dust, no exposure-
response relationship; Boysen et al. (1990)—wood dust 
exposure  for  some  workers  and  exposures  to  >2 ppm 
formaldehyde (not further quantified) for almost a quar-
ter of the cohort; Edling et al. (1988)—smoking, wood 
dust exposure for some workers, unknown numbers of 
peak exposures up to 5 ppm and no exposure-response 
relationship; and Holmstrom et al. (1989)—wood dust, 
resin exposure, smoking, and lack of exposure-response 
relationship.
Similarly, most studies conducted in residential dwell-
ings (including both conventional homes as well as man-
ufactured housing such as trailers and mobile homes) 
with the goal of assessing potential formaldehyde-related 
effects on sensory irritation are also typically confounded 
by  co-exposures  to  active  smoking,  environmental 
tobacco smoke, volatile organic chemicals (VOCs), smoke 
from wood fires, cooking fumes, house dust, pet dander, 
molds, fungi, etc. These co-exposures make it impossible 
to conclude with confidence that any results reported are 
due solely to formaldehyde. In addition, the results of 
some residential and/or community studies can also be 
confounded by selection bias (e.g., offers of free testing 
due to adverse publicity, emotional media stories, etc.), 
which can be substantially influenced by false-positive 
results  (i.e.,  reporting  of  symptoms  in  the  absence  of 
formaldehyde or at concentrations insufficient to elicit 
symptoms [e.g., Main et al., 1983; Bracken et al., 1985; 
Kilburn et al., 1985; Imbus et al., 1985; Anderson et al., 
1979; Ritchie and Lehnen, 1987]).
A  striking  example  of  these  issues  is  illustrated  by 
a  study  that  actually  tested  whether  effects  attributed 
to formaldehyde in a residential setting might be con-
founded by other exposures and/or psychological fac-
tors. Broder et al. (1991) investigated a large group of 
about 200 control homes and 600 houses that had been 
insulated  with  urea  formaldehyde  foam  insulation 
(UFFI)  and  then,  due  to  complaints  and  government-
provided subsidies for UFFI removal, about half of the 
UFFI houses were remediated to remove the insulation. 
Each of the houses and occupants were investigated on 
two occasions separated by an interval of 12 months. In 
the first survey of the population, prior to remedial work, 
there was a moderate excess of many signs and symp-
toms of irritation, including nasal problems, eye, throat 
discomfort,  cough,  headache,  and  dizziness.  These 
symptoms were associated with an exposure-response 
relationship  between  formaldehyde  levels  in  the  UFFI 
homes (0.046 ppm), but no such relationship in control 
homes (0.035 ppm). In the second survey conducted in 
controls and houses following UFFI removal, there was 
an appreciable reduction in the reported incidence of 
irritation symptoms and the disappearance of the expo-
sure-response  relationship,  even  though  the  remedia-
tion efforts had no effect on formaldehyde levels in the 
remediated homes (0.044 ppm). The authors concluded 
that the symptoms in the initial survey were not due to 
formaldehyde  alone  and  that  their  observations  were 
“…indicative of the complexities that may arise in assess-
ing and understanding health risks…related to chemicals 
in indoor air.”
Despite the problems and issues with these studies, 
they are still inexplicably relied upon for health-based 
conclusions concerning formaldehyde levels in indoor 
air. For example, a recent report from the Centers for 
Disease Control and Prevention (CDC, 2008) addressed a 
number of issues pertaining to formaldehyde concentra-
tions in Federal Emergency Management Agency (FEMA) 
trailers. In reaching conclusions about the formaldehyde 
concentrations that might be associated with symptoms 
of sensory irritation, none of the studies cited were those 
involving  controlled  human  exposures.  Instead,  this 
report concluded that “… formaldehyde-sensitive persons 
have reported symptoms at levels around 100 ppb,” citing 
Main and Hogan (1983) and Bender et al. (1983), and 
that “Additional studies have found health effects at 100 
ppb in sensitive persons chronically exposed to formalde-
hyde,” citing Ritchie and Lehnen (1987). It is illustrative 
to compare the rigor of studies relied upon by CDC to the 
controlled human exposure studies.
Main and Hogan (1983) involved a symptom survey 
of 21 subjects who worked in two trailers where formal-
dehyde levels between 0.12 and 1.6 ppm had been mea-
sured. Because of this study’s design, it is not possible to 
ascertain whether any reported symptoms were the result 
of exposure to 0.12 ppm (or any other specific concentra-
tion)  and  “formaldehyde-sensitive  persons”  are  never 
addressed. The study by Bender et al. (1983) was obviously 
erroneously cited as evidence that symptoms can occur in 
formaldehyde-sensitive persons at levels around 100 ppb. 
This study is one of the earliest controlled human volun-
teer chamber studies, testing responses to formaldehyde 
at concentrations of 0.35, 0.56, 0.7, 0.9, and 1.0 ppm; 100 
ppb (i.e., 0.1 ppm) was not tested. Severity of response 
rated  above  “slight”  occurred  only  at  the  highest  test 
concentration of 1.0 ppm and, as noted by the authors, 
“These data agree with other reported studies in which eye 
irritation occurred between 0.4 and 1.0 ppm rather than 
those which report eye irritation at extremely low levels but 
where other irritants may have been present.”
The study by Ritchie and Lehnen (1987) was conducted 
in response to widespread publicity and subsequent offers 
of free formaldehyde testing. The study involved a survey 
of approximately 2000 people living in conventional and 
mobile homes where formaldehyde concentrations were 
measured in air samples taken from two rooms in each 
residence. The percentages of subjects with eye irritation, 
nose/throat  irritation,  headaches,  and  skin  rash  were 
recorded  for  homes  with  formaldehyde  concentrations 
classified  as  “low”  (<0.1 ppm),  “medium”  (0.1 ppm  to 
<0.3 ppm), or “high” (>0.3 ppm). In both conventional and 
mobile  homes  with  air  concentrations  >0.3 ppm,  more 
than 60% of subjects reported eye irritation, nose/throat 
irritation, or headache; with air concentrations between 
0.1 and 0.3 ppm, respective reporting percentages ranged 
from 10% to 20% for eye irritation, 15% to 20% for nose/682  R. Golden
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throat  irritation,  and  20%  to  25%  for  headache.  Based 
on the controlled human exposure studies, the reported 
responses between 0.1 and 0.3 ppm would be difficult to 
distinguish from false positives (i.e., exposure to 0 ppm 
formaldehyde).  At  concentrations  <0.1 ppm,  less  than 
10% reported effects for each of these three symptoms. 
This study has several limitations, including (1) the par-
ticipants, in order to be eligible for the study, had already 
complained  about  symptoms  and  were  a  self-selected 
group with a potential bias; and (2) there is no way to know 
what the actual formaldehyde exposure levels >0.3 ppm 
might have been because no such data were provided. The 
most substantial limitation of the study, and the one that 
raises questions about the reported results as they pertain 
to potential sensory irritation at formaldehyde levels of 
<0.1 ppm or between 0.1 and 0.3 ppm, is the strong likeli-
hood that some unknown number of the reported effects 
could have been false positives. In fact, this study appears 
to validate the documented incidence of 20–30% false pos-
itives described below at formaldehyde exposure levels of 
<1.0 ppm, with about 10% reporting symptoms at <0.1 ppm 
and 10–20% reporting symptoms at 0.1–0.3 ppm.
With respect to studies conducted in residential set-
tings, a NAS (2007) committee expressed skepticism about 
the use of such studies rather than those conducted under 
controlled conditions, “One of the largest studies involved 
nearly 2,000 residents of 397 mobile homes and 494 con-
ventional homes (Ritchie and Lehnen, 1987). Participants 
were not selected randomly; they responded to a free 
testing service for formaldehyde, which was offered to 
individuals by the state of Minnesota when an examining 
physician made a written request. Thus, those recruited 
in the study had complained of symptoms thought to be 
related to airborne formaldehyde exposures” [emphasis 
added]. The other studies cited by CDC (2008) as the basis 
for conclusions on sensory irritation at a formaldehyde 
level of 100 ppb have similar confounding issues.
2.Controlled human exposure chamber studies
Were the above types of studies the only data available 
(despite their obvious limitations) for deriving a weight of 
evidence-based concentration that would be protective for 
even the most sensitive individuals, such data would nec-
essarily have to be relied upon. Fortunately, however, the 
availability of numerous controlled chamber studies using 
human volunteers (often including sensitive individuals 
and asthmatics as well as excluding insensitive individu-
als such as smokers or non-responders at formaldehyde 
levels  that  produced  eye  irritation  in  other  volunteers) 
provides a far more appropriate data set for assessing the 
exposure  concentrations  of  formaldehyde  required  to 
elicit the symptoms of sensory irritation, in the absence of 
confounding by potential co-exposures to any other sub-
stances. At least 20 published studies or critical reviews 
of such studies of respiratory function and/or irritation of 
the eyes, nose, and throat in human volunteers are avail-
able  that  involve  controlled  exposure  to  formaldehyde, 
generally at concentrations up to 3 ppm or greater (e.g., 
Andersen,  1979;  Andersen  and  Molhave,  1983;  Bender 
et al., 1983; Day et al., 1984; Gorski et al., 1992; Green, 1987; 
Krakowiak et al., 1998; Kulle, 1993; Kulle et al., 1987; Lang 
et al., 2008; Pazdrak et al., 1993; Schachter, 1986, 1987; 
Weber-Tschopp et al., 1977; Witek, 1987). This large body 
of  data,  now  relied  upon  by  numerous  regulatory  and 
authoritative bodies worldwide, permits a more accurate 
assessment of formaldehyde concentrations associated or 
not associated with sensory irritation than workplace or 
residential studies. These data will be helpful in assessing 
whether an empirically based exposure concentration pro-
tective for sensory irritation would be protective for more 
serious effects such as cancer and formaldehyde-induced 
nasal tumors for which mode-of-action data demonstrate 
a threshold concentration for such effects.
Controlled chamber studies expose human volunteers 
to known concentrations of formaldehyde, with the best 
of these studies including clean air controls (i.e., 0 ppm 
formaldehyde),  in  order  to  unequivocally  determine 
the air concentrations of formaldehyde that can reliably 
elicit symptoms of sensory irritation in the absence of any 
potential confounders. Some of these studies have also 
masked the odor of formaldehyde in order to eliminate 
odor alone as the “cause” of symptoms of sensory irrita-
tion.  In  an  extensive  review, Paustenbach  et  al.  (1997) 
convened  a  panel  of  experts  who  evaluated  approxi-
mately 150 studies, 52 of which were human studies with 
10 of greatest relevance for establishing a concentration-
response relationship for sensory irritation. As discussed 
in this review, “The panel concluded that for most persons, 
eye irritation clearly due to formaldehyde does not occur 
until at least 1.0 ppm. Information from controlled studies 
involving volunteers indicated that moderate to severe eye, 
nose, and throat irritation does not occur for most persons 
until airborne concentrations exceed 2.0–3.0 ppm.... Based 
on the weight of evidence from published studies, the panel 
found that persons exposed to 0.3 ppm for 4–6 h in cham-
ber studies generally reported eye irritation at a rate no 
different than that observed when persons were exposed to 
clean air.” This conclusion is notable because all subse-
quent independent reviews, which incorporate additional 
controlled human studies performed since Paustenbach 
(1997), have reached essentially identical conclusions.
The  Organisation  for  Economic  Co-operation  and 
Development Screening Information Data Set (OECD/
SIDS,  2002)  concluded,  “Studies  in  the  literature  have 
reported  a  variety  of  responses  induced  by  exposure  to 
gaseous formaldehyde, generally beginning in the range 
of 0.3 to 0.5 ppm for eye irritation, the most sensitive end-
point. However, the severity of response at these levels is 
generally mild, and only a small portion of the population 
may respond.” Moderate eye, nose, and throat irritation 
occurs at 2 to 3 ppm. The majority of critical assessments 
of formaldehyde levels that would be protective for the 
symptoms of sensory irritation for all individuals, includ-
ing those with self-reported sensitivity to formaldehyde 
as well as asthmatics, support a lowest effective irritant 
concentration of 0.3 ppm (Table 1).Indoor air exposure limit for formaldehyde  683
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3.False positives in formaldehyde-induced sensory irritation
A  crucial  distinction  between  controlled  studies  and 
those  where  responses  are  simply  reported  based  on 
ambient  exposure  levels  (whatever  they  might  be)  is 
that it is difficult (if not impossible) to reliably determine 
whether formaldehyde actually causes irritation at levels 
below about 1 ppm. This is because when some people 
are intentionally exposed to air with formaldehyde lev-
els below 1 ppm and some are exposed to clean air (i.e., 
formaldehyde-free), 20–30% of those exposed to clean air 
will still report responses of sensory irritation (i.e., false 
positives) (Bender, 2002; OECD/SIDS, 2002). For exam-
ple, after reviewing this large body of data, the Australian 
government (NICNAS, 2006) determined that “…chamber 
studies also found that some individuals begin to sense 
irritation from 0.5 ppm (0.6 mg/m3), although the response 
rate is often similar to that reported in controls. There is 
limited evidence that some individuals report sensory irri-
tation as low as 0.25 ppm (0.3 mg/m3), however, the data is 
very unreliable. Therefore, the lowest observed effect level 
(LOEL) is considered to be 0.5 ppm.” Although there are no 
data specifically identifying different formaldehyde con-
centrations below 1 ppm and the associated frequencies 
of false-positive reports of sensory irritation, it appears 
reasonable that such reports would be greater at 0.1 ppm 
than at 0.3 ppm, the consensus level below which sensory 
Table 1.  Summary of authoritative or comprehensive evaluations and other relevant data on formaldehyde exposure concentrations 
associated with or protective from symptoms of sensory irritation or other adverse effects.
Formaldehyde air 
concentration (ppm) Source Comment/observation
6−15 Monticello et al. 1996; Kerns et al. 
1983a, b;
Chronic inhalation dose range required for the sustained cytotoxicity and 
regenerative proliferation leading to development of nasal tumors.
1.0 TNO, 2003; Arts et al., 2006 “..… minimal/mild/slight eye irritation starts at levels of 1.0 ppm formaldehyde 
and higher.”
0.9 EPA, 2004; Acute exposure 
guideline level (AEGL)
“At 0.35 to 0.9 ppm, the subject’s subjective eye irritation responses ranged 
from none to slight, the same as their responses to clean air.”
0.75 OSHA, 2006; (Occupational 
exposure standard)Noisel et al. 
2007
In effect for many years with no evidence of significant worker complaints of 
sensory irritation. “The level of 0.75 ppm can be considered as a safe level that 
allows protecting virtually all workers.” Noisel et al. (2007)
  Noisel et al., 2007 “The level of 0.75 ppm can be considered as a safe level that allows protecting 
virtually all workers.”
0.7 Andersen et al., 2008, 2010 Inhaled concentration in rats that produces no significant toxicogenomic 
changes in nasal epithelial cells following 21 or 90 days of exposure.
0.5 Lang et al., 2008 (most recent 
controlled human study) EPA/
NCEA 2005
““ … the no-observed-effect level for subjective and objective eye irritation due 
to formaldehyde exposure was 0.5 ppm in case of constant exposure level and 
0.3 ppm with peaks of 0.6 ppm in terms of short term peak exposures.”Clear 
threshold at 0.5 ppm for any effects (including odor) with an effective 
concentration at 1.5 ppm for moderate effects.
  US EPA/NCEA, 2005 Clear threshold at 0.5 ppm for any effects (including odor) with an effective 
concentration at 1.5 ppm for moderate effects.
0.3 ATSDR, 1999, 2007 NAS, 2007 
WHO, 2010 ACGIH, 2001 MAK, 
2006 OECD/SIDS, 2002 NICNAS, 
2005
Most weight of evidence–based reviews conclude that 0.3 ppm is a reasonable 
and appropriate level below which symptoms of sensory irritation are unlikely 
to occur, e.g., “…symptoms of eye and mucous membrane irritation at that 
concentration were not increased above control conditions in controlled 
chamber studies.” (NAS, 2007) and “Studies in the literature have reported a 
variety of responses induced by exposure to gaseous formaldehyde, generally 
beginning in the range of 0.3 to 0.5 ppm for eye irritation, the most sensitive 
endpoint. However, the severity of response at these levels is generally mild, and 
only a small portion of the population may respond.” (OECD/SIDS, 2002).
0.2 SCOEL, 2008 “This especially considers possible interindividual differences in susceptibility 
to irritation by formaldehyde, which may be expected based on the entire 
body of data.”
0.1 BfR, 2006; Health Canada, 2001, 
2005; ASHRAE NASA/NAS, 2008
Partially derived from animal data, i.e., “The proposed level of 0.1 ppm is 2 
fold lower than the level derived from animal data by applying appropriate 
safety factors.” [emphasis in original]. 0.1 ppm (1 hour) = 1/5th of NOAEL (i.e., 
0.5 ppm) for eye irritation.
0.08 WHO, (2010); Wolkoff and Nielsen, 
2010
“An air quality guideline of 0.1mg/m3 (0.08 ppm) is considered protective 
against both acute and chronic sensory irritation in the airways in the 
general population assuming a log normal distribution of nasal sensory 
irritation.” “Thus, prevention of nasal cancer is considered to prevent 
lymphohematopoietic malignancies…. the guideline value of the WHO [of]…
0.08 ppm FA, is considered preventive of carcinogenic effects in compliance 
with epidemiological findings.”
  WHO, 2010; Nielsen and Wolkoff, 
2010
“Thus, prevention of nasal cancer is considered to prevent lymphohematopoietic 
malignancies…the guideline value of the WHO [of]…0.08 ppm FA, is considered 
preventive of carcinogenic effects in compliance with epidemiological findings.”684  R. Golden
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irritation is unlikely to occur. This is why, for example, that 
the residential studies that report unequivocal symptoms 
of sensory irritation at 0.1 ppm, but lack a clean air control 
(e.g., Ritchie and Lehnen, 1987; Main and Hogan, 1983), 
do not provide a credible basis for drawing conclusions 
concerning airborne concentrations of formaldehyde that 
might be associated with sensory irritation.
E.Sensory irritation effects in children and other 
potentially sensitive individuals
Although almost all of the data on sensory irritation have 
been derived from studies in adults, there is limited evi-
dence available to determine whether infants or children 
are either more or less susceptible to the irritant effects of 
formaldehyde than adults. Although differences between 
children and adults have been documented for absorp-
tion, metabolism, and excretion of potentially toxic sub-
stances (ILSI, 1992), such considerations are less relevant 
to a sensory irritant such as formaldehyde because there 
is no appreciable difference in the targets for irritation 
(i.e., eyes, nose, or throat) between children and adults. As 
concluded by ATSDR (1999), “Whereas there are numer-
ous studies of adults occupationally exposed to formalde-
hyde and exposed under acute controlled conditions, data 
regarding the toxicological properties of formaldehyde in 
children are limited. Nevertheless, the same type of effects 
that occur in adults are expected to occur in children…. 
Symptoms expected to occur in children include eye, nose, 
and throat irritation from exposure to airborne concen-
trations between 0.4 and 3 ppm…”
In an extensive review of upper respiratory tract and 
eye  irritation  effects  of  volatile  chemicals  by  a  group 
of  experts,  greater  susceptibility  among  children  was 
not mentioned (Doty et al., 2004). In another study by 
Meininghaus et al. (2003), sensory irritation was reported 
in school children. The airborne levels of several respira-
tory irritants were measured (e.g., SO2, ammonia, acetic 
acid, formic acid, hexanal, butanal, acetaldehyde, and 
formaldehyde). Formaldehyde air concentrations were 
between 20 and 25 μg/m3 (17 and 21 ppb). Interestingly, 
the reported symptoms (i.e., dry sensation of the eyes, 
irritation of the upper respiratory tract, headache, and a 
rough tongue) were initially reported by adults (teachers) 
and it was only after those reports that several children 
complained about similar symptoms, suggesting either 
a  higher  sensitivity  in  adults  than  in  children  or  pos-
sibly adult responses influencing children’s responses. 
With respect to this latter issue, the authors concluded 
that psychological factors (e.g., increased attention from 
authorities,  the  presence  of  “experts”  and  sampling 
equipment,  and  a  strong  group  behavior)  may  have 
resulted in individuals paying more attention to health 
effects related to sensory irritation. Also notable in these 
studies is that exposure involved a complex mixture of 
chemicals, which makes it difficult to attribute reported 
effects to a single chemical.
Krzyzanowski et al. (1990) compared the sensitivity of 
children and adults to formaldehyde-induced effects on 
chronic respiratory symptoms and pulmonary function, 
reporting  a  greater  prevalence  of  asthma  and  chronic 
bronchitis in children whose houses had 60–120 ppb of 
formaldehyde.  Researchers  questioned  a  group  of  298 
children (ages 6 to 15) and 613 adults using a self-admin-
istered respiratory questionnaire and found no significant 
association  between  exposures  in  children  and  self-
reported chronic respiratory symptoms. More than 83% 
of the subjects in the study lived in homes in which the 
2-week average formaldehyde concentrations were less 
than 40 ppb. The average concentration measured was 
26 ppb, with only a few homes exceeding 90 ppb, indicat-
ing that the average concentrations appear to have been 
driven by a few outliers. Prevalence rates of chronic bron-
chitis or asthma reportedly diagnosed by a physician were 
significantly  higher  when  residential  concentrations  of 
formaldehyde exceeded 60 ppb, especially in the presence 
of tobacco smoke. Effects on peak expiratory flow rates 
(PEFRs) were measured in children and adults and effects 
assessed in conjunction with formaldehyde air concentra-
tions of <40 ppb, 40–60 ppb, and > 60 ppb. Whereas effects 
on PEFR in adults were transient and associated mainly 
in  smokers,  effects  in  children  decreased  linearly  with 
formaldehyde exposure and were observed at the lowest 
measured concentrations, with greater effects in children 
with asthma. However, there was no dose-response rela-
tionship between the reported effects and formaldehyde 
concentrations. Since only formaldehyde and NO2 were 
measured in the air (with no effects from NO2 observed), 
the assumption that all effects can be attributed to form-
aldehyde alone is difficult to substantiate.
It is well documented (i.e., Garrett et al., 1998, 1999; 
Rumchev  et  al.,  2002,  2004)  that  other  substances  in 
indoor air (e.g., VOCs and fungal spores) can cause and/
or  exacerbate  respiratory  symptoms  quite  apart  from 
formaldehyde. Consequently, it is likely inappropriate to 
conclude that the results reported by Krzyzanowski et al. 
(1990) can be unequivocally attributed to formaldehyde 
alone in indoor air. Findings of this study (i.e., PEFRs) 
are questionable in view of the low levels of formalde-
hyde found in the homes and at odds with controlled 
studies where formaldehyde was the only variable (e.g., 
Lang et al., 2009). In addition, as in most studies of this 
kind,  the  lack  of  measurements  of  allergens  or  other 
chemical agents that may have been present in indoor 
air and possibly contributed to reported symptoms is a 
major cofounder. Although the authors did report greater 
changes in PEFR in children than in adults, the use of this 
measure does not confirm the presence or absence of 
asthma or bronchitis or that formaldehyde (or something 
else) was responsible for this finding. This is the only 
study  suggesting  differential  effects  in  children  versus 
adults, hardly a convincing basis for concluding that chil-
dren are more sensitive to formaldehyde. Finally, a com-
prehensive evaluation by the World Health Organization 
(WHO, 2010) derived a value of 0.08 ppm (0.125 mg/m3) 
as a residential indoor air level for formaldehyde. In this 
evaluation, it was concluded that this value is also valid Indoor air exposure limit for formaldehyde  685
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for children “…because there is no indication that chil-
dren are more susceptible to formaldehyde exposure than 
adults.” Nonetheless, the potential for children’s greater 
sensitivity deserves further research.
The same holds true for other potentially sensitive popu-
lations such as the elderly or infirmed individuals who may 
spend the majority of their time indoors. Although certain 
metabolic functions decline with age (e.g., Vestal, 1982; 
Reaven and Reaven, 1980; Schumacher, 1980; Michielsen 
and Vande, 2010), thereby possibly influencing metabo-
lism-related responses, these factors are far less likely to 
contribute to sensory irritation. There do not appear to be 
empirical data suggesting age-related changes in response 
to  sensory  irritants.  Moreover,  as  previously  discussed, 
time spent at a specific formaldehyde concentration does 
not appreciably influence the severity of the symptoms 
produced. As noted by NAS (2007), “Individual suscepti-
bility to formaldehyde appears to be difficult to predict, and 
typically sensitive groups, such as asthmatic individuals, do 
not appear to be any more sensitive to irritation effects than 
healthy subjects at exposure concentrations below 3 ppm.” 
That conclusion is supported by BfR (2006), “There is, how-
ever, no indication that a higher sensitivity is present for 
locally acting substances at the portal of entry, in particular 
when the effect is related to the concentration, as it is the 
case for formaldehyde.” As further evidence of this, in con-
trolled studies, volunteers who claimed to be sensitive to 
formaldehyde eye irritation were exposed to levels of 0.35 
to 1.0 ppm for 6 minutes. At formaldehyde concentrations 
of less than 1 ppm, eye irritation responses in sensitive test 
subjects were no different than with exposure to clean air, 
whereas  at  concentrations  of  1 ppm,  responses  ranged 
from slight to moderate (Bender, 2002).
Another consideration for potentially sensitive indi-
viduals concerns the issue of polymorphisms in metabo-
lizing enzymes such as aldehyde dehydrogenase (ADH). 
For example, individuals with a genetic polymorphism 
for the slow form of aldehyde dehydrogenase (ADH2), 
which is in virtually all tissues, may be more sensitive 
to the irritant effects of acetaldehyde because of slower 
removal  from  upper  respiratory  tract  tissues  (Deitrich 
et al., 2007). This aspect of sensitivity was considered in 
establishing  air  levels  in  submarines  for  acetaldehyde 
by  the  use  of  an  uncertainty  factor  of  2  (NRC,  2009). 
However, this situation would not appear to be relevant 
for formaldehyde, which is principally metabolized by a 
different aldehyde dehydrogenase (i.e., ADH3), for which 
polymorphic forms have not been identified.
F.Asthma
Asthma, particularly in children, is often mentioned as an 
endpoint of concern with respect to either being caused 
or exacerbated by the irritant properties of formalde-
hyde. Although there are isolated reports of associations 
between formaldehyde and asthma-like symptoms, they 
are generally based on small, poorly controlled studies 
that do not show dose-response relationships between 
formaldehyde and asthma or surrogate measures (e.g., 
atopy) or that report results at implausible formaldehyde 
concentrations (e.g., low ppb). With respect to many of 
the  studies  reporting  potential  associations  between 
formaldehyde  exposure  and  asthma,  it  is  noteworthy 
that  many  types  of  non-specific  exposures  (e.g.,  cold 
air, nuisance dust, molds, etc.) can initiate asthma-like 
complaints. Because of this, the potential contribution 
of other factors cannot reliably be confirmed or ruled 
out. This difficulty in establishing causal relationships 
is particularly a problem when residential or occupa-
tional studies report asthma-related associations with 
formaldehyde  in  cases  where  all  subjects  were  also 
simultaneously co-exposed to numerous other airborne 
contaminants.
1.Residential indoor air studies
Studies by Garrett et al. (1999) and Rumchev et al. (2002, 
2004) are often cited as a basis for concluding that form-
aldehyde is a cause of asthma and atopy. The case-control 
study by Garrett et al. (1999) involved a total of 148 chil-
dren, 53 of whom were asthmatic prior to participation 
in the study. Consequently, causal associations between 
anything (including formaldehyde) and asthma cannot 
be proven by this study. Although provoking symptoms 
in  asthmatic  children  might  hypothetically  be  related 
to indoor air levels of any number of substances, with 
median indoor formaldehyde level in this study of 12.6 
ppb (maximum of 111 ppb), it is questionable whether 
such levels of formaldehyde alone would be associated 
with provoking symptoms. Although there was an asso-
ciation between formaldehyde exposure and atopy, this 
was not significant (odds ratio [OR] = 1.4, 95% confidence 
interval  [CI]  0.98–2.0)  and  there  was  “…no  significant 
increase  in  the  adjusted  risk  of  asthma  or  respiratory 
symptoms with formaldehyde exposure.” It is noteworthy 
that another study on this same cohort of children is often 
not considered with respect to this issue. In this study 
(Garrett et al., 1998), indoor airborne fungal spores were 
assessed in conjunction with asthma and atopy. Asthma 
was significantly associated with exposure to Penicilium 
in winter (OR = 1.43, 95% CI 1.03–2.00) and atopy signifi-
cantly associated with Aspergilis spores (OR = 1.48, 95% 
CI  1.10–1.99).  As  noted  by  the  authors,  “…results  pre-
sented in this paper suggest a large overall effect of fungal 
exposure on child health (especially in winter). Asthma, 
atopy  and  respiratory  symptoms  were  all  significantly 
associated with exposure to one or more genera of fungal 
spores.” It appears inappropriate to rely solely on Garrett 
et al. (1999) (without any consideration of Garratt et al., 
1998) as justification for a conclusion that formaldehyde 
exposure alone either causes or exacerbates of asthma or 
atopy.
The two studies by Rumchev et al. (2002, 2004) have 
often been interpreted as showing a causal association 
between formaldehyde and asthma. Both of these case-
control studies were conducted on the same population 
of children with the cases (N = 88) previously identified 
as having asthma prior to the onset of the study with 686  R. Golden
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the  goal  to  determine  if  formaldehyde  exposures  in 
their homes might have been responsible. Although the 
Rumchev  et  al.  (2002)  study  concluded  that  children 
exposed to formaldehyde levels of >60 μg/m3 (49 ppb) 
were at increased risk of having asthma, it does not rule 
out the potential contributory role of other exposures, 
particularly those reported in a later follow-up study by 
the same authors. This later study (Rumchev et al., 2004) 
investigated associations between domestic exposure to 
volatile organic compounds (VOCs) and asthma. After 
controlling for confounding variables, the authors noted 
that “…children exposed to concentrations of total VOCs 
of >60 mg/m3 (median level of exposure) had a fourfold 
increased risk of having asthma while children exposed 
to single compounds such as benzene at levels of >20 mg/
m3 (median level of exposure) had an eightfold increased 
risk of asthma.” Since the studies by Rumchev et al. (2002, 
2004) are among the only ones that explore the potential 
effects of multiple indoor air pollutants (i.e., formalde-
hyde and numerous VOCs) on childhood asthma, it is 
not possible to conclude that formaldehyde acting alone, 
in  the  absence  of  other  potential  co-exposures,  either 
causes or exacerbates asthma.
2.Other studies and evaluations
In a study by Ezratty et al. (2007), 12 subjects with inter-
mittent asthma and allergy to pollen were exposed, at 
rest, in a double-blind crossover study to either formalde-
hyde (0.4 ppm) or purified air for 60 minutes. The order of 
exposure to formaldehyde and air-only was randomized, 
and exposures were separated by 2 weeks. There was also 
an  allergen  inhalation  challenge  after  each  exposure. 
Airway responsiveness to methacholine and lower air-
way  inflammation  (i.e.,  as  measured  by  inflammatory 
cells in sputum) were also assessed 8 hours after allergen 
challenge. Formaldehyde exposure did not affect aller-
gen-induced increase in responsiveness to methacholine 
and there was no formaldehyde-associated effect on the 
airway inflammatory response. In this study, exposure 
to 0.4 ppm formaldehyde had no significant deleterious 
effect on airway allergen responsiveness of patients with 
intermittent asthma.
A comprehensive report by the National Academy of 
Sciences  Institute  of  Medicine  (NAS,  2000)  examined 
the evidence for associations between indoor biologic 
and  chemical  exposures  and  either  the  development 
or  exacerbation  of  asthma.  The  report  concluded  that 
there is inadequate evidence to determine an association 
between formaldehyde exposure and asthma induction 
and  only  limited  evidence  of  an  association  between 
formaldehyde and respiratory symptoms. More recently, 
a National Academy of Sciences report summarized the 
available controlled clinical studies evaluating the irritant 
effects of formaldehyde in asthmatic and non-asthmatic 
individuals, finding no differences in sensitivity between 
the two groups (NAS/NRC, 2007). The report concluded 
that “asthmatic individuals exposed to airborne formalde-
hyde at exposure concentrations at or below 3 ppm do not 
appear to be at greater risk of suffering airway dysfunction 
than nonasthmatic individuals.”
ATSDR  (1999)  concluded  that  investigations  into 
the possibility of a relationship between formaldehyde 
and asthma have provided very limited evidence of an 
association. In addition, several clinical investigations 
of asthma cases suspected to be due to formaldehyde 
failed to confirm even a single case based on inhala-
tion challenge tests (Frigas et al., 1984; Grammer et al., 
1993; Pross et al., 1987; Krakowiak et al., 1998). There 
are also studies indicating that asthmatic individuals 
are not more sensitive to the irritant effects of formalde-
hyde than healthy people (Sheppard et al., 1986; Sauder 
et al., 1987; Kulle et al., 1993; Green et al., 1987; Witek 
et al., 1987).
A recent meta-analysis of seven studies that reported 
associations between formaldehyde exposure and asthma 
in children concluded that there was a significant posi-
tive association (McGuin et al., 2010), with the majority 
of the weight for this association based on the studies by 
Garrett et al. (1999) and Rumchev et al. (2002). Although 
the  studies  in  this  meta-analysis  were  heterogeneous 
with respect to the definition of asthma (e.g., self-report 
vs. physician diagnosis), the conclusions are based on 
the assumption that formaldehyde was the sole cause of 
the reported results. Although acknowledging the largely 
cross-sectional nature of the studies underlying the meta-
analysis, and the need for prospective studies, there was 
no discussion of (or citations to) the companion studies 
by Garrett et al. (1998) or Rumchev et al. (2004) on the 
same cohort of children in which asthma symptoms were 
also  associated  with  other  constituents  (e.g.,  VOCs  or 
fungal spores) of indoor air.
Formaldehyde is primarily metabolized via an initial 
spontaneous  reaction  with  glutathione  (GSH)  to  form 
S-hydroxymethylglutathione,  followed  by  a  reaction 
catalyzed by formaldehyde dehydrogenase (ADH3), an 
enzyme in the family of alcohol dehydrogenases, which 
converts the intermediate to S-formylglutathione, which 
is  further  metabolized  by  S-formylglutathione  hydro-
lase  to  yield  formate  and  reduced  glutathione.  Active 
research  is  presently  underway  to  determine  whether 
ADH3, also termed formaldehyde dehydrogenase (FDH) 
or  S-nitrosoglutathione  reductase  (GNSO),  which  has 
been shown to play a key role in the enzymatic oxida-
tion of formaldehyde and reduction of nitrosothiols that 
regulate bronchial tone, may also play a role in the risk 
of  asthma  (Staab  et  al.,  2009;  Thompson  et  al.,  2009). 
However, it is presently unknown if there are polymor-
phic forms of ADH3, which would suggest a hypotheti-
cal possibility of differential sensitivity to formaldehyde 
effects on bronchial sensitivity.
Considering the reported associations between form-
aldehyde vapor exposure and childhood or adult asthma 
risk, there remain a number of unanswered questions 
ranging from whether formaldehyde is not a risk factor at 
all, the only risk factor, or may act in concert with other 
identified or as yet unidentified factors in the etiology of Indoor air exposure limit for formaldehyde  687
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asthma or its exacerbation. In exploring possible mecha-
nisms  for  formaldehyde-induced  bronchoconstriction, 
Thompson and Grafstrom (2008) noted that “The poten-
tial for formaldehyde to provoke asthma, hypersensitivity, 
and airway constriction in adults and children has received 
extensive attention over the years, yet data regarding these 
effects  remain  equivocal.”  Although  the  hypothetical 
mechanism proposed by those authors may or may not 
lead to a better understanding of whether formaldehyde 
plays a causative role in asthma-related bronchoconstric-
tion, at present the evidence suggests that asthma is nei-
ther caused nor exacerbated by low-level exposure (i.e., 
less than 1–2 ppm) (Noisel et al., 2007). Additional mech-
anistic support for why asthmatics are not more sensitive 
to  formaldehyde  at  environmentally  relevant  levels  is 
the well-documented effective scrubbing of low levels of 
this highly water-soluble gas in the upper airways below 
3 ppm (i.e., Schlosser et al., 2003; Kimbell et al., 1993, 
2001; Overton et al., 2001; Garcia et al., 2009). As a result, 
little formaldehyde at these concentrations reaches the 
mid to lower airways where an asthmatic reaction may 
be triggered. The lack of sensitivity of asthmatics at these 
lower air levels in controlled chamber studies is consis-
tent with expected patterns of absorption in the upper 
airways.
Although  formaldehyde  is  clearly  a  sensory  irritant 
at  sufficient  concentrations  with  different  individual 
sensitivities, its potential to cause or exacerbate asthma 
is  far  less  certain  particularly  at  low  exposure  levels 
(<1–2 ppm). There are no studies in which exposure to 
formaldehyde alone has been shown to cause or exac-
erbate this disease. Instead, studies that have reported 
this effect are all confounded, to an unknown extent, by 
simultaneous co-exposures to other chemicals, many of 
which themselves have been associated with exacerbat-
ing asthmatic symptoms.
G.Data from which to derive an indoor air 
formaldehyde concentration protective for sensory 
irritation
1.Key studies or evaluations
In 2007, testing was conducted to determine formalde-
hyde  levels  in  unoccupied  FEMA  temporary  housing 
units in order to assess the most effective way to ventilate 
these units and to identify a health-protective indoor air 
concentration limit for formaldehyde (ATSDR, 2007b). 
A target indoor air concentration of 0.3 ppm formalde-
hyde was selected by ATSDR because this level was “…
below the level of concern for sensitive individuals of 369 
ug/m3 (0.3 ppm).” This empirically derived concentra-
tion (0.3 ppm) was taken from ATSDR documents and, 
as shown in Table 1, is the same concentration selected 
by the National Academy of Sciences (NAS, 2007) (and 
numerous other entities) as a continuous exposure guid-
ance level (CEGL) for formaldehyde in submarines. As 
noted in the NAS publication, “Reported symptoms of eye 
and mucous membrane irritation at that concentration 
[i.e., 0.3 ppm] were not increased above control conditions 
in controlled chamber studies.” In establishing the 0.3 ppm 
value, both ATSDR and NAS relied on extensive human 
volunteer exposure data (i.e., chamber studies) as the 
basis for their identical determinations.
The  conclusion  that  an  exposure  limit  of  0.3 ppm 
formaldehyde in indoor air is conservative and health 
protective  is  fully  supported  by  recent  independent 
evaluations. For example, in an evaluation of the human 
data on formaldehyde a Dutch review noted that “…it 
can be concluded that minimal/mild/slight eye irritation 
starts at levels of 1.0 ppm formaldehyde and higher.” The 
same review also concluded that nasal and throat irrita-
tion start at formaldehyde levels of 2.0 ppm and 3.0 ppm, 
respectively (TNO Nutrition and Food Research, 2003). 
In deriving Acute Exposure Guideline Levels (AEGLs), US 
EPA (2004) selected 0.9 ppm as the AEGL for an 8-hour 
exposure, noting that “At 0.35 to 0.9 ppm, the subjects sub-
jective eye irritation responses ranged from none to slight, 
the same as their responses to clean air.” As summarized in 
Table 1, authoritative and comprehensive reviews recog-
nize 0.3 ppm as a prudent level of exposure to formalde-
hyde in indoor air, with most evaluations of the empirical 
evidence clustering at this value. In fact, based on human 
chamber  studies,  0.3 ppm  essentially  incorporates  an 
additional “margin of safety” of 3 because 1.0 ppm is the 
lowest formaldehyde exposure level for eye irritation not 
confounded by the likelihood of false-positive reports.
In a comprehensive review of formaldehyde-induced 
sensory irritation, Arts et al. (2006) evaluated 10 of the 
controlled  human  studies  and  the  subjectively  mea-
sured sensory irritation threshold levels at which effects 
occurred. On a normalized scale (i.e., response severity 
index from all studies standardized as 0 = none, 1 = slight, 
2 = moderate,  3 = severe)  in  which  all  available  studies 
were similarly evaluated, mild/slight eye irritation was 
observed at formaldehyde levels ≥1 ppm, and respiratory 
tract irritation at levels ≥2 ppm. In rating studies in which 
sensory irritation was sufficiently described to incorpo-
rate  evaluation  by  the  benchmark  dose  methodology, 
“...it was estimated that at a level of 1 ppm, only 9.5 % of 
healthy volunteers experience ‘moderate’ (i.e., annoying) 
eye irritation (95% upper confidence limit).” It was also 
concluded that an important factor modulating the per-
ception  of  irritation  and  health  symptoms  most  likely 
includes  the  perception  of  odor  intensity,  particularly 
since in several studies the 0 ppm control condition was 
missing. This is a critical consideration because, as noted 
by Arts et al. (2006), “In some of the studies measuring 
subjective irritation in which a 0-ppm control concentra-
tion was included, a response percentage of eye irritation 
of up to about, 20% was found at 0 ppm. Also, nasal and/
or throat irritation up to almost 30% was reported in the 
absence of formaldehyde…therefore, response percentages 
of about, 20–30%, if at all responses, should be interpreted 
with caution, especially in those studies in which a 0-ppm 
control condition is missing.”
Similarly, Noisel et al. (2007) conducted an assessment 
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of the most sensitive effects related to acute formalde-
hyde exposure based on a pooled analysis of 11 published 
controlled human studies (including healthy individuals 
and asthmatics). Parameters evaluated included concen-
tration range (i.e., 0 to <0.3 ppm; 0.3 to <0.75 ppm; 0.75 
to <1 ppm; 1 to <2 ppm; 2 to <3 ppm;.>3 ppm), site of the 
irritating effect (i.e., eye, nose, or throat), and degree of 
severity of the effect (baseline [effect in the absence of 
formaldehyde exposure], mild effects, moderate effects, 
and severe effects). As concluded by Noisel et al. (2007), 
“The  experimental  data  show  that  there  was  no  differ-
ence in the proportion of individuals experiencing effects 
between the control group without occupational exposure 
and groups exposed to formaldehyde concentrations under 
0.75 ppm.  For  this  reason,  the  theoretical  percentage  of 
response attributable to formaldehyde exposure was con-
sidered to be zero for the moderate effects on the eyes, nose 
and throat for all the concentrations below 0.75 ppm…. 
According to our analysis of the defined exposure–response 
relationship, at concentrations below 0.75 ppm, there is 
thus little probability for formaldehyde-induced irritation 
to occur...” This analysis was conducted by considering 
formaldehyde exposure alone and not mixed-exposure 
situations such as in occupational settings where form-
aldehyde is used and where other chemical substances 
(e.g.,  phenol,  sodium  hydroxide,  etc.)  and  dusts  (e.g., 
wood or paper dust) may also be present with irritating 
effects of their own.
The US EPA (US EPA/NCEA, 2005) conducted a quan-
titative analysis of controlled human exposure data to 
derive human health effects criteria for formaldehyde. 
Response data from six human volunteer studies com-
prising 250 observations and reported symptoms were 
categorized  into  the  four  numerical  descriptors  and 
symptoms: (0) no effect noted or reported; (1) mild signs 
and  symptoms:  irritation  noticed,  but  not  considered 
annoying; (2) moderate signs and symptoms: irritation 
annoying; and (3) severe signs and symptoms: incapaci-
tating. From these data, a number of mathematical mod-
els were used to assess responses arriving at a conclusion 
that “An important advantage of this approach is that all 
relevant data can be used in the derivation as opposed 
to a NOAEL for the critical effect. The benefit of doing so 
allows health risks to be estimated across various exposure 
levels.” This approach was also endorsed by the US EPA 
Science Advisory Board, which observed that the process 
“…makes use of every bit of data available…The under-
lying premise of the approach is that the severity of the 
effect, not the specific measurement or outcome incidence, 
is the information needed for assessing exposure-response 
relationships for non-cancer endpoints…” This detailed 
modeling process showed a clear threshold at 0.5 ppm 
for any symptoms of sensory irritation and an effective 
concentration at 1.5 ppm for moderate effects.
Some reviews concerning the issue of formaldehyde-
induced  sensory  irritation  have  commented  that  the 
above-described values have been derived for short peri-
ods of time or for generally healthy individuals, with the 
implication that they are somehow inadequate for the 
general population. This erroneous assumption is based 
on an interpretation that such values are not sufficiently 
protective for longer-term exposures or for particularly 
sensitive  individuals.  However,  formaldehyde-induced 
observed symptoms of sensory irritation are dependent 
on the concentration and not on the length of time (i.e., 
duration) of exposure as well as the fact that many of 
the controlled studies specifically included people who 
claimed to be sensitive to formaldehyde. In fact, as noted 
in ATSDR (2007a), the value of 0.3 ppm was considered 
specifically because it was below the level of concern for 
sensitive individuals. Even the Occupational Safety and 
Health Administration (OSHA) standard of 0.75 ppm is 
protective for sensory irritation for individuals exposed 
at this level for an 8-hour work shift and there is no con-
cept “built into” this value for a “recovery” period as is 
often done for other chemicals.
Several  slightly  lower  acceptable  exposure  concen-
trations  for  formaldehyde  have  been  established  (e.g., 
SCOEL, 0.2 ppm; BfR, 0.1 ppm; and WHO, 0.08 ppm) and 
although  these  are  predominantly  weight  of  evidence 
based, they incorporate an extra “margin of safety” to 
the  derived  value  based  on  considerations  other  than 
just the concentrations eliciting the symptoms of sen-
sory irritation. For example, the SCOEL value is based on 
several studies of acknowledged questionable design or 
reliability (i.e., lack of sham controls or inadequate study 
documentation). The BfR value of 0.1 ppm is not derived 
solely based on sensory irritation, but rather incorporates 
considerations of cytotoxicity, cell proliferation, and the 
biologically based dose-response model for nasal tumors 
(none of which are relevant to sensory irritation), even 
while acknowledging that the epidemiological findings 
for nasal cancer were not causal. The value established by 
WHO (0.08 ppm) was based on an experimental study by 
Lang et al. (2008), which reported conjunctival redness 
and  increased  eye  blink  frequency  following  a  4-hour 
exposure  of  0.5 ppm  (0.63 mg/m3),  which  was  consid-
ered as the no observed adverse effect level (NOAEL). 
This value was adjusted by an “assessment factor” of 5, 
which was derived from the standard deviation of nasal 
pungency (i.e., sensory irritation) thresholds, leading to 
a value of 0.12 mg/m3 (0.09 ppm), which was rounded 
down  to  0.1 mg/m3  or  0.08 ppm.  This  value  was  also 
reached based on the concept that there is no indication 
of accumulation of effects over time following prolonged 
exposure and that neither increased sensitivity nor sensi-
tization was considered plausible at such concentrations 
in either adults or children
Finally,  OEHHA  (Office  of  Environmental  Health 
Hazard  Assessment;  Cal/EPA)  and  the  INDEX  project 
have  derived  even  lower  Chronic  Reference  Exposure 
Levels (CRELs), with formaldehyde inhalation exposure 
values  of  0.002 ppm  (2  ppb)  and  1 μg/m3  (0.815  ppb), 
respectively. These values were derived by the applica-
tion of various safety/uncertainty factors to empirically 
derived data. However, given that each falls close to or Indoor air exposure limit for formaldehyde  689
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even below measured formaldehyde concentrations in 
normal human breath (i.e., ≈2 ppb) as well as rural air 
ambient formaldehyde concentrations (i.e., ≈8 ppb), it 
is unclear how such values should be interpreted in the 
context  of  providing  realistic  public  health  protection. 
Importantly, with respect to the value of 0.815 ppb estab-
lished by OEHHA, a recent (2008) joint communiqué from 
the Department of Health and Human Services (DHHS), 
the Centers for Disease Control and Prevention (CDC), 
the  Department  of  Homeland  Security  (DHS),  FEMA, 
and  US  EPA  noted  that  “Due  to  the  fact  that  OEHHA 
determined that the CREL for formaldehyde is less than 
typical ambient levels, they (i.e., OEHHA) recommended 
an office concentration level of 23 ppb, based upon the 
concept of “as low as reasonably achievable.” However, 
even 23 ppb is far below the empirically derived value of 
0.3 ppm (300 ppb) that will be protective even for sensi-
tive individuals.
Another example of a lower exposure limit is ATSDR’s 
(1999) chronic Minimum Risk Level (MRL) of 0.008 ppm 
(8 ppb). That level was based on an occupational study, 
instead of controlled studies, in which nasal histopathol-
ogy was evaluated in one group of workers exposed pre-
dominantly to formaldehyde and another group exposed 
to both formaldehyde and wood dust (Holmstrom et al., 
1989).  Because  the  subjects  worked  “…in  a  chemical 
industry in which formaldehyde and products based on 
formaldehyde were produced as resins,” they apparently 
were not exposed solely to formaldehyde as the only nasal 
irritant. In addition, workers were exposed to frequent 
formaldehyde peaks above 1 mg/m3 (≈1 ppm) so that the 
formaldehyde exposure concentrations associated with 
mean biopsy scores could be characterized only as >0.5 
for nearly 30% of the group. The well-known confound-
ing due to wood dust has already been described. ATSDR 
determined 0.24 ppm to be the lowest observed adverse 
effect level (LOAEL) from this study. An uncertainty fac-
tor of 3 was then used to obtain a presumed NOAEL and 
an uncertainty factor of 10 was applied for human vari-
ability (0.24/3 × 10  =  0.008). Such co-exposures and lack 
of defined exposure concentrations make it questionable 
that reported effects were due solely to formaldehyde.
2.Derivation of recommended value
Although  0.3 ppm  represents  the  best  science-based 
exposure limit for formaldehyde in indoor air, an alter-
native, even more health-protective approach also can 
be  justified.  Based  on  the  substantial  amount  of  data 
derived from controlled human studies and on numer-
ous reviews of those data, 1.0 ppm is the LOAEL that is 
unequivocally  associated  with  eye  irritation  and  with 
substantial scientific certainty that false positives play no 
confounding role. Using the weight of evidence–based 
value of 1.0 ppm and dividing by a “certainty factor” of 10 
would yield an indoor air concentration limit of 0.1 ppm 
(100 ppb). This limit is a conservative target level that 
provides  scientifically  documentable  protection  from 
formaldehyde-induced sensory irritation as well as from 
odor  and  annoyance  effects  for  everybody,  including 
sensitive individuals, children, and people with asthma. 
This value was endorsed by the expert panel assembled 
by Paustenbach et al. (1997), which stated, “The panel 
concluded that any occupational or environmental guide-
line for formaldehyde should be based primarily on con-
trolled studies in humans, since nearly all other studies are 
compromised by the presence of other contaminants. The 
panel also concluded that if concentrations of formalde-
hyde are kept below 0.1 ppm in the indoor environment 
(where exposures might occur 24 h/d) this should prevent 
irritation  in  virtually  all  persons.”  Likewise,  in  a  NAS 
(2008) report prepared for the National Aeronautics and 
Space Administration (NASA), the issue of deriving an 
airborne concentration (AC) for formaldehyde for per-
sonnel exposed for long durations was critically assessed. 
As noted in this report, “…a formaldehyde concentration 
of 0.1 ppm is being identified as a reasonable guideline 
for  long-term  exposure  that  is  unlikely  to  result  in  any 
irritant effects, even with sensitive individuals. Instead of 
relying on one particular study, multiple lines of evidence 
support this AC as appropriate. This evidence…includes 
the findings from a number of controlled human studies, 
evaluations from several comprehensive scientific reviews, 
community health surveys, and practical NASA experience 
with formaldehyde in an enclosed environment designed 
to mimic conditions relevant to spacecraft exposures.”
Finally, a value of 0.1 ppm is also in close agreement 
with  the  most  recent  comprehensive  evaluation  of 
formaldehyde in indoor air including a recommended 
indoor  air  level  by  Wolkoff  and  Nielsen  (2010).  This 
evaluation, carried out in the framework of the WHO 
Indoor Air Quality Guideline development (2006–2010), 
concluded that, “With the eye the most sensitive organ, 
subjective irritation is reported at 0.3–0.5 mg/m3 [0.24–
0.5 ppm], which is somewhat higher than reported odour 
thresholds. Objective effects in the eyes and airways occur 
around  0.6–1 mg/m3  [0.46–0.8  ppm].  Dose–response 
relationships between FA and lung function effects have 
not been found in controlled human exposure studies 
below  1 mg/m3  [0.8  ppm],  and  epidemiological  asso-
ciations between FA concentrations and exacerbation of 
asthma in children and adults are encumbered by com-
plex exposures. Neither experimental nor epidemiologi-
cal studies point to major differences in susceptibility to 
FA among children, elderly, and asthmatics…. An air 
quality guideline of 0.1 mg/m3 (0.08 ppm) is considered 
protective against both acute and chronic sensory irrita-
tion in the airways in the general population assuming 
a log normal distribution of nasal sensory irritation.” 
Consequently, based on the weight of evidence from 
the numerous controlled human studies in which expo-
sure to formaldehyde was the only variable, any derived 
“safe” concentration of formaldehyde which falls below 
the range of 0.08–0.1 ppm (80–100 ppb) cannot be justi-
fied, since there are no un-confounded empirical data 
that  demonstrate  formaldehyde-associated  sensory 
irritation effects below this level.690  R. Golden
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H.Implications of Table 1 for non-cancer effects
Table  1  is  primarily  a  comprehensive  compilation  of 
the  formaldehyde  air  concentrations  that  have  been 
determined by numerous regulatory and/or authorita-
tive entities as protective from the symptoms of sensory 
irritation as derived from the controlled human expo-
sure data. The majority of the reviews of the controlled 
human exposure have determined that 0.3 ppm is a form-
aldehyde exposure level below which the symptoms of 
sensory irritation are unlikely to occur. Although several 
entities have derived slightly lower values (i.e., 0.2, 0.1, 
and 0.08 ppm), it is clear that with most comprehensive 
evaluations clustering at 0.3 ppm that a formaldehyde 
level of 0.1 ppm as derived and justified in the present 
review represents a conservative and health-protective 
concentration  for  indoor  air  in  residential  dwellings. 
Even the OSHA standard of 0.75 ppm is protective for 
the symptoms of sensory irritation for the vast major-
ity of individuals from occupational exposures. Because 
Haber’s Law does not apply to formaldehyde-induced 
sensory irritation, the value of 0.1 ppm derived in the 
present review provides an additional margin of pro-
tection  for  a  lifetime  of  24/7  exposures.  Importantly, 
because virtually all of the values listed in Table 1 have 
been  derived  from  controlled  human  exposure  data, 
which include sensitive individuals as well as asthmat-
ics, there is no basis for the application or use of arbi-
trary uncertainty factors to derive lower numbers.
IV.Cancer effects
A.Recent agency reviews of potential formaldehyde 
carcinogenicity
In 2006, the International Agency for Research on Cancer 
(IARC)  elevated  formaldehyde  into  the  category  of  a 
“known” human carcinogen based on a conclusion that 
nasopharyngeal  cancer  (NPC)  was  etiologically  associ-
ated with exposure. This was based primarily on the find-
ings from a large 10-plant study conducted by the National 
Cancer Institute (NCI) involving more than 25,000 work-
ers by Hauptmann et al. (2004). While expressing concern 
about  a  possible  association  with  leukemia  based  on 
epidemiology  data,  IARC  (2006)  also  expressed  skepti-
cism about this association because there was no known 
mechanism to explain how this might occur. Following 
the  most  recent  formaldehyde  meeting,  IARC  (2009) 
concluded that the evidence was sufficient to conclude 
that formaldehyde was also a “known” cause of leuke-
mia.  This  change  in  listing  presumably  was  related  to 
data presented during the meeting that appeared to sup-
port a hypothesized potential mode of action concern-
ing  formaldehyde-induced  leukemia.  Although  IARC’s 
conclusions on leukemia were based substantially on an 
update of the NCI cohort by Beane Freeman et al. (2009), 
they were also supported by a misguided interpretation of 
formaldehyde toxicokinetics and a new study in Chinese 
workers by Zhang et al. (2010) in which it was reported 
that formaldehyde was associated with negative effects on 
blood counts and certain chromosomes in formaldehyde-
exposed workers. Relevant aspects of the key epidemiol-
ogy studies, the Chinese worker study, and mechanistic 
issues for both NPC and leukemia are discussed.
An expert panel of the National Toxicology Program 
(NTP, 2009) concluded that formaldehyde should be listed 
as a “known human carcinogen” in the upcoming 12th 
Report  on  Carcinogens  (RoC)  for  NPC,  sinonasal  can-
cer and myeloid leukemia. It should be noted that IARC 
(2009), based on a review of the same epidemiology data, 
did not conclude that formaldehyde was “known” to cause 
sinonasal cancer, which is even rarer than NPC. The deci-
sion of the NTP expert panel for NPC and myeloid leuke-
mia was based on essentially the same epidemiology data 
as relied upon by IARC, the study by Zhang et al. (2010) 
in Chinese workers, and also included some discussion on 
possible mechanisms of formaldehyde-induced leukemia. 
Because of a number of controversial issues pertaining to 
the proposed listing by NTP, particularly for myeloid leu-
kemia, at the time of this writing, it is not yet known if the 
12th RoC, when finalized, will include this endpoint.
The US Environmental Protection Agency (US EPA, 
2010a) in its draft Integrated Risk Information System 
(IRIS)  assessment  of  formaldehyde  concluded  that 
formaldehyde was etiologically associated with NPC, all 
forms of leukemia (i.e., acute myeloid leukemia [AML], 
chronic myeloid leukemia [CML], acute lymphoid leuke-
mia [ALL], and chronic lymphoid leukemia [CLL]) and 
Hodgkin’s lymphoma. As with the IARC and NTP deci-
sions, this conclusion was also substantially based on the 
NCI cohort data (i.e., Beane Freeman et al., 2009), a study 
by Hauptmann et al. (2009) in embalmers, the Zhang et al. 
(2010) study in Chinese workers, as well as a meta-anal-
ysis of the epidemiology data by Zhang et al. (2009). The 
IRIS review also concluded that neither animal data nor 
mode-of-action data were sufficient to support the epi-
demiology findings for lymphohematopoieitc malignan-
cies. Since all of these studies and issues are discussed in 
this review, other than for a few specific mechanistic and 
risk assessment-related issues, the conclusions of the US 
EPA/IRIS assessment will not be further analyzed. 
The  draft  EPA  formaldehyde  IRIS  assessment  was 
recently reviewed by a committee of the National Research 
Council (NRC) (NAS 2011).  This review concluded that 
the  assessment  failed  to  support  a  causal  association 
between  formaldehyde  and  leukemia  or  other  health 
problems.    The  NRC  committee  concluded  that  EPA’s 
claims  that  formaldehyde  causes  leukemia,  myeloid 
leukemia or related hematopoietic cancers are not sup-
ported in the EPA/IRIS assessment noting “As with the 
respiratory tract cancers, the draft IRIS assessment does 
not provide a clear framework for causal determinations. 
As a result, the conclusions appear to be based on a subjec-
tive view of the overall data, and the absence of a causal 
framework for these cancers is particularly problematic 
given the inconsistencies in the epidemiologic data, the 
weak animal data, and the lack of mechanistic data.”  In 
particular, the committee noted that the epidemiologic Indoor air exposure limit for formaldehyde  691
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data were limited by “…uncertainties of exposure assess-
ment, possible confounding by other pollutants, and reli-
ance on mortality data rather than incidence data….”
Although EPA postulated a mutagenic mode of action 
for leukemia and other hematopoietic cancers, the evi-
dence is very weak, particularly as it relates to low, envi-
ronmental exposures with the NRC committee observing 
that “Although EPA postulated that formaldehyde could 
reach  the  bone  marrow  either  as  methanediol  or  as  a 
byproduct  of  nonenzymatic  reactions  with  glutathione, 
numerous  studies…have  demonstrated  that  systemic 
delivery of formaldehyde is highly unlikely at concentra-
tions below those which overwhelm metabolism accord-
ing to sensitive and selective analytic methods that can 
differentiate  endogenous  from  exogenous  exposures.”   
Additionally, while EPA suggested a mode of action in 
which hematopoietic cells in the nasal epithelium are 
affected by inhaled formaldehyde and return to the bone 
marrow the NRC committee considered this possibility 
and concluded, “As a result, EPA could only speculate that 
circulating hematopoietic stem cells that percolate through 
nasal capillary beds or nasal-associated lymphoid tissues 
may be the target cells for mutations and clastogenic effects 
that  eventually  result  in  lymphohemotopoietic  cancers. 
Experimental evidence of this mechanism is lacking.”
With respect to how data were selected and evaluated 
the committee stated that “EPA should revisit its argu-
ments and include detailed descriptions of the criteria that 
were used to weigh evidence and assess causality.”  The 
report also notes that EPA’s draft assessment “provides 
little discussion about how asthma could be caused or 
exacerbated by formaldehyde exposure” and that a study 
relied  upon  for  development  of  the  asthma  RfC  (i.e., 
Rumchev et al. 2002) “…most likely suffers from misclas-
sification of infection-associated wheezing in young chil-
dren as asthma.”  On the issue of sensory irritation the 
NRC committee was critical of EPA for not including the 
controlled human studies and that “…EPA set aside the 
chamber and occupational studies too soon in the process.” 
As for the studies selected and relied upon (the study 
by Ritchie and Lehnen 1987 was rejected as invalid and 
“EPA should not have used it”) for establishing the RfC for 
sensory irritation the committed observed that “…study 
details…and study weaknesses (such as the limitations of 
the exposure assessments performed in the residential and 
occupational epidemiologic studies) were not thoroughly 
presented or critically evaluated in a consistent manner by 
EPA.”  While the committee agreed that respiratory tract 
cancers were plausible since this is the first site of contact 
with inhaled formaldehyde they concluded that, “…the 
draft IRIS assessment does not present a clear framework 
for causal determinations and presents several conflicting 
statements that need to be resolved regarding a causal 
association between formaldehyde and respiratory tract 
cancers.”   Finally, the committee was supportive of the 
biologically based dose response (BBRD) model devel-
oped for risk assessment of formaldehyde induced nasal 
tumors and critical of EPA’s development “of alternative 
models  that  yielded  the  most  extreme  deviations  from 
the Conolly et al. (2004) low-dose extrapolations”  which 
“produced unrealistically high added risks for humans at 
concentrations that have been observed in the environ-
ment or occupationally exposed workers (100% incidence 
at concentrations as low as about 0.1-1 ppm).”
B.Nasopharyngeal cancer (NPC)
1.Animal data
Rat  studies  showing  nasal  tumors  following  chronic 
exposure  to  sufficient  concentrations  of  formaldehyde 
provide support for the hypothetical possibility for the 
epidemiological findings of NPC (e.g., Kerns et al., 1983a, 
b; Tobe et al., 1989; Sellakumar et al., 1985; Feron et al., 
1989). For example, in what is generally considered to be 
the definitive study of formaldehyde-induced nasal can-
cer, rats were exposed by inhalation to formaldehyde at 
concentrations of 0, 0.7, 2, 6, 10, and 15 ppm for 2 years 
(Monticello et al., 1990). Nasal tumors occurred only at 
formaldehyde concentrations of 6 (1%), 10 (22%), and 
15 (45%) ppm. Those concentrations are far in excess of 
tolerable irritant levels for humans and are sufficient to 
cause cytotoxicity of the rat nasal epithelium, with sub-
sequent regenerative proliferation observed. Exposures 
at  6 ppm  and  above  for  a  sufficient  duration  produce 
substantial  toxicogenomic  and  histopathological  der-
rangements directly associated with the development of 
nasal tumors.
2.Mutagenicity data
With  respect  to  formaldehyde-induced  nasal  tumors 
in rats, a key issue is whether early mutations play an 
etiologic role in this process. Although in vitro studies 
demonstrate that formaldehyde is mutagenic in a num-
ber of test systems (ATSDR, 1999; IARC, 2006), none of 
these  studies  have  been  conducted  in  whole  tissues 
in the presence of formaldehyde dehydrogenase and 
other metabolizing enzymes. The lack of such metabolic 
capability  suggests  that  in  vitro  studies  are  unlikely 
to mimic potential effects in rodents or humans with 
background endogenous formaldehyde concentrations 
and substantial detoxification capacity. Consequently, 
without the ability to metabolize formaldehyde, in vitro 
mutagenicity data may not provide an adequate basis 
for determining what role, if any, mutations might have 
played in the development of formaldehyde-induced 
rat nasal tumors. It is clearly established that sufficient 
doses of formaldehyde cause substantial cytotoxicity 
in nasal epithelial cells, double-stranded DNA breaks, 
and  various  DNA  adducts  that  in  sufficient  quantity 
can lead to mutations and transformation. Unresolved, 
however, is whether dose-dependent, sub-cytotoxicity–
induced mutations play an early etiologic role in tumor 
formation or appear only later in the tumorigenic pro-
cess subsequent to frank cytotoxicity and regenerative 
proliferation. Consequently, for formaldehyde-induced 
nasal tumors in rats, it seems reasonable to also assume 
that if early mutations play an etiological role in the 692  R. Golden
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process, DNA repair and associated genes in nasal tis-
sues would be activated at all exposure doses, but this 
has not been reported.
Toxicogenomic data from 21-day (Andersen et al., 
2008)  and  13-week  (Andersen  et  al.,  2010)  expo-
sure studies at the same inhalation doses used in the 
chronic cancer bioassays showed no changes in DNA 
repair  genes  at  formaldehyde  doses  of  <2 ppm.  A 
  primary conclusion in the Andersen et al. (2008) paper 
is  that  genomic  changes,  including  those  suggestive 
of  mutagenic  effects,  did  not  temporally  precede  or 
occur at lower doses than phenotypic changes in the 
tissue. These findings are in contrast to several stud-
ies by Hester et al. (2003, 2005) that report changes in 
DNA repair genes following nasal instillation of a single 
dose  of  formaldehyde  (400 mM).  This  instilled  dose 
altered more than 3 times as many genes of varying 
types as compared to the 15 ppm inhalation exposure 
(Andersen et al., 2008),  suggesting  that  the  reported 
finding of effects on DNA repair genes from single high-
dose nasal installation studies have limited relevance 
with respect to demonstrating a role of early mutations 
in the development of nasal tumors via inhalation.
Another  recent  in  vivo  study  suggests  that  early 
formaldehyde-induced p53 mutation is unlikely to play 
a role in tumorigenesis. In this study by Meng et al. 
(2010), F344 rats were exposed to formaldehyde at con-
centrations of 0, 0.7, 2, 6, 10, or 15 ppm for 13 weeks, 
with nasal epithelial tissues examined for the presence 
of one of the p53  mutations  that  had  been  detected 
in the squamous cell carcinomas induced by chronic 
formaldehyde  exposure  in  a  2-year  bioassay  (Recio 
et al., 1992). In addition, because cytotoxicity-induced 
regenerative cell proliferation is considered a key event 
in  formaldehyde-induced  carcinogenesis  (McGregor 
et al., 2006), nasal mucosal cell proliferation was moni-
tored  by  bromodeoxyuridine  (BrdU)  incorporation. 
Although  there  was  a  low  spontaneous  background 
level of p53 mutation, this level was not increased by 
formaldehyde exposure, even at tumorigenic doses. In 
contrast, BrdU labeling showed the percentage of pro-
liferating cells increased with increasing formaldehyde 
dose and was significantly increased at 10 and 15 ppm 
compared to controls. These data showing no increase 
in p53 mutation, but significant changes in regenerative 
cell proliferation, following 13 weeks of formaldehyde 
exposure at tumorigenic doses suggest that p53 muta-
tion is a late event not involved in the carcinogenic MOA 
in  formaldehyde-induced  carcinogenesis  and  occurs 
only  after  other  key  events  (e.g.,  DNA-protein  cross-
links,  cytotoxicity,  cell  proliferation)  have  occurred. 
Although these results do not rule out the possibility 
that  other  earlier  mutations  might  play  an  etiologic 
role in tumor formation, it is reasonable to expect that 
such mutations would trigger responses in DNA repair 
mechanisms if they were present. As shown in the toxi-
cogenomic study by Andersen et al. (2010), the lack of 
any up-regulation of DNA repair genes at the two lowest 
formaldehyde concentrations (i.e., 0.7 or 2 ppm) sug-
gests that this pathway is not activated at any exposure 
duration examined, i.e., 1, 4, or 13 weeks.
3.Mode of action for nasal tumors
The  key  finding  in  rat  studies  is  that  the  sequence  of 
events leading to nasal tumor formation occurs only at 
formaldehyde doses (i.e., ≥6 ppm) sufficient to produce 
frank  cytotoxicity  and  regenerative  proliferation.  This 
general mode of action has been critically evaluated by 
McGregor  et  al.  (2006)  following  US  EPA’s  Guidelines 
for Cancer Risk Assessment (US EPA, 2005) in conjunc-
tion with the methods and approaches established by 
the  International  Life  Sciences/Risk  Sciences  Institute 
(ILSI-RSI) and International Program on Chemical Safety 
(IPCS) (i.e., Cohen et al., 2003, 2004; Meek et al., 2003; 
Boobis et al., 2006). Using this methodology, McGregor 
et al. (2006) determined that all of the mode-of-action 
elements (i.e., cytotoxicity, cell proliferation, and DNA 
effects)  for  formaldehyde-induced  nasal  tumors  are 
highly non-linear and do not occur unless a particular 
threshold dose (6 ppm) has been exceeded. The authors 
concluded, “From a weight-of-evidence point of view, the 
hypothesized mode of action for formaldehyde-induced 
nasal tumors satisfies several criteria, including consis-
tency, concordance of dose-response relationships across 
all key events, and biological plausibility and coherence 
of the database. Given the extensive experimental data 
that addresses and is consistent with the proposed mode 
of action of formaldehyde in the induction of tumors in the 
nasal cavity, a high degree of confidence may be ascribed 
to it.”
4.Biologically based dose-response (BBDR) model
The extensive database on the MOA for formaldehyde-
induced nasal tumors in rodents, in conjunction with the 
established differences between rodents and humans in 
upper respiratory tract physiology, has been used as the 
basis for the development of a biologically based dose-
response (BBDR) model (Conolly et al., 2003, 2004). Use 
of this model greatly minimizes the necessity for relying 
on many of the default assumptions that have become an 
integral part of how potential cancer risks from chemical 
exposures are assessed in a regulatory context.
To compare potential effects in rats, monkeys, and 
humans,  models  were  developed  using  anatomically 
precise computer reconstructions of the nasal passages 
that simulate the complex patterns of airflow and tissue 
uptake of inhaled formaldehyde. Using computational 
fluid dynamics, the specific doses of inhaled formalde-
hyde that can reach various regions of the respiratory 
tract in all three species was predicted and compared. 
For rats and monkeys, those predictions are consistent 
with the sites of formaldehyde-induced lesions observed 
experimentally. In other words, the model can predict 
where tumors will or will not occur. The combination 
of experimental data and modeled predictions show a 
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in  tissues  of  the  nose  and  resulting  nasal  tumors  in 
rodents.
As predicted by the cross-species modeling and the 
flux of formaldehyde into the nasal mucosa leading to the 
formation of DNA-protein cross-links (DPX), in conjunc-
tion with the extensive rodent and primate data on cyto-
lethality/regenerative cellular proliferation (CRCP), the 
model was used to predict potential upper respiratory 
tract cancer risks in humans. The model was calibrated 
against respiratory tract cancer incidence data for non-
smokers, smokers, and a mixed population of nonsmok-
ers and smokers, respectively. Based on the CRCP rat 
data, additional risks of respiratory tract cancer were pre-
dicted to be negative for formaldehyde exposures up to 
about 1 ppm for all three cases. The implications of the rat 
nasal tumor data for humans showed that upper respira-
tory tract cancer associated with inhaled formaldehyde 
are de minimis (i.e., 10−6 or less) at relevant exposure lev-
els and that preventing non-cancer effects (i.e., sensory 
irritation) would be sufficient to protect from potential 
carcinogenic effects as well.
Some (e.g., Subramaniam et al., 2008; Crump et al., 
2008, 2010; Cal EPA, 2005) have taken issue with certain 
details of the BBDR model (e.g., kinetics of the initiated 
precursor cell) to derive alternative predictions of greater 
risks at lower doses of formaldehyde than those predicted 
by Conolly et al. (2004). However, the wide acceptance 
of the basis for and the predictions from this model by 
numerous regulatory and/or authoritative organizations 
attests to its applicability and utility (e.g., BfR, 2006; US 
EPA,  2006a,  2006b;  Health  Canada,  2005;  NAS,  2007; 
NICNAS, 2006; OECD, 2002; WHO, 2010).
A recent publication that questions the utility of all 
BBDR models due to their inherent uncertainty focuses 
particular attention on the model developed by Connolly 
et  al.  (2004)  for  formaldehyde.  This  critique  (Crump 
et  al.,  2010)  raises  the  issue  that  “…small  changes  to 
assumptions  regarding  the  mathematical  form  of  the 
dose  response  assumed  for  the  division  rates  or  death 
rates  of  initiated  cells—changes  too  small  to  meaning-
fully degrade the correspondence of the model with the 
underlying  data—increased  estimates  of  cancer  risk 
from formaldehyde by several orders of magnitude over 
those considered to be conservative in the original work.” 
Although it is recognized that initiated cells represent 
a small minority of cells in the nasal epithelial tissues, 
they are still cells (but not cancer cells) and therefore 
should behave (unless shown otherwise) like cells at low, 
non-tumorigenic levels of formaldehyde exposure (i.e., 
<6 ppm). However, some consideration must be afforded 
the  vast  body  of  histopathological,  cytotoxicity,  cell 
proliferation,  and  toxicogenomic  data  extended  up  to 
90 days, all demonstrating clear dose-dependent transi-
tions in the responses of nasal epithelial tissues to graded 
formaldehyde exposures. The lack of any significant toxi-
cogenomic responses in the nasal epithelium at form-
aldehyde concentrations of 0.7 ppm following 13 weeks 
of exposure as reported by Andersen et al. (2010) are 
difficult to reconcile with assumptions of formaldehyde-
induced cellular events related to tumor formation.
In addition, modeled predictions must also be con-
sistent  with  the  abundant  epidemiology  findings.  For 
example, as part of the sensitivity analysis of the BBDR 
model, Crump et al. (2008) derived an alternative version 
of the model that predicts unrealistically high lifetime 
cancer  risk.  By  making  adjustments  to  certain  model 
parameters,  the  model  predicts  lifetime  cancer  risks 
from  formaldehyde  exposure  ranging  from  0.01  up  to 
essentially 1 (i.e., everyone gets cancer) for exposures 
of approximately 0.1 ppm. Not only is this inconsistent 
with the epidemiological data (i.e., no cases of NPC are 
reported by Hauptmann et al. [2003] at the lowest peak 
exposure, >0 to <2 ppm, and lack of any cases of NPC 
in 14,000 chemical workers or 11,000 garment workers 
occupationally  exposed  to  formaldehyde  [i.e.,  Coggin 
et al., 2003; Pinkerton et al., 2004]), such risks are also not 
consistent  with  numerous  rodent  tumor  studies  dem-
onstrating that nasal tumors are not produced following 
2  years  exposure  to  ≤2 ppm  formaldehyde.  Although 
Crump et al. (2008) noted that they “…have not examined 
whether the upper end of the range of additional risk is 
consistent with existing human epidemiology because that 
is not germane to the point we are making,” this assertion 
makes little biological or practical sense. When a model 
predicts risks greater than those empirically observed in 
epidemiology  and/or  animal  studies  (now  augmented 
by considerable toxicogenomic data), it is questionable 
whether such models can play a useful role in informing 
biologically  realistic  risk  assessments.  This  is  particu-
larly the case since the general MOA for formaldehyde-
induced nasal tumors as described by McGregor et al. 
(2006) and now augmented by considerably more data 
(e.g., Andersen et al., 2008, 2010) has not been challenged 
in the literature.
A recent study by Lu et al. (2010b) in F344 rats appears 
to add further support to the basic concepts of the BBDR 
model at the molecular level. In this study, both endoge-
nous and exogenous N2-hydroxymethyl-dG (dG) adducts 
in nasal DNA of rats exposed to 0.7, 2, 5.8, 9.1, or 15.2 ppm 
13CD2-formaldehyde for 6 hours were quantified. The data 
clearly  demonstrated  that  exogenous  formaldehyde-
DNA adducts form in a highly non-linear fashion, with a 
21.7-fold increase in exposure (i.e., 0.7 to 15.2 ppm) caus-
ing a 286-fold increase in exogenous adducts. The ratio 
of exogenous to endogenous DNA adducts showed that 
endogenous DNA adducts dominated at low exposures, 
comprising more than 99% of all adducts. Endogenous 
DNA adducts did not demonstrate a similar effect, with 
levels essentially identical at all exposure concentrations, 
indicating no effect from exogenous exposures. As noted 
by Lu et al. (2010b), “…if the number of exogenous adducts 
formed by a single 6 hour exposure to 0.7 ppm [13CD2]-
formaldehyde (0.039 ± 0.19 adducts/107 dG) is compared 
with the overall average number of endogenous formalde-
hyde adducts (4.7 ± 1.8 adducts/107 dG), that means that 
only 83 out of 10,000 formaldehyde adducts arise from the 694  R. Golden
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0.7 ppm exposure for 6 hours.” If formaldehyde-induced 
nasal tumors in rodents were formed in a non-threshold 
manner as a consequence of early mutations, one would 
not expect the results as reported by Lu et al. (1010b). 
Instead, it is difficult to envision a scenario in which the 
83 exogenously formed formaldehyde DNA dG adducts 
(which  are  identical  to  those  formed  endogenously) 
would  drive  nasal  tumorigenesis,  whereas  the  10,000 
endogenous dG adducts play no role in the process.
The National Research Council (NAS, 2007) endorsed 
the BBDR risk assessment approach when it developed 
exposure guidance levels for formaldehyde in the indoor 
air of submarines (assuming exposure 24 hours per day 
for several weeks at a time), concluding that this meth-
odology “ …more accurately reflects the scientific weight of 
the evidence for formaldehyde than does EPA’s approach.” 
Similarly, in its latest assessment of formaldehyde, the 
Australian  Department  of  Health  and  Aging  (NICNAS, 
2006)  stated  that  the  model  is  a  “…biologically-based, 
dose-response model that incorporates mechanistic data…
It  is  considered  a  more  reliable  estimate  of  cancer  risk 
than the use of standard default assumptions, due to the 
incorporation of all available biological data.” Finally, in 
its review of formaldehyde under its Existing Chemicals 
program,  the  Organisation  for  Economic  Co-operation 
and  Development  (OECD,  2002)  issued  a  Screening 
Information  Data  Set  (SIDS)  Initial  Assessment  Report 
that stated, “The increasing severity of damage in higher 
concentrations is a function of the concentration. Another 
way of expressing this result is that formaldehyde toxicity 
is independent of the total dose (c x t) but that it depends 
on the dose rate [(c × t)/t = c] or concentration. This can be 
explained by saturation of detoxification pathways for form-
aldehyde at high concentrations. Strong non-linearity in 
the induction of cell proliferation, DNA-protein-crosslinks, 
cytotoxic  effects  and  carcinogenicity  are  observed  (CIIT, 
1999). The observed non-linearity is likely attributable to a 
large extent to mechanisms present in biological systems to 
deal with low levels of formaldehyde…Taking into account 
the extensive information on its mode of action, formal-
dehyde is not likely to be a potent carcinogen to humans 
under low exposure conditions” (OECD, 2002).
The  weight  of  the  evidence  calls  into  question  the 
default that serves as the basis for US EPA’s current can-
cer 10−6 risk potency value for formaldehyde (0.08 ppb), 
which assumes there is no threshold for nasal tumorigen-
esis and thus no safe level of exposure (IRIS, 1991). The 
most recent US EPA/IRIS (2010a) evaluation of formalde-
hyde has lowered the 10−6 risk value to 0.008 ppb (8 ppt). 
According to US EPA’s cancer risk assessment guidelines, 
the default assumption is meant to be used when there 
are no data establishing a mode of action inconsistent 
with low-dose linearity or the absence of a threshold (US 
EPA, 2005). The amount and consistency of the data that 
have been developed characterizing the MOA for form-
aldehyde-induced nasal tumors clearly support depart-
ing from a no-threshold default and applying a mode of 
action–based risk value.
Additional new data further challenge the regulatory 
presumption of no threshold for formaldehyde-induced 
nasal tumors in rodents and derivation of cancer risk val-
ues based on extrapolations from either animal or epi-
demiology data. A recent study by Moeller et al. (2010) 
determined the presence of endogenous and exogenous 
adducts in DNA from nasal mucosa and bone marrow 
of cynomolgus macaques exposed to 1.9 and 6.1 ppm of 
13CD2-formaldehyde for 6 hours a day for 2 consecutive 
days.  Both  exogenous  and  endogenous  adducts  were 
readily detected and quantified in the nasal tissues of 
both  exposure  groups,  with  an  exposure-dependent 
increase in exogenous adducts observed. In the nasal tis-
sue DNA, exogenous formaldehyde-DNA adducts were 
present at 0.26 ± 0.04 and 0.41 ± 0.41 adducts/107 dG (N2-
hydroxymethyl-dG) following the 1.9 and 6.1 ppm expo-
sures, respectively, whereas endogenous adducts were 
present in the nasal DNA of all animals, with an average 
of 2.24 ± 0.50 adducts/107 dG. It is unlikely a mechanism 
would  exist  in  which  exogenous  formaldehyde-DNA 
adducts  formed  following  1.9  or  6.1 ppm  exposures, 
which  contribute  less  than  the  standard  deviation  of 
identical  endogenous  formaldehyde-DNA  adducts, 
could drive the biology that leads to nasal carcinogenesis 
in a non-threshold manner.
Finally, the 10−6 cancer risk value of 0.008 ppb (8 ppt) 
as derived in the most recent US EPA/IRIS (2010a) form-
aldehyde assessment is well below the upper end of con-
centrations of formaldehyde measured in human breath 
(i.e., 1.7 ppb) or associated with air concentrations in 
rural locations (i.e., 9 ppb), another fact that challenges 
a presumption that there is no safe level of exposure for 
formaldehyde. Consequently, it can be concluded that a 
formaldehyde vapor concentration of 0.1 ppm, which is 
protective for sensory irritation of the eyes, will also be 
far below the level that would likely initiate the sequence 
of events leading to nasal cancer.
5.Toxicogenomic data
The scientific underpinnings of the BBDR model is further 
supported by toxicogenomic data that help illuminate 
some of the key biological events involved in formalde-
hyde-induced nasal tumors in rodents. Andersen et al. 
(2008)  exposed  rats  to  the  same  doses  (0,  0.7,  2,  and 
6 ppm) of formaldehyde that had been used to character-
ize the nasal tumorigenicity threshold in the chronic bio-
assay (Monticello et al., 1996), 5 days/week for 3 weeks, 
with interim sacrifices. Nasal epithelium was taken from 
the same locations at which tumors had developed in 
rats exposed to 10 and 15 ppm in the chronic bioassay 
and evaluated by histopathology and microarray analy-
ses. Gene expression fold changes >1.5 or <1.5 and a false 
discovery rate–corrected p value <.05 were the criteria 
for determining significance. No genes were significantly 
altered at 0.7 ppm at any time point, indicating a clear 
threshold for formaldehyde-induced effects. On day 5, 
15 genes were significantly changed at 2 ppm and many 
more genes were changed at 6 ppm. Most importantly, Indoor air exposure limit for formaldehyde  695
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by day 15 no genes were significantly changed at 2 ppm, 
thereby demonstrating that even at this concentration, 
nasal cells initially show some minor changes, but after a 
few days the tissues rapidly adapt and return to a pattern 
of gene expression identical to 0 and 0.7 ppm. This study 
provides empirical support that formaldehyde exposure 
at concentrations less than 2 ppm are incapable of caus-
ing tissue damage that could lead to tumor formation.
The genomic findings of Andersen et al. (2008) pro-
vide  parallel  mechanistic  information  consistent  with 
histopathological  findings  at  the  formaldehyde  doses 
associated  with  transient  and  more  serious  effects  on 
nasal tissues. Most of the genes affected with maximal 
responses at 2 ppm are thus associated with cell mem-
brane and architecture, or otherwise, external aspects of 
the cell. None of these genes were statistically affected at 
the lower inhaled concentrations at day 15. The most sen-
sitive responses (i.e., those apparent at the lowest con-
centrations) are consistent with actions of formaldehyde 
on the periphery of the cell or at the plasma membrane 
(i.e.,  adaptive  responses).  Conversely,  gene  responses 
associated with cellular stress (e.g., up-regulation of cel-
lular antioxidants) were altered only at the higher inhaled 
concentrations when antioxidant control appeared to be 
overwhelmed, leading to cellular toxicity and activation 
of inflammatory pathways. At even higher concentrations 
(≥10 ppm), activation of genes involved in apoptosis lead 
to programmed cell death pathways.
Andersen et al. (2010) reports the results of a 90-day 
inhalation toxicogenomic study in F344 rats using the same 
formaldehyde doses used in the Monticello et al. (1996) 
chronic bioassay (0, 0.7, 2.0, 6.0, 10, and 15 ppm). Tissues 
were collected for genomic analysis following 5, 20, and 
91 days of exposure, with RNA isolated from epithelium in 
the high tumor region in the nose. Significant fold changes 
in gene expression were the same as in the previous study. 
As  was  expected,  based  on  other  formaldehyde-related 
effects, patterns of gene expression varied with concen-
tration and duration. Seven genes were combined into a 
grouping designated as sensitive response genes (SRGs) 
for benchmark dose (BMD) evaluation. At 0.7 ppm, little 
change was observed, since this was well within the meta-
bolic capability to maintain homeostasis of formaldehyde 
acetal  (i.e.,  methanediol)  and  glutathione.  However,  at 
2 ppm, SRGs associated with cellular stress, thiol trans-
port/reduction, inflammation, and cell proliferation were 
up-regulated at all exposure durations. These low-expo-
sure gene responses with BMDs of approximately 1 ppm 
at each exposure duration “…likely represent extracellular 
responses  to  irritancy,  reduction  of  extracellular/plasma 
membrane anti-oxidant thiols, and associated responses to 
maintain reduced thiols and export GSH to the extracellular 
spaces. BMDs for the SRG group of genes are close to known 
irritancy levels of formaldehyde and were similar over all 
three exposure durations” (Andersen et al., 2010). The tis-
sue responses at 2 ppm were restricted to mild squamous 
metaplasia  that  was  more  intense  at  1  week  and  then 
tended to decrease. At 6 ppm, gene expression changes at 
13 weeks showed enrichment of pathways involved in cell 
cycle, DNA repair, and apoptosis processes consistent with 
a conclusion that DNA replication, stress, enhanced prolif-
eration, and metaplasia are associated with formaldehyde 
carcinogenesis at 6 ppm and above. A major conclusion of 
this study is that dose dependencies in the mode of action, 
the presence of high physiological levels of formaldehyde 
acetal (i.e., methanediol), and non-linear formaldehyde 
acetal/GSH tissue kinetics indicate that inhaled formal-
dehyde concentrations below irritant levels (i.e., ~1 ppm) 
would not increase cancer risks of inhaled formaldehyde 
(Andersen et al., 2010).
6.Human data
IARC (2006, 2009), NTP (2009), and US EPA (2010a) have 
concluded  that  formaldehyde  is  a  known  human  car-
cinogen for NPC, based largely, but not exclusively, on 
the results of a study conducted by the National Cancer 
Institute  (NCI)  that  reported  increased  mortality  from 
NPC  in  formaldehyde-exposed  workers  (Hauptmann 
et al., 2004). The scientific support for this conclusion, 
however,  can  be  questioned  if  a  thorough  review  of 
the  remaining  epidemiology  and  mechanistic  data  is 
included. For example, in another study of more than 
14,000 British chemical workers with elevated formalde-
hyde exposures (including some 4000 workers with expo-
sures >2 ppm), there was no evidence of elevated NPC. 
The authors of this study (which involved formaldehyde 
exposures in excess of the NCI cohort) concluded that the 
evidence  for  formaldehyde  carcinogenicity  in  humans 
was unconvincing (Coggon et al., 2003). In a study con-
ducted by the National Institute of Occupational Safety 
and Health (NIOSH) of more than 11,000 garment work-
ers occupationally exposed to formaldehyde, no cases 
of NPC were observed (Pinkerton et al., 2004). Another 
study from NCI conducted by Hauptmann et al. (2009) in 
embalmers, which mainly addressed the issue of myel-
oid leukemia, reported no excess of NPC in the cohort. 
Finally, subsequent to the IARC (2006) decision, several 
comprehensive  quantitative  evaluations  of  the  epide-
miological literature have concluded that the weight of 
evidence does not support a causal association between 
formaldehyde  exposure  and  NPC  (Bosetti  et  al.,  2008; 
Duhayon et al., 2008). Moreover, several meta-analyses 
have addressed the epidemiological data pertaining to 
both NPC and leukemia and concluded that there are 
insufficient data to associate formaldehyde with these 
diseases. These studies are reviewed below.
The  study  conducted  by  NCI  evaluated  a  group  of 
more than 25,000 industrial workers at 10 US industrial 
plants where formaldehyde was either produced or used 
in the production of other products (Hauptmann et al., 
2004). There were a total of nine deaths from NPC, with 
five of the cases coming from only one plant (Plant 1) 
and the remaining four cases randomly occurring in the 
other nine plants. Such an atypical pattern is unusual if 
formaldehyde were actually the cause of NPC. For NPC, 
in the total cohort the standardized mortality rate (SMR) 696  R. Golden
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was 2.10 (95% CI 1.05–4.21), with significant relative risks 
(RRs) associated with peak (ptrend <.001) and cumulative 
ptrend = .025) exposures, respectively.
The  highest  peak  exposure  metric  as  used  by 
Hauptmann et al. (2004) is unconventional and it is dif-
ficult to interpret exposure history based on this metric, 
since it is not based on measured exposures. For example, 
in  the  exposure-response  analysis  of  the  highest  peak 
exposure, this metric is treated as a time-dependent vari-
able. That is, as workers experience different peak expo-
sures over their working career, they are allocated to the 
highest peak exposure category experienced. Thus, it is 
possible for a worker to be exposed to their highest peak 
during their first day of exposure, receive very little expo-
sure the remainder of their work history, then die and be 
assigned to the category associated with this single, early 
peak.  Conversely,  a  worker  could  have  received  very 
little exposure up to a point close in time to their death 
date, then experience a similar high peak. This worker 
would  end  up  in  the  same  peak  category  as  the  first 
example. Many other feasible exposure scenarios could 
be described that would result in workers being assigned 
to  the  same  category  under  very  different  patterns  of 
exposure  (Marsh  et  al.,  2004).  Consequently,  defining 
the peak exposure metric, as done by Hauptmann et al. 
(2004), potentially would place groups with very differ-
ent exposures into similar categories. An update of the 
Hauptmann et al. (2004) study has been completed but 
the results have yet to be published.
Although the RR for NPC reported by Hauptmann 
et al. (2004) was significant, a prior independent analy-
sis of Plant 1 by Marsh et al. (2002) had already chal-
lenged  a  formaldehyde-NPC  association  by  showing 
that (1) four of the five workers with NPC had worked 
<1  year;  (2)  five  had  worked  <5  years;  and  (3)  their 
average intensity of exposure was low, with a median 
concentration  of  0.14 ppm.  As  concluded  by  Marsh 
et al. (2002), “Overall, the pattern of findings suggests 
that the large, persistent nasopharngeal and other PC 
[pharyngeal  cancers]  excesses  observed  among  the 
Wallingford  [Plant  #1]  workforce  are  not  associated 
with formaldehyde exposure, and may reflect the influ-
ence  of  nonoccupational  risk  factors  or  occupational 
risk  factors  associated  with  employment  outside  the 
Wallingford plant.” Additional detailed analysis of the 
NCI data by Marsh et al. (2007) provides further evi-
dence that the NPC reported in this cohort may not be 
related  etiologically  to  formaldehyde  exposure.  That 
analysis involved a careful investigation of the previous 
employment history of the individuals from Plant 1 who 
died from NPC. Four of the five NPC cases at this plant 
had previously worked in silver-smithing occupations 
involving substantial exposures to potential risk factors 
for upper respiratory system cancers, including sulfuric 
acid mists and metal dusts. According to the authors, 
“The  results  of  our  nested  case–control  study  suggest 
that the large nasopharyngeal cancer mortality excess 
in [plant #1] may not be due to formaldehyde exposure, 
but rather reflects the influence of external employment 
in  the  ferrous  and  nonferrous  metal  industries  of  the 
local  area  that  entailed  possible  exposures  to  several 
suspected risk factors for upper respiratory system can-
cer (e.g., sulfuric acid mists, mineral acid, metal dusts 
and heat). Our findings may also help to explain why 
the  associations  with  formaldehyde  and  nasopharyn-
geal cancer reported in the, 1994 update of the 10-plant 
NCI  formaldehyde  cohort  study  were  unique  to  plant 
#1.”  Marsh  et  al.  (2007)  provide  numerous  citations 
to the literature documenting the causal relationships 
between NPC and exposures to acid mists and metal 
dusts. If the five cases of NPC with previous confound-
ing exposures are excluded from the Hauptmann et al. 
(2004) study, there would appear to be no significant 
association between formaldehyde exposure and NPC 
(Marsh  et  al.,  2007)  (see  discussion  of  the  Bachand 
et al. [2010] meta-analysis).
Nonetheless, NTP (2009) concluded that formalde-
hyde was a known human carcinogen for NPC, with 
the primary emphasis placed on the NCI study as the 
basis for this conclusion, i.e., “The only cohort study that 
is individually informative for evaluating the potential 
carcinogenicity of formaldehyde is the National Cancer 
Institute’s  (NCI)  cohort  of  workers  in  formaldehyde 
industries,  for  which  NPC  results  were  presented  in 
Hauptmann et al. (2004).” Consequently, it was surpris-
ing that NTP (2009) accepted on face value the findings 
reported  by  Hauptmann  et  al.  (2004)  while  ignoring 
completely the Marsh et al. (2002, 2007) publications. 
Instead, NTP (2009) referred to a previous reanalysis by 
Marsh et al. (2005) to conclude that, “The comparatively 
high number of cases in Plant 1 may be due to potential 
confounding  from  an  unidentified  agent”  [emphasis 
added]. Instead of acknowledging the critical and rel-
evant analysis of Plant 1 as summarized above that the 
“unidentified agent” had in fact been identified as previ-
ous exposures to known risk factors for NPC (i.e., Marsh 
et  al.,  2007),  NTP  (2009)  constructed  another  expla-
nation  without  accounting  for  the  well-documented 
peculiarities of the Plant 1 findings perhaps to justify 
continued  inclusion  of  the  Plant  1  population  in  the 
25,000 person NCI cohort. As noted in the NTP (2009) 
report, “An alternative explanation for the high number 
of NPC cases observed in Plant 1 is that this plant included 
a large proportion of the highly-exposed persons in the 
NCI study…Plant 1 comprised 17% of the cohort study 
population and, 20% of all deaths, and had the second-
highest median concentration of formaldehyde (1.1 ppm; 
second only to Plant 2 which had a median concentration 
of 3.3 ppm, but only comprised 3% of the study popula-
tion and 3% of all deaths). If formaldehyde causes NPC, 
then we would expect to see a high proportion of cases 
occurring in Plant 1.” This explanation ignores known 
facts concerning worker exposure history in Plant 1. For 
example, the fact that four of the NPC cases in the NCI 
cohort had worked <1 year at Plant 1 and all five had 
worked <5 years, an exposure scenario not compatible Indoor air exposure limit for formaldehyde  697
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with  a  causal  association  of  NPC  and  formaldehyde, 
where  time,  in  addition  to  concentration,  appears  to 
play a substantial contributory role, unlike for sensory 
irritation.
7.Meta-analysis of NPC data
A comprehensive meta-analysis of all relevant epidemi-
ology data on formaldehyde and NPC was conducted by 
Bachand et al. (2010), which assessed study results and 
confounder information from cohort, case-control, and 
proportionate mortality (PMR) studies. In support of the 
suggestion that the association between formaldehyde 
exposure and NPC would not appear to be significant if 
the Plant 1 findings are excluded, the authors explicitly 
observed that “Summary estimates for nasopharyngeal 
cancers were not elevated, after excluding a single plant 
with an unexplained cluster of nasopharyngeal cancers 
(cohort RR = 0.72, 95% CI: 0.40, 1.28). The summary esti-
mate was increased for case-control studies overall, but 
the summary OR for smoking-adjusted studies was 1.10 
(95% CI: 0.80, 1.50).” Bachand et al. (2010) also acknowl-
edged the Marsh et al. (2007) analysis which suggested 
that a short duration of employment of the workers at 
Plant 1 with previous employment in other occupations 
was compatible with a strong likelihood of exposure to 
other risk factors for NPC.
C.Leukemia
1.Animal data
a.Inhalation  studies  A  large  study  was  conducted 
by Battelle (i.e., Kerns et al., 1983) in which male and 
female Fischer 344 rats and B6C3F1 mice were exposed 
to 0, 2, 6, and 15 ppm formaldehyde for 6 hours a day, 5 
days a week for 24 months, followed by up to 6 months 
of non-exposure. Gross pathology was conducted on all 
animals that died or were sacrificed, with histopathology 
performed on 50 tissue samples per animal in the con-
trol and highly exposed groups. Survival was affected at 
the higher doses and the only significant formaldehyde-
induced lesions were in the nasal cavity and proximal 
trachea in both species. The tissue slides from the Kerns 
et al. (1983) study were reevaluated by Woutersen (2007) 
and a recent IARC working group (Baan et al., 2009) to 
assess the occurrence of leukemia. There were no asso-
ciations between formaldehyde exposure and leukemia 
in male or female rats at the end of the 24-month expo-
sure period or in the 6-month recovery period based on a 
mortality-adjusted trend test to account for early deaths 
due to nasal cancer. Although the incidence of leukemia 
in females exposed to 15 ppm was increased compared to 
controls based on a survival-adjusted analysis, it should 
be noted that the type of leukemia seen in F344 rats (i.e., 
mononuclear cell leukemia, MCL) is a common, sponta-
neously occurring neoplasm in the F344 rat strain with 
no  human  counterpart  disease.  Several  reviews  have 
concluded that MCL is not predictive for human cancer 
risk (Ishmael and Dugard, 2006; Caldwell, 1999; Thomas 
et al., 2007).
In another study, Sprague-Dawley rats were exposed 
to 15 ppm formaldehyde for 6 hours/day, 5 days/week 
for life (Sellakumar et al., 1985). Complete necropsy was 
conducted  on  each  animal  with  histolopathology  per-
formed on the lung, trachea, larynx, liver, kidney, testes, 
and  other  organs  where  gross  pathology  was  present. 
Although there was increased mortality in the formalde-
hyde group compared with the controls, no leukemia was 
reported.
In a 28-month study, male F344 rats were exposed 
to formaldehyde for 6 hours a day, 5 days a week at 0, 
0.3, 2, and 15 ppm (Kamata et al., 1997). The number of 
rats alive at 18 months or later and therefore available 
for  histopathology  was  19,  22,  17,  and  7,  respectively. 
Hematological, biochemical, and pathological examina-
tions were performed. Increased mortality was observed 
at the highest exposure concentration. No microscopic 
lesions were attributed to formaldehyde exposure except 
those in the nasal cavity. In addition, there were no expo-
sure-related abnormal hematological findings.
Overall,  inhalation  studies  in  rats  and  mice  do  not 
show an increased incidence of leukemia and the rodent 
data are not convincing for this endpoint. Nevertheless, 
even if it is assumed that there is a causal association 
with  mononuclear  cell  leukemia,  the  association  was 
only seen at the highest exposure level (i.e., 15 ppm) in 
F344 rats, which caused a high incidence of nasal can-
cer. Consequently, even if there was a causal linkage, the 
exposure-response relationship is highly non-linear.
b.Ingestion studies  Although a less appropriate route of 
administration, there are at least three chronic oral expo-
sure studies with formaldehyde. For example, Til et al. 
(1989) conducted a 2-year drinking water study of formal-
dehyde in Wistar rats with mean administered doses of 0, 
1.2, 15, or 82 mg/kg/day and 0, 1.8, 21, or 109 mg/kg/day, 
for male and female animals, respectively. Treatment-
related changes were only noted in the gastric mucosa, 
with no evidence of carcinogenicity either in the stomach 
or any other site or tissue, including the hematopoietic 
system. Takahashi et al. (1986) and Tobe et al. (1989) also 
provide no evidence that oral exposure to formaldehyde 
resulted  in  increased  incidence  of  lymphohematopoi-
etic  malignancies  or  pathology.  None  of  these  studies 
reported adverse effects on hematological parameters.
In an ingestion study by Soffritti et al. (1989, 2002), 
male  and  female  Sprague-Dawley  rats  were  exposed 
to formaldehyde in drinking water at concentrations of 
0, 10, 50, 100, 500, 1000, 1500, and 2500 mg/L for up to 
104 weeks, with a reported increase in ‘‘lymphoblastic 
leukemias  and  lymphosarcomas”  and  ‘‘immunoblastic 
lymphosarcomas.”  However,  the  results  of  this  study 
have been challenged on numerous grounds (e.g., lack 
of  statistical  analysis,  use  of  unusual  nomenclature, 
discrepancy  with  historical  controls,  questionable  his-
topathological conclusions, etc.) by both the Agency for 
Toxic Substances and Disease Registry (ATSDR, 1999) as 
well as the Cancer Assessment Committee of the Center 698  R. Golden
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for Food Safety and Applied Nutrition, US Food and Drug 
Administration (FDA), which concluded that “…there is 
no basis to conclude that formaldehyde is a carcinogen 
when ingested” (USFDA, 1998).
2. Human data
IARC (2006) suggested that there was some information 
available  to  link  formaldehyde  inhalation  exposure  to 
leukemia. There was skepticism about this link, however, 
because a biological mechanism to explain how this dis-
ease outcome might have occurred was not identified. 
Several  hypotheses  have  now  been  put  forward  in  an 
attempt to fill this key knowledge gap. Nonetheless, both 
IARC (2009) and NTP (2009) have concluded that there 
is sufficient evidence linking exposure to formaldehyde 
and leukemia (IARC, 2009), and specifically myeloid leu-
kemia (NTP, 2009), in humans. In addition, as previously 
noted, US EPA (2010a) in its draft IRIS assessment has 
concluded that the epidemiological evidence was suffi-
cient to support a causal relationship between exposure 
to formaldehyde and all forms of leukemia (i.e., AML, 
CML, ALL, and CLL) as well as non-Hodgkin’s lymphoma. 
However, in the following discussion the emphasis is on 
leukemia, since this is the endpoint that IARC and NTP 
concluded is associated with exposure to formaldehyde. 
Despite the conclusions of US EPA/IRIS that all forms of 
leukemia (i.e., both myeloid and lymphatic) were associ-
ated with exposure to formaldehyde, since none of the 
occupational  cohort  studies  have  reported  significant 
elevations in lymphatic leukemia, this endpoint will not 
be discussed.
The  NCI  25,000  person  occupational  cohort 
described  in  the  discussion  of  NPC  was  also  evalu-
ated for leukemia (Hauptmann et al., 2003). Although 
there was no overall increased risk of leukemia in the 
exposed cohort (SMR = 0.85, 95% CI 0.67–1.09), there 
was a significantly increased risk of leukemia associ-
ated with peak exposure (RR = 2.46, 95% CI 1.31–4.62, 
ptrend = .001).  Of  interest,  no  increased  risk  was  found 
when assessed by other exposure metrics (i.e., cumu-
lative, duration, or average intensity). In the follow-up 
to this study (see below), a new metric (i.e., number of 
peaks ≥4 ppm) was added and this showed no statisti-
cally  significant  association  with  leukemia  mortality 
or any other lymphohematopoietic (LHP) malignancy. 
The study by Hauptmann et al. (2003) was the princi-
pal basis upon which IARC (2006) concluded that there 
was some information to link formaldehyde inhalation 
exposure to leukemia. However, in 2004, neither IARC 
nor NCI was aware of the fact (later revealed by Beane 
Freeman et al., 2009) that more than 1000 deaths were 
not included from the 1994 follow-up of the NCI cohort 
and that proportionally more of these missing deaths 
occurred among subjects in the unexposed subgroup 
that served as the baseline for comparison in the inter-
nal relative risk comparisons. Omission of these deaths 
has substantial implications to the outcome reported by 
Hauptmann et al. (2003).
Using  the  original  data  from  the  NCI  study  (i.e., 
Hauptmann et al., 2003), the cohort was reanalyzed by 
Marsh and Youk (2004). This analysis revealed an unex-
plained  statistical  anomaly,  i.e.,  significant  deficits  in 
deaths  from  leukemia  in  both  the  internal  (i.e.,  unex-
posed) control group as well as the low-exposed group 
used as internal comparisons, which, when compared to 
the essentially normal death rate in the exposed groups, 
substantially influenced the finding of elevated risk of 
leukemia reported by Hauptmann et al. (2003). This con-
trol-group anomaly strongly suggests that the elevated 
risks reported by Hauptmann et al. (2003) are more likely 
the result of, or at least strongly influenced by, the deficits 
in deaths from these diseases in the internal comparison 
groups. Importantly, when an external comparison group 
with expected mortality from leukemia was used, there 
was no significant increase in leukemia mortality. Thus, 
this  unusual  artifact  illuminated  by  Marsh  and  Youk 
(2004) in their reanalysis questions the conclusion of a 
causal association between formaldehyde exposure and 
increased mortality from leukemia in this cohort.
Two  other  large  occupational  cohort  studies  (i.e., 
Pinkerton et al., 2004, and Coggin et al., 2003) are gen-
erally highlighted as additional important data for dis-
cerning  potential  effects  between  formaldehyde  and 
the different cancers. Although neither of these studies 
analyzed the data based on peak exposure, it should be 
emphasized that when the leukemia findings reported by 
Hauptmann et al. (2003) were assessed by Beane Freeman 
et al. (2009), based on the number of peaks ≥4 ppm, there 
was no significant association with leukemia. The study 
by Pinkerton et al. (2004) on more than 11,000 garment 
workers occupationally exposed to formaldehyde showed 
no  significant  association  with  leukemia  (SMR = 1.14, 
95% CI 0.52–2.17, and SMR = 1.09, 95% CI 0.70–1.62, for 
the  original  study  period  and  the  total  (i.e.,  updated) 
study period, respectively); trend data were not reported. 
Neither myeloid leukemia (SMR = 1.44, 95% CI 0.80–2.37) 
nor acute myeloid leukemia (AML) (SMR = 1.34 95% CI 
0.61–2.54) were significantly increased. There was a sta-
tistically  significant  finding  for  leukemia  (SMR = 1.91) 
after  more  than  20  years  since  first  exposure,  but  the 
trend was not significant. In the study by Coggon et al. 
(2003)  on  more  than  14,000  occupationally  exposed 
chemical  workers,  with  formaldehyde  exposures  that 
exceeded those in the NCI cohort, there was no signifi-
cant increase in leukemia mortality (SMR = 0.91, 95% CI 
0.62–1.29, and SMR = 0.71, 95% CI 0.31–1.39, for deaths in 
the total cohort and deaths in men with high exposures, 
respectively).
The NCI cohort (Beane Freeman et al., 2009) reports 
mortality  follow-up  through  2004.  Although  leuke-
mia  was  still  not  significantly  elevated  in  the  cohort 
(SMR = 1.02, 95% CI 0.85–1.22), there was a significant 
trend (ptrend = .02) with peak exposure (but not with aver-
age  intensity,  cumulative,  or  duration  of  exposure  or 
number of peak exposures) that was achieved only when 
unexposed and low-exposed workers were included in Indoor air exposure limit for formaldehyde  699
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the  analysis.  Importantly,  NTP’s  (2009)  determination 
stating that formaldehyde exposure is specifically asso-
ciated with myeloid leukemia is not supported, as there 
was not a significant elevation for any exposure metric 
(i.e.,  peak,  number  of  peaks,  duration,  cumulative  or 
average intensity). Notable again is the fact that deficits 
(approaching statistical significance) in leukemia mor-
tality in non-exposed workers (SMR = 0.48, 95% CI 0.23–
1.01) continued as in the previous study of this cohort. 
Although the issues identified by Marsh and Youk (2004) 
in their analysis of the previous study were acknowledged 
by Beane Freeman et al. (2009), no attempt was made to 
compare mortality with an external comparison group. 
It is likely that an analysis of these data similar to that 
conducted by Marsh and Youk (2004) using the previous 
data (i.e., mortality comparison with an external group) 
would similarly yield findings of no significant increase 
in leukemia mortality.
Another issue that bears substantially on the leuke-
mia findings reported by both Hauptmann et al. (2003) 
and Beane Freeman et al. (2009) concerns the number 
of deaths in the cohort. As reported in Hauptmann et al. 
(2003), there were a total of 8486 deaths in the cohort 
upon which the 1994 follow-up analysis was conducted. 
In the most recent 2004 follow-up of the NCI study, Beane 
Freeman et al. (2009a) revealed that NCI had not analyzed 
1006 deaths among cohort members in the previous 1994 
follow-up. This led to the 2009 online publication by NCI 
(Beane Freeman et al., 2009b) of corrected tables from 
the  earlier  2003  and  2004  publications  (Hauptmann 
et al., 2003, 2004). A key change in the original findings 
reported for leukemia (Hauptmann et al., 2003) was that 
NCI  had  missed  proportionally  more  deaths  (includ-
ing  seven  leukemia  deaths)  among  the  low-exposed 
and unexposed subgroups that served as the baseline 
groups  in  the  internal  relative-risk  comparisons.  This 
new finding is consistent with results of the Marsh and 
Youk (2004) reanalysis, which showed that the exposure-
response association for leukemia originally reported by 
Hauptmann et al. (2003) was due largely to statistically 
significant deficits in deaths among the low-exposed and 
unexposed subgroups. As shown in Table 2, inclusion of 
the  “missed”  1006  deaths  substantially  attenuates  the 
outcome of the 1994 follow-up (Hauptmann et al., 2003) 
and also illustrates how the statistically significant defi-
cits in leukemia in the unexposed or low-exposed groups 
creates a misleading exposure-response relationship.
Although the above discussion focuses on leukemia 
(as was done by IARC, 2006, 2009), recent deliberations 
by  NTP  (2009)  focused  more  specifically  on  myeloid 
leukemia, concluding that there was “…evidence of sig-
nificant excess of three types of cancer with a positive dose-
response relationship: nasopharyngeal carcinoma (NPC), 
sinonasal  adenocarcinoma  and  myeloid  leukemia. 
Chance, bias, and confounding are unlikely to explain the 
observed excess in these cancers.”
According to NTP (2009), four studies played a “key 
role” in the evaluation of the association between form-
aldehyde and leukemia, and that the “strongest evidence 
for an association between formaldehyde exposure and 
leukemia is for myeloid leukemia.” The four studies ref-
erenced are Hauptmann et al. (2009), Beane Freeman 
et al. (2009a), Coggon et al. (2003), and Pinkerton et al. 
(2004).  However,  a  review  of  these  four  studies  does 
not  support  this  conclusion.  For  example,  in  Beane 
Freeman et al. (2009a), whereas all leukemia was sig-
nificantly elevated for the peak exposure metric, myeloid 
leukemia was not significantly elevated based on peak 
exposure  and  the  trend  was  not  significant  (ptrend = .13 
and.07 compared to exposed and unexposed workers, 
respectively). Moreover, there were no significant asso-
ciations  for  myeloid  leukemia  observed  with  average 
intensity,  duration,  or  cumulative  exposure  to  formal-
dehyde. In addition, particularly for this study, it would 
appear that chance in the form of significant deficits in 
leukemia mortality in the unexposed and low-exposed 
internal comparison groups played a substantial role in 
the reported findings. Coggon et al. (2003) reported no 
significant increase in all forms of leukemia and myeloid 
leukemia was not separately assessed. In Pinkerton et al. 
(2004), there was no significant increase in leukemia in 
the cohort, and for myeloid leukemia, also no significant 
association in the cohort (SMR = 1.44, 95% CI 0.80–2.37), 
whereas the significant association reported in workers 
after 20 years since first exposure was not supported by 
a significant exposure-response trend. Collectively, the 
studies by Beane Freeman et al. (2009), Coggon et al. 
(2003),  and  Pinkerton  et  al.  (2004)  do  not  support  a 
causal association between formaldehyde exposure and 
myeloid leukemia.
The study by Hauptmann et al. (2009) was a case-con-
trol study embedded in a proportional mortality study 
(PMR) investigation of lympohematopoietic malignan-
cies in embalmers exposed to formaldehyde. Based on 
Table 2.  Correction of NCI 1994 data and additional follow-up for leukemia and resulting attenuated exposure-response relationships.
Highest 
peak(ppm)
NCI study Marsh et al. (2004) 
re-analysise 1994 follow-up originala,b 1994 follow-up revisedc 2004 follow-upd
No. deaths RR (95% CI) No. deaths RR (95% CI) No. deaths RR (95% CI) SMR (95% CI)
Unexposed 4 0.78 (0.25–2.43) 4 0.52 (0.17–1.57) 7 0.59 (0.25–1.36) 0.38* (0.10–0.97)
>0–1.9 (base) 16 1.00 (—) 23 1.00 (—) 41 1.00 (—) 0.50* (0.28–0.81)
2.0− 3.9 20 2.04 (1.0–4.01) 20 1.36 (0.73–2.51) 27 0.98 (0.60–1.62) 1.04 (0.63–1.60)
>4.0 29 2.46 (1.31–4.62) 29 1.60 (0.90–2.82) 48 1.42 (0.92–2.18) 1.31 (0.88–1.89)
aUsed by IARC in 2004;. b ptrend  = .001 (all groups), ptrend = .004 (exp. only); ccptrend = .021 (all groups), ptrend = .094 (exp. only); dptrend = .02 (all 
groups), ptrend = .12 (exp. only); ep < 0.05.700  R. Golden
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modeled  exposure  estimates  (no  formaldehyde  mea-
surements were available), mortality from myeloid leu-
kemia was significantly increased with number of years 
of embalming (ptrend = .02) and increasing peak formal-
dehyde exposure (ptrend = .036). Compared with subjects 
who  performed  fewer  than  500  lifetime  embalmings, 
myeloid leukemia mortality was elevated among those 
with more than 34 years of embalming (OR = 3.9, 95% 
CI 1.2–12.5, p = .012), with more than 3068 embalmings 
(OR = 3.0, 95% CI 1.0–9.2, p = .043). However, a key issue 
in  the  Hauptmann  et  al.  (2009)  study  calls  into  ques-
tion the rigor of their analysis and the likelihood that 
the reported results are correct. Because there was only 
one case of myeloid leukemia in the reference group of 
non-embalmers, risks for this condition were evaluated 
in a different comparison group consisting of individu-
als who performed less than 500 lifetime embalmings in 
order to include five additional cases of myeloid leuke-
mia in the reference group for purposes of risk assess-
ment.  As  stated  by  the  authors,  “These  represent  more 
conservative but probably more reliable risk estimates for 
high-level exposure than those shown in Table 3.” A simple 
inspection of the ORs for myeloid leukemia in their Table 
4 shows quite clearly that there is no significant trend, 
even though the ptrend values are reported as significant. 
However, in a footnote to Table 4, it is noted that “Trend 
tests for LHPM of non-lymphoid origin and myeloid leuke-
mia are the same as those presented in Table 3.” In other 
words, none of the results presented in Table 4, which 
are described as “more reliable risk estimates” than those 
shown in Table 3, were actually tested for statistical sig-
nificance. This substantial error calls into question the 
conclusions of this study.
This issue was the subject of a Letter-to-the Editor of 
the Journal of the National Cancer Institute (JNCI) by Cole 
et al. (2010), which noted that “Surprisingly, the more 
reliable exposure–response analyses are not accompa-
nied by their attendant P values. Even more perplexing 
is that they were accompanied by the P values obtained 
from the less reliable data…We are left with a study that 
is described as positive for a formaldehyde–myeloid leu-
kemia association among embalmers but which provides 
little evidence of an overall excess of myeloid leukemia 
among them and whose most reliable data on exposure–
response  relationships  were  not  tested  for  statistical 
significance.” In their response, Hauptmann et al. (2010) 
failed to address the key issue raised by Cole et al. (2010) 
of transferring the same p values from Table 3 to Table 4 
without actually testing the findings presented in Table 4 
for statistical significance.
The findings reported by Hauptmann et al. (2009) are 
not new, since most of the previous studies on embalm-
ers, pathologists, and anatomists have reported increased 
risk  of  leukemia.  These  findings  have  been  attributed 
to  either  reporting  bias,  some  exposure  other  than 
formaldehyde-related  substances  in  the  embalming, 
or to infectious agents (Harrington and Shannon, 1975; 
Walrath and Fraumeni, 1983, 1984; Stroup et al., 1986; 
Hayes et al., 1990). In the Hauptmann et al. (2009) study, 
formaldehyde exposure was never measured but rather 
inferred based on the number of embalming used as a 
surrogate. As noted by Hauptmann et al. (2009), embalm-
ing fluids are complex mixtures including other chemi-
cals  along  with  formaldehyde,  including  isopropanol, 
ethylene glycol, methanol, phenol, and glutaraldehyde. 
In addition, these fluids often contain a variety of organic 
dyes (some of which may be mutagenic) used as color-
ing agents and the mixture of chemicals in embalming 
fluids has changed over the years. Although the potential 
carcinogenicity of this mixture of chemicals is unknown, 
it is apparent that embalming involves exposure to more 
than just formaldehyde. Because the number of embalm-
ings was one of the best predictors of risk of leukemia 
according to Hauptmann et al. (2009), it is possible that 
another component of embalming fluids is related to the 
increased risk to the extent that any increased risk was 
even demonstrated based on the issues pertaining to the 
reporting of results.
Consequently, although there might be some equivo-
cal evidence of a possible association between formal-
dehyde exposure and myeloid leukemia, this evidence 
can hardly be characterized as “strong,” since three of 
the four studies (Coggon et al., 2003; Pinkerton et al., 
2004; Beane Freeman et al., 2009) expressly state that 
there was not a statistically significant association and/
or exposure-response relationship between formalde-
hyde exposure and myeloid leukemia. This consistent 
finding among three diverse studies, which collectively 
involved  more  than  50,000  occupationally  exposed 
workers, calls into question the strength or confidence 
of the results of the fourth study (Hauptmann et al., 
2009). Consequently, there is only a weak foundation for 
the NTP (2009) expert panel’s conclusion that there was 
“sufficient” evidence of an association between formal-
dehyde exposure and myeloid leukemia. This is particu-
larly evident because the largest of these studies (Beane 
Freeman et al., 2009) unequivocally does not show any 
significant association between formaldehyde exposure 
and myeloid leukemia in a cohort of more than 25,000 
exposed workers.
The recent US EPA (2010a) IRIS assessment of form-
aldehyde  goes  beyond  the  conclusions  of  either  IARC 
or NTP by concluding that there is a causal association 
between exposure to formaldehyde and all forms of leu-
kemia, including acute myeloid leukemia (AML), chronic 
myeloid  leukemia  (CML),  acute  lymphoid  leukemia 
(ALL), and chronic lymphoid leukemia (CLL) as well as 
Hodgkin’s lymphoma. As described in the US EPA (2005) 
cancer risk assessment guidelines, a weight-of-evidence 
evaluation for cancer requires consideration of existing 
human data, animal data, and mode-of-action data. As 
acknowledged in the IRIS (2010) assessment, there are 
neither  animal  data  nor  leukemia-specific  empirical 
mode-of-action (MOA) data supporting a conclusion that 
formaldehyde causes any kind of lymphohematopoietic 
(LHP)  malignancies.  Consequently,  the  epidemiology Indoor air exposure limit for formaldehyde  701
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data  must  be  unequivocal  in  demonstrating  a  causal 
association between exposure to formaldehyde and all 
forms  of  leukemia  and  non-Hodgkin’s  lymphoma.  In 
fact, as shown in this review, the available epidemiologic 
data do not support this conclusion.
3.Meta-analyses of leukemia data
Several  conflicting  meta-analyses  attest  to  the  uncer-
tainty of the formaldehyde-leukemia association. Collins 
and Lineker (2004) examined 18 epidemiology studies 
of  workers  exposed  to  formaldehyde  where  leukemia 
rates  were  reported  and  calculated  meta-relative  risk 
(mRR) values. The analysis stratified exposure according 
to occupation, thereby providing the ability to compare 
results  based  on  formaldehyde  exposure.  There  was  a 
small increase in leukemia among embalmers (mRR = 1.6, 
95% CI 1.2–6.0), and pathologists/anatomists (mRR = 1.4, 
95%  CI  1.0–1.9).  However,  in  industrial  workers,  who 
have been reported to have the highest formaldehyde 
exposures, the mRR was 0.9 (95% CI 0.8–1.0).
In a more recent meta-analysis, Zhang et al. (2008) 
assessed many of the same studies, although there was 
no stratification according to exposure. In this analysis 
the overall mRR for leukemia was 1.54 (95% CI 1.18–2.00), 
but it is not possible to ascertain if the RR would have 
been higher in the less-exposed cohorts compared to the 
more highly exposed cohorts, as reported by Collins and 
Lineker (2004).
In the most recent meta-analysis of the data for both 
leukemia and NPC, Bachand et al. (2010) assessed all 
cohort, case-control, and proportional mortality (PMR) 
studies conducted to date. For leukemias the summary 
relative risk (RR) for cohort studies was 1.05 (95% CI 0.93–
1.20) and the summary odds ratio (OR) for case-control 
studies was 0.99 (95% CI 0.71–1.37). Although the sum-
mary PMR was significantly elevated (PMR = 1.44, 95% CI 
1.25–1.67), by design such studies are far less informative 
than cohort or case-control studies. Most importantly, 
based on cohort and case-control studies, no significant 
differences  were  seen  by  leukemia  subtype,  job  type, 
publication period, or region. After excluding the single 
plant (Plant 1) with the cluster of NPC cases, the sum-
mary cohort estimate for nasopharyngeal cancers was 
not elevated (RR = 0.72, 95% CI 0.40–1.28). Although the 
summary  OR  estimate  was  increased  for  case-control 
studies  overall,  it  was  not  elevated  when  considering 
smoking-adjusted studies (OR = 1.10, 95% CI 0.80–1.50). 
The Bachand et al. (2010) meta-analysis was not cited in 
or considered by US EPA (2010a) in the IRIS assessment 
of formaldehyde even though it was available. The Zhang 
et al. (2009) was exclusively relied on as support for the 
findings reported by Beane Freeman et al. (2009).
With respect to the three meta-analyses, some meth-
odological  issues  may  influence  reported  outcomes, 
including selection bias and inadequate consideration of 
the potential for heterogeneity. For example, of the three 
meta-analyses,  both  Collins  and  Lineker  (2004)  and 
Bachand et al. (2010) stratify and analyze the data based 
on separate consideration of low-exposure (i.e., embalm-
ers and anatomists) and high-exposure (i.e., industrial 
workers) occupations, whereas Zhang et al. (2009) does 
not.  This  stratification  may  be  important  because  the 
high-exposure industries have, if anything, a lower collec-
tive indication of effect than the low-exposure industries. 
Althugh Zhang et al. (2009) reported a significant effect 
across industries, they used what may be considered a 
subjective  means  of  selecting  and  combining  studies. 
Rather than using “ever exposed” or “never exposed” as 
metrics, Zhang et al. (2009) used different measures of 
exposure, selecting only one from each study even if sev-
eral were examined, resulting in their selection of peak 
exposure for some studies, average exposure for others, 
cumulative exposure for still others, and exposure dura-
tion for the balance. Moreover, when several categories 
or levels of exposure were examined, they took data from 
only the highest among them, and what constituted a 
“high”  category  also  varied  considerably  among  stud-
ies,  depending  on  how  each  study  established  grada-
tions of exposure. As a consequence, the comparisons 
across studies are very heterogeneous, and it is not clear 
whether a comparable question was being examined in 
each case, which may lead to unreliable results in a meta-
analysis. Because of the above issues, the conclusions 
from Zhang et al. (2009) should be interpreted with cau-
tion, especially in view of their lack of concordance with 
other meta-analyses of essentially the same data set.
Despite an abundance of epidemiological data, pos-
sible conclusions concerning an etiological association 
between formaldehyde exposure and leukemia remain 
elusive. As a result, considerations of biological plausibil-
ity are that much more important in attempting to shed 
light on this controversial issue.
4.Leukemia mode-of-action issues
When IARC (2006) evaluated formaldehyde, there was 
skepticism about the reported leukemia findings (e.g., 
Hauptmann  et  al.,  2003)  because  no  mode  of  action 
had been identified to help explain how leukemia might 
have occurred. There is a detailed understanding of how 
chemicals  cause  leukemia  (i.e.,  leukemogenesis)  and 
several critical analyses demonstrate that formaldehyde 
is not one of those chemicals (Heck and Casanova, 2004; 
Golden et. al., 2006; Pyatt et al., 2008). In contrast, the 
chemicals that are known to cause leukemia (e.g., ben-
zene and some cancer chemotherapeutic agents such as 
melphalan, chlorambucil, cyclophosphamide, nitrosou-
rea, and topoisomerase inhibitors) share a number of 
common characteristics. They enter the systemic circu-
lation, are distributed to the bone marrow, and induce 
pancytopenia  and  myelotoxicity.  Most  importantly, 
known human leukemogens also produce leukemia (or 
some variant lymphohematopoietic malignancy) when 
administered to rats or mice. In other words, chemical 
leukemogens produce a similar spectrum of effects in 
rodents  and  humans  (Golden  et  al.,  2006;  Eastmond, 
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leukemogenic  chemicals  are  shared  by  formaldehyde. 
Inhaled formaldehyde, even up to 15 ppm, does not enter 
the blood and reach any sites distal to the nasal epithe-
lium or alter normal endogenous blood levels (Lu et al., 
2010a; Heck et al., 1985. Cassanova et al., 1988), and does 
not cause hematotoxicity, pancytopenia, or myelotoxico-
ity in animals or humans (Golden et al., 2006; ATSDR, 
1999).
Despite  the  established  inconsistency  of  inhaled 
formaldehyde with the biological properties of known 
human leukemogens, DeVoney et al. (2006a, 2006b) pro-
posed a hypothetical mode of action. The most impor-
tant characteristic of this hypothesis is that it avoids the 
necessity for formaldehyde entering the systemic circu-
lation, transporting to the bone marrow, or producing 
myelotoxicity.  Instead,  DeVoney  et  al.  (2006a,  2006b) 
postulate the involvement of nasal-associated lymphoid 
tissue (NALT) at the point of entry in the nose, with form-
aldehyde adversely affecting stem cells or hematopoietic 
progenitor cells (HPCs) that circulate in NALT, causing 
those cells to be malignantly transformed. These trans-
formed cells are assumed to travel to the bone marrow 
leading to the development of leukemia in the absence of 
myelotoxicity. Several similar MOAs incorporating many 
of the same elements have also been proposed by Zhang 
et al. (2009a, 2009b).
Due to the central importance of NALT in the DeVoney 
et al. hypotheses, Kuper et al. (2009) investigated whether 
NALT and local lymph nodes might be affected by inhaled 
formaldehyde.  This  28-day  inhalation  study  was  con-
ducted in F344 rats and B6C3F1 mice at formaldehyde 
concentrations of 0, 0.5, 1, 2, 6, 10, and 15 ppm to deter-
mine if local lymphoid tissues are a target. Both NALT 
and upper-respiratory-tract draining lymph nodes were 
stained with hematoxylin and eosin (H&E) or immuno-
histochemically for cell proliferation via BrdU incorpo-
ration.  Light  microscopy  revealed  slight-to-moderate 
hyperplasia of NALT lymphoepithelium and an increased 
epithelial cell proliferation rate in rats exposed to 15 ppm. 
Analysis of rat NALT and lymph nodes did not reveal 
effects at lower exposure levels, whereas similar tissues 
from mice were not affected at any dose. As concluded by 
the authors, “…the only distinct effect of FA vapor on NALT 
and local lymph nodes in Fischer 344 rats and B6C3F1 
mice was simple hyperplasia of the lymphoepithelium of 
NALT in rats exposed to15 ppm. Therefore, the results of 
the present study did not support the hypothesis that FA 
may induce hematological malignancies by reacting with 
local lymphoid tissues such as NALT.”
Another  study  directly  relevant  to  the  hypothesis 
proposed by DeVoney et al. (2006a, 2006b) (i.e., transfer 
from affected cells in NALT to circulating myeloid pro-
genitor cells) was conducted by Neuss et al. (2010), in 
which primary human nasal epithelial cells (HNECs) and 
isolated lymphocytes were co-cultivated in vitro to deter-
mine whether reactive formaldehyde can be passed from 
nasal epithelial cells (site of first contact) to lymphocytes 
located in close proximity and induce DNA damage in 
these cells. A modified comet assay was used as a sensi-
tive method for the detection of formaldehyde-induced 
DNA-protein  cross-links  (DPX)  because  these  are  the 
most relevant type of formaldehyde-induced DNA dam-
age. The results clearly indicated that co-cultivation of 
lymphocytes  with  HNECs  exposed  to  formaldehyde 
for 1 hour causes a concentration-related induction of 
DPX  in  these  cells  when  co-cultivation  takes  place  in 
the  exposure  medium.  However,  when  the  exposure 
medium was changed after formaldehyde treatment of 
HNECs and before lymphocytes are added, no induc-
tion  of  DPX  was  measured  in  lymphocytes  even  after 
exposure  of  HNECs  to  high  formaldehyde  concentra-
tions (300 μM) and extended duration of co-cultivation 
(4 hours). Direct measurement of formaldehyde in the 
cell  culture  medium  demonstrated  that  formaldehyde 
was not released even from highly exposed cells into the 
cell culture medium. These results suggest that formal-
dehyde that comes into contact with nasal epithelial cells 
is not released and therefore cannot damage other cells 
in close proximity to the epithelial cells. Assuming these 
results also apply in vivo, formaldehyde would only be 
genotoxic to directly exposed cells with no delivery to 
other cells or to distant sites. These results do not support 
the hypothetical mechanism proposed by DeVoney et al. 
(2006a, 2006b) that formaldehyde-induced leukemia is 
initiated by damaging circulating hematopoietic stem or 
progenitor cells in the nasal passages, with subsequent 
distribution to the bone marrow leading to the develop-
ment of leukemia.
Rodents  chronically  exposed  to  high  formaldehyde 
concentrations for 2 years in the numerous inhalation 
bioassays  had  NALT  and  other  local  lymphoid  tissues 
and none of those animals were reported to have devel-
oped leukemia. Interestingly, lymphoid tissues identical 
to NALT are also found in the stomach, i.e., gastric-as-
sociated lymphoid tissue (GALT). Consequently, if the 
hypothesized formaldehyde-induced mutations in stem 
or hematopoietic progenitor cells in NALT are a proxi-
mate cause of leukemia, the same must be hypothesized 
as occurring in GALT. However, several chronic inges-
tion studies in which animals were exposed via drinking 
water to large concentrations of formaldehyde have not 
produced any cancers, including leukemia or lymphoma 
(e.g.,  Tobe  et  al.,  1989;  Til  et  al.,  1989).  Also,  neither 
of  these  studies  showed  any  effects  on  hematological 
parameters.
The  issue  pertaining  to  GALT  was  also  indirectly 
addressed  in  comments  submitted  by  scientists  from 
other government agencies who reviewed the draft US 
EPA/IRIS assessment prior to its release. Because form-
aldehyde is naturally found in many foods (fruits and 
vegetables  [3−60 mg/kg],  meat  and  fish  [6−20 mg/kg], 
shellfish  [1−100 mg/kg],  and  milk  and  milk  products 
[1−3.3 mg/kg]) (US EPA, 2010a), there is a potential for 
substantial dietary exposure. As with the formaldehyde 
drinking water studies, this would also result in direct 
contact with GALT. After first observing that “The toxicity Indoor air exposure limit for formaldehyde  703
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values in [the US EPA/IRIS] document appear to be in the 
range of normal concentrations in the body and in foods. 
If formaldehyde is toxic at normally occurring concentra-
tions it seems that leukemia rates should be much higher 
than  they  are,”  the  agency  scientists  observed  that  “A 
reality check of formaldehyde in the diet and in healthy 
individuals  compared  with  lifetime  risks  of  leukemia 
should be presented. Although an estimated 1 to 10 mg per 
day ingestion is cited (page 2–11), it is not in proximity 
to, nor compared with, either the existing data on risk of 
leukemia from all sources nor with the unit cancer risk of 
8.1 × 10−2 per ppm (6.6 × 10−5 per μg/m3)” (DOD, 2010). 
As previously noted, IARC (2006) was initially skep-
tical  concerning  the  reported  epidemiology  findings 
of  an  association  between  exposure  to  formaldehyde 
and leukemia due to the inability to identify a mode of 
action. Indeed, as discussed by IARC (2006), the idea that 
formaldehyde may cause leukemia “…raises a number of 
mechanistic questions, including the processes by which 
inhaled formaldehyde may reach a myeloid progenitor.” 
IARC  continues,  “…a  clastogenic  product  of  FA  could 
conceivably be formed in the blood and circulate to the 
bone marrow although this has not been suggested in the 
literature.” And finally, “…it is possible that circulating 
myeloid progenitor stem cells could be the source of leu-
kemia...such cells are present in the blood and plausibly 
could be exposed to formaldehyde in the respiratory tract 
vasculature; however, there is no known prototype for such 
a mechanism of leukemogenesis.”  IARC (2006) appears to 
have addressed and ruled out many of the assumptions 
and critical issues pertaining to the biological plausibility 
of the mode of action proposed by DeVoney et al. (2006a, 
2006b) and Zhang et al. (2009, 2010).
The DeVoney et al. hypotheses has also been critically 
evaluated by Pyatt et al. (2008) with the conclusions that 
(1) there was no scientific support that the proposed MOA 
or any of its elements actually occurs, since there are no 
relevant supporting data; (2) the apparent speculation 
that inhaled formaldehyde would cause leukemia via this 
MOA was unsubstantiated; (3) formaldehyde does not fit 
the toxicological profile of a chemical capable of inducing 
leukemogenic transformation in humans; and (4) there 
is no biologically plausible mechanism to explain how a 
chemical with no documented hemato- or myelotoxicity 
could induce leukemia in animals or humans.
5.Chinese worker study
Zhang et al. (2010) has brought additional attention to 
the  issue  of  formaldehyde-induced  myeloid  leukemia. 
In this study, Chinese workers (43 exposed and 51 con-
trols  exposed  to  median  formaldehyde  concentrations 
of 1.28 ppm and 0.026 ppm, respectively) in two factories 
either producing or using formaldehyde-melamine resins 
were examined. Endpoints measured included complete 
blood counts and peripheral stem/progenitor cell colony 
formation (i.e., colony-forming units [CFUs]). In addition, 
myeloid progenitor cells were cultured from 10 exposed 
and  12  unexposed  workers  to  quantify  chromosome 
changes, including monosomy 7 and trisomy 8, in meta-
phase spreads of these cells. Using peripheral blood from 
study subjects, colony formation from circulating colony-
forming unit (CFU)–granulocyte/macrophage (CFU-GM) 
progenitor cells was also investigated. A 20% decrease in 
colony formation from progenitor cells in formaldehyde-
exposed workers was reported; however, this was not sta-
tistically significant (p = .10). The major findings from the 
study were the significant difference between exposed 
and controls in red and white blood cell counts, although 
all measurements were in the normal clinical range and 
with the exposed group showing significantly increased 
frequencies of aneuploidy as reflected by monosomy 7 
and trisomy 8 in metaphase spreads of cultured myeloid 
progenitor  cells  from  peripheral  blood.  Zhang  et  al. 
(2010) interpreted the blood count results as evidence 
of early bone marrow toxicity (i.e., pancytopenia) and 
therefore consistent with other known leukemogens such 
as benzene. The findings of monosomy 7 and trisomy 8 
were  characterized  as  leukemia-specific  changes  also 
similar to that produced by benzene or therapy-induced 
AML. However, the reference (i.e., Rowley, 2000) cited 
by Zhang et al. (2010) as support for the statement that 
monosomy 7 and trisomy 8 “…are among the most fre-
quent cytogenetic changes observed in myeloid leukemia 
and myelodysplastic syndromes” does not mention either 
of these aneuploidies.
The Zhang et al. (2010) study appears to have method-
ological and interpretative deficiencies that could under-
mine the stated conclusions, including (1) chromosomes 
7  and  8  are  minimally  relevant  to  leukemia  and  their 
count number in peripheral blood lymphocytes is not 
known (nor are any references cited in support of this) to 
have predictive value; (2) there is no accepted diagnos-
tic test in clinical medicine, hematology, or hematopa-
thology that can establish the presence of leukemia, or 
increased risk of developing leukemia, by detection of 
monosomy 7 or trisomy 8 in cultured myeloid progenitor 
cells from peripheral blood; (3) there are methodologi-
cal questions whether the reported aneuploid effects in 
whatever cells where actually cultured were a reflection 
of in vivo events or were in vitro artifacts; (4) only infor-
mation for chromosomes 7 and 8 were reported, whereas 
no  information  was  provided  for  other  chromosomes, 
translocations, or any of the common genetic lesions that 
are well established as associated with leukemia; (5) in 
the exposed and control individuals there was no assess-
ment of the other common genetic abnormalities seen 
in AML, e.g., t(8;21), t(15:17), inv(16), or 11q23; and (6) 
chromosomes 7 and 8 are not typically involved in leuke-
mia or therapy-related leukemia (e.g., Rowley and Olney, 
2002). For example, as reported by Zheng et al. (2008), in 
122 AML patients in China, none had monosomy 7 and 
only 4 had trisomy 8.
A related question is whether formaldehyde induces 
aneuploidy,  since  the  mutagenic  mode  of  action  of 
formaldehyde  has  been  extensively  characterized. 
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a  consequence  of  un-repaired  or  mis-repaired  DNA-
protein cross-links (DPX) and the preponderence of data 
shows that formaldehyde acts predominantly by a clasto-
genic and not by an aneugenic mode of action. Molecular 
characterization of formaldehyde-induced micronuclei 
in cultured human lymphocytes and V79 cells as well 
as  micronuclei  measured  in  buccal  and  nasal  cells  of 
formaldehyde-exposed subjects showed that micronu-
clei occurred as a consequence of chromosome break-
age and not of aneuploidy (Schmid and Speit, 2007; Speit 
et al., 2007a, 2007b, 2008; Titenko-Holland et al., 1996). 
The  only  reported  association  between  formaldehyde 
exposure and aneuploidy comes from a biomonitoring 
study with subjects exposed to formaldehyde at the work-
place (Orsiere et al., 2006); however, the plausibility and 
reliability of this result has been questioned (Schmid and 
Speit, 2007). A negative in vivo micronucleus test with 
rats exposed to formaldehyde by inhalation for 4 weeks at 
concentrations up to 15 ppm showed that formaldehyde 
does not induce aneuploidy in bone marrow cells (Speit 
et al., 2009). Recent reports of no exogenously derived 
13CD2-formaldehyde-DNA adducts in the bone marrow 
or lymphocytes (Lu et al., 2010a; Moeller et al., 2011) 
also challenges the likelihood that formaldehyde was the 
cause of the findings reported by Zhang et al. (2010).
The findings on the lack of delivery of inhaled form-
aldehyde to the bone marrow have now been extended 
to  non-human  primates.  As  described  in  conjunction 
with NPC, the study by Moeller et al. (2010) also deter-
mined  the  presence  of  endogenous  and  exogenous 
formaldehyde in DNA from bone marrow of cynomolgus 
macaques exposed to 1.9 and 6.1 ppm of  13CD2-formal-
dehyde for 6 hours a day for 2 consecutive days. In bone 
marrow, no exogenous DNA adducts were detected, even 
though ~10-fold larger amounts of DNA were analyzed. 
However,  endogenous  N2-hydroxymethyl-dG  adducts 
were present at 17.48 ± 2.61 and 12.43 ± 3.63 adducts/107 
dG in bone marrow DNA from the 1.9 and 6.1 ppm expo-
sures, respectively.
Using the stable isotope data in primates reported by 
Moeller et al. (2010), Swenberg et al. (2010) developed a 
cancer risk estimate approach using a unique “bottom 
up” methodology that extrapolates upward from back-
ground  (endogenous)  exposure  and  response,  rather 
than the typical “top down” approach that often requires 
downward  extrapolation  from  exogenous  exposures. 
Since  no  exogenous  formaldehyde-dG  DNA  adducts 
were  detected  in  the  bone  marrow  and  white  blood 
cells, it was assumed that if such adducts were present 
their amounts would have to be less that the limit of 
detection (LOD) of the sensitive analytical method used. 
Since  endogenous  and  exogenous  formaldehyde  dG 
adducts are chemically indistinguishable following an 
environmental exposure, both should be implicated to 
the same extent in the carcinogenicity of low exposures 
to formaldehyde. It was further assumed that the levels 
of endogenous and exogenous dG adducts in various rat 
and primate tissues are similar to what would be found 
in corresponding human tissues, after adjusting for spe-
cies differences. As noted by Swenberg et al. (2010), “…no 
[13CD2]-OH-methyl  dG  adducts  were  detectable  when 
312 μg of bone marrow DNA was analyzed. In contrast, 
high numbers of endogenous OH-methyl dG adducts were 
present  in  bone  marrow  DNA.  The  number  of  endog-
enous adducts in the 312 μg sample of bone marrow DNA 
was 13.9 adducts/107 dG. If one constructs a worst case 
scenario by assuming that exogenous adducts were just 
below the LOD in this sample, less than 1 [13CD2]-OH-
methyl dG adducts/1010 dG could have existed. This would 
mean that less than 1 exogenous DNA adduct was present 
for every 13,900 endogenous formaldehyde adducts. It is 
difficult to conceive of a mechanism by which 1/13,900 
identical DNA adducts could drive the biology that leads 
to carcinogenesis.”
6.Potential NPC and leukemia risks based on stable isotope 
studies
Swenberg et al. (2010) also used the results from the “bot-
tom up” approach described above to calculate upper 
bound estimates of extra lifetime cancer risk from contin-
uous exposure to 1 ppm formaldehyde with comparisons 
to the risks calculated in the US EPA/IRIS document. For 
NPC, the upper bound extra risk estimates span a near 
20-fold range, from a low of 0.39 × 10−3 (using monkey 
data)  up  to  7.49 × 10−3  (using  rat  data),  both  of  which 
were  less  than  the  corresponding  US  EPA  estimate  of 
1.1 × 10−2. Even greater disparity with US EPA’s values was 
reported for the risk estimates for Hodgkin’s lymphoma 
and leukemia. At 1 ppm, the two Hodgkin’s lymphoma 
estimates were 81-fold (rat data) and 250-fold (monkey 
data), respectively, lower than the US EPA’s estimate of 
1.7 × 10−3.  The  leukemia  estimates  ranged  from  45-fold 
(rat data) to more than 19,000-fold (monkey data) lower 
than the US EPA estimate of 0.057. At 1 ppb, the lifetime 
risk estimates for these two cancers were all well below 
the de minimus 1 × 10−6 level. As described by Swenberg 
et al. (2010), the disparities between the adduct-based 
and epidemiology-based cancer risk estimates for distant 
sites strongly suggest that the excess risks of leukemia 
and  Hodgkin’s  lymphoma  reported  from  occupational 
exposures to formaldehyde exposures cannot be due to 
formaldehyde. As concluded by Swenberg et al. (2010) 
based on the plausible assumption that “…formaldehyde 
dG adducts provide a valid molecular dosimeter for relat-
ing potential human cancer risks to formaldehyde expo-
sure, the far larger risks derived from adult human data 
are simply not credible.”
7.Formaldehyde hematotoxicity
There  is  also  the  question  of  formaldehyde-induced 
hematotoxicity  (i.e.,  decreased  blood  counts)  and  the 
conclusion by Zhang et al. (2010) that this was consis-
tent with toxic effects on the bone marrow (i.e., myelo-
toxicity).  Of  interest,  Zhang  et  al.  (2010)  equate  their 
reported  findings  with  formaldehyde  as  being  similar 
to those produced by benzene or therapy-related AML. Indoor air exposure limit for formaldehyde  705
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Notwithstanding the inability to detect 13CD2-formalde-
hyde-DNA adducts in blood or bone marrow following 5 
days’ exposure to 10 ppm formaldehyde, the preponder-
ance of credible animal and human data indicates that 
hematotoxicity  is  not  a  consequence  of  formaldehyde 
exposure, even up to very high exposure concentrations.
This is a keystone issue because hematotoxicity (i.e., pan-
cytopenia), which is an indicator of myelotoxicity, has been 
associated with all known human leukemogenic chemicals 
and appears to be a necessary precursor for chemical leu-
kemogenesis (Golden et al., 2006). Tang et al. (2009) briefly 
reviews and tabulates a number of studies (almost all of 
which are published in Chinese journals) that purport to 
demonstrate that exposure to formaldehyde is a cause of 
hematotoxicity. However, from the various studies cited, 
although some formaldehyde levels are listed, there is not 
enough information in the tabular summary of study results 
to understand exposure conditions or other experimental 
variables that were present in order to evaluate whether the 
reported results on white blood cell counts, platelet counts, 
or hemoglobin levels were valid or due to formaldehyde 
or another exposure. For example, Tang et al. (2009) cite 
only one study in English by Kuo et al. (1997) in support of 
adverse hematological effects. This study was conducted 
on 50 hemodialysis nurses and controls from four hospitals 
in Taiwan and concluded that the white blood cell (WBC) 
counts were significantly lower in the exposed group com-
pared to controls. Although this study provided a matrix 
suggesting a negative correlation coefficient for WBC count 
and formaldehyde concentration, no actual blood count 
data are provided and no significant correlation with any 
other blood variables was reported. Therefore, it cannot be 
determined if the change in WBC count was outside the 
normal range. In addition, the correlation matrix suggested 
increased rather than decreased red blood cell counts. This 
study, however, is suspicious because the formaldehyde 
mean personal sampling concentrations are extremely low 
and basically at background levels (e.g., 0.015, 0.017, 0.033, 
and 0.054 ppm) in the four hospitals. Indeed, these levels 
are similar to the formaldehyde exposure levels of controls 
as reported in Zhang et al. (2010).
The majority of the more carefully conducted studies 
show essentially no reported adverse hematological effects 
following exposure of either humans or animals to formalde-
hyde. This finding has substantial implications with respect 
to  any  proposed  mechanism  for  formaldehyde-induced 
myeloid leukemia. No matter how one might hypothesize 
that  this  occurs  (e.g.,  formaldehyde-induced  myelotoxic-
ity or formaldehyde-induced mutations to stem cells with 
subsequent transport to the bone marrow), all mechanisms 
require pancytopenia as an early indicator of potential dis-
ease. This relationship occurs because myeloid leukemia is 
a malignant disease of the bone marrow in which the ability 
to make normal amounts of blood cells (e.g., erythrocytes, 
leukocytes, and platelets) is compromised. This results in 
decreased numbers of red and white blood cells and plate-
lets in the peripheral blood. There is no consistent evidence 
that formaldehyde produces similar effects.
Although an accidental ingestion of a large quantity 
of formaldehyde was reported to cause an intravascu-
lar coagulopathy (Burkhart et al., 1990), several reports 
of human ingestion of lower doses have not shown any 
effects on the blood or blood-forming organs (Eells et al., 
1981; Freestone and Bentley, 1989; Koppel et al., 1990). In 
animal studies, neither inhalation exposure (Appelman 
et  al.,  1988;  Kamata  et  al.,  1997;  Kerns  et  al.,  1983; 
Woustersen et al., 1987) nor oral exposure (Johannsen 
et al., 1986; Til et al., 1989; Tobe et al., 1989) to high doses 
of formaldehyde has produced any evidence of adverse 
hematological effects. A single study in rats exposed to 
massive oral doses of formaldehyde (e.g., 80 mg/kg for 
4 weeks) reported minor increases in erythrocyte count 
and hemoglobin values (Vargova et al., 1993). As noted in 
ATSDR (1999), the lack of hematopoietic toxicity in these 
studies is “likely related to rapid metabolism prior to the 
formaldehyde  reaching  the  blood  and  blood-forming 
components (bone marrow).” These data are also sup-
ported by the 2-year chronic inhalation study conducted 
by Battelle (1981) in male and female B6C3F1 mice and 
F344 rats following exposure to formaldehyde at 0, 2, 6, 
and 15 ppm, with blood collected for analysis at 6, 12, 
and 24 months. Although there were sporadic significant 
effects  compared  to  controls  on  random  hematologic 
parameters, e.g., decreased lymphocyte counts in male 
rats at 6 months, none of the abnormalities observed in 
treated  groups  at  any  observation  period  was  consid-
ered  as  related  to  formaldehyde  exposure.  Because  of 
the absence of any trends or evidence of an exposure-
response relationship in mice or rats, the findings were 
considered incidental.
Finally, there is an historical aspect to consider per-
taining to the issue of whether inhaled formaldehyde 
causes  adverse  effects  on  blood  cell  counts  consis-
tent with pancytopenia. The American Conference of 
Governmental  Industrial  Hygienists  (ACGIH)  thresh-
old limit values (TLVs) for formaldehyde have steadily 
declined  with  maximum  allowable  concentrations 
(MACs)  or  time-weighted  averages  (TWAs),  show-
ing  the  following  progression  over  time:  1946–1947 
(10 ppm  MAC-TWA),  1948–1962  (5 ppm  TLV-TWA), 
1963–1971  (5 ppm  TLV-ceiling),  1972–1984  (2 ppm 
TLV-ceiling),  1985  (1 ppm  TLV-TWA),  1992  (0.3 ppm 
ceiling)  (Paustenbach  et  al.,  1997).  With  allowable 
formaldehyde exposures of 2–10 ppm from 1946–1984, 
one might expect at least isolated case reports of work-
ers with either decreased blood cell counts if not frank 
pancytopenia. While it is unlikely that workers could 
tolerate exposure at the upper end of this range, the 
lack of such reports suggests that even these formalde-
hyde exposures do not lead to hematotoxic effects.
D.Derivation of an indoor air level of formaldehyde for 
carcinogenic effects
A  particular  challenge  arises  when  attempting  to 
synthesize  from  the  data  summarized  in  this  review 
an exposure level that would be protective from any 706  R. Golden
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potential  carcinogenic  effects  of  formaldehyde.  Part 
of  the  problem  concerns  the  endpoints  and  data 
sets  from  which  to  undertake  such  an  exercise.  Two 
widely disparate types of cancer, NPC and leukemia, 
have been determined to be causally associated with 
exposure to formaldehyde by IARC, NTP, and US EPA. 
However,  despite  the  collective  conclusions  of  these 
organizations, as summarized in this review, there is 
no biologically plausible explanation for how formal-
dehyde might initiate the sequence of obligatory events 
required for chemical leukemogenesis, i.e., entry into 
the blood with subsequent transport to the bone mar-
row  with  resulting  myelotoxicity  and  pancytopenia 
as early precursors of subsequent leukemia. With no 
credible evidence that even high-dose formaldehyde 
exposure, whether by inhalation or ingestion, causes 
hematotoxicity,  there  appears  to  be  no  hypothetical 
pathway to the development of lymphohematopoietic 
malignancies. The lack of biological plausibility is also 
the  most  likely  explanation  for  the  highly  equivocal 
body of epidemiology data that has been the subject 
of so much debate and controversy, i.e., reported posi-
tive findings must be due to other factors, e.g., chance, 
errors in study design, confounding, etc. (see Table 5). 
This  conclusion  is  certainly  the  case  with  the  NCI 
cohort studies in which an unexplained deficit in leu-
kemia mortality in the non-exposed and low-exposed 
groups  can  readily  explain  the  reported  findings  for 
leukemia. Consequently, there is no basis for attempt-
ing to calculate even a hypothetical safe exposure level 
for formaldehyde-induced leukemia.
A  formaldehyde  vapor  concentration  of  0.1 ppm, 
which is protective for sensory irritation of the eyes, 
falls well below the exposure level (i.e., ≥6 ppm) that 
has been shown to initiate the sequence of events, i.e., 
cytotoxicity and regenerative proliferation with appro-
priate  accompanying  dose-dependent  transitions  in 
toxicogenomic  changes  leading  to  nasopharyngeal 
cancer, the tumor that has long been of primary con-
cern from the point of view of public health protection. 
The MOA for formaldehyde-induced nasal tumors in 
rodents is well characterized and now augmented with 
substantial toxicogenomic data demonstrating a clear 
no  observed  effect  level  (NOEL)  for  this  event.  This 
NOEL of 0.7 ppm produced no statistically significant 
gene  changes  with  the  evaluation  criteria  used  (i.e., 
a 2-fold increase with a false discovery rate corrected 
p value <.05) in the 13-week study by Andersen et al. 
(2010), consistent with the lack of any other formalde-
hyde-induced changes in nasal epithelial tissues at this 
concentration (i.e., cytotoxicity, regenerative prolifera-
tion). Since chronic exposure at this concentration is 
clearly  protective  for  the  development  of  formalde-
hyde-induced nasal tumors, the recommended indoor 
air level of 0.1 ppm would offer even a further margin of 
protection for this endpoint.
The above logic has been endorsed by a number of 
regulatory and other standard-setting organizations that 
have evaluated the carcinogenic potential of formalde-
hyde and determined that an indoor air exposure limit 
based on sensory irritation is adequate to protect human 
health  from  cancer  risk.  For  example,  Health  Canada 
(2005)  concluded  that  “…formaldehyde-induced  carci-
nogenicity appears to be a consequence of proliferative 
regeneration following cytotoxicity, and the risk of cancer 
associated  with  formaldehyde  levels  sufficiently  low  to 
prevent  irritation  and  inflammatory  responses  appears 
therefore to be negligible.” A similar position was taken 
by  the  European  Commission’s  Scientific  Committee 
on Occupational Exposure Limits (SCOEL, 2008), which 
stated, “It is generally considered that avoidance of sensory 
irritation of the eye and the upper respiratory tract would 
automatically imply a safety margin to avoid irritation-
induced local cell proliferation.” Similarly, as noted by 
Germany’s  Federal  Institute  for  Risk  Assessment  (BfR, 
2006), “In the absence of cytotoxicity and regenerative pro-
cesses, the theoretical increase in tumor incidence caused 
by formaldehyde is practically non-relevant.” It should be 
pointed out that all of the above conclusions are based on 
the presumption that NPC is the endpoint of concern.
However, a recent assessment by Nielsen and Wolkoff 
(2010),  carried  out  using  the  framework  of  the  WHO 
Indoor Air Quality Guideline development (2006–2009), 
reached the following more comprehensive conclusion 
concerning  both  NPC  and  leukemia,  “For  nasal  can-
cer in rats, the exposure–response relationship is highly 
non-linear,  supporting  a  no-observed-adverse-effect 
level  (NOAEL)  that  allows  setting  a  guideline  value…. 
Epidemiological studies reported no increased incidence 
of NPC in humans below a mean level of 1 ppm and peak 
levels below 4 ppm, consistent with results from rat stud-
ies….  Rat  studies  indicate  that  cytotoxicity-induced  cell 
proliferation (NOAEL at 1 ppm) is a key mechanism in 
development  of  nasal  cancer….  Lymphohematopoietic 
malignancies  are  not  observed  consistently  in  animal 
studies and if caused by formaldehyde in humans, they 
are  high-dose  phenomenons  with  non-linear  exposure–
response relationships. Thus, prevention of nasal cancer 
is considered to prevent lymphohematopoietic malignan-
cies…the guideline value of the WHO [of]…0.08 ppm FA, 
is considered preventive of carcinogenic effects in compli-
ance with epidemiological findings.”
V.Discussion
The data summarized in this review cover a wide spec-
trum of issues pertaining to formaldehyde chemistry, 
toxicokinetics,  and  potential  adverse  health  effects. 
Although it was not the intent to exhaustively examine 
everything known about these issues, a number of key 
overarching messages are worth noting. Unlike most 
other chemicals, as a naturally occurring endogenous 
compound with substantial concentrations in the blood 
and all tissues and with prodigious metabolic capabili-
ties in the nasal epithelium and upper respiratory tract, 
formaldehyde must be considered differently. Data in Indoor air exposure limit for formaldehyde  707
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rodents, non-human primates, and humans showing 
that inhaled formaldehyde does not change endoge-
nous levels in the blood has substantial implications for 
any postulated distant site toxicity. This has now been 
further confirmed in rodents and non-human primates 
unequivocally, demonstrating that formaldehyde-DNA 
adducts derived from exogenous inhalation exposure to 
13CD2-formaldehyde are undetectable at any sites distal 
to the nasal epithelium, making it difficult to explain 
how adverse effects other than at the point of contact 
might occur. This is especially relevant when assessing 
whether inhaled formaldehyde is capable of inducing 
leukemia.
The  large  database  on  formaldehyde  has  been 
reviewed, summarized, and relied upon by IARC, NTP, 
and US EPA in their recent evaluations, which have led 
to firm conclusions concerning the major endpoints of 
concern as discussed in this review. However, particu-
larly for the evaluations from NTP and US EPA, accord-
ing to applicable information quality guidelines (i.e., the 
Information Quality Act [IQA] as well as agency-specific 
guidelines  [US  EPA  IQA  Guidelines]),  such  “influen-
tial” scientific data are subject to a rigorous standard of 
quality to ensure and maximize the quality, objectivity, 
utility, and integrity of the information (US EPA, 2002). 
Instead, on several issues of central importance, partic-
ularly with respect to formaldehyde-induced cancers, 
key study data are either not mentioned or incompletely 
characterized. The most striking example of this is the US 
EPA (2010a) assessment that cited Lu et al. (2010) for the 
finding of endogenous formaldehyde-DNA adducts in 
various tissues (a long known phenomenon), but fails to 
mention that formaldehyde-DNA adducts formed from 
exogenous inhaled formaldehyde cannot be detected at 
any target sites distal to the nasal epithelium, including 
the blood and bone marrow. The same failure to prop-
erly characterize these data, which call into question 
how  inhalation  of  a  chemical  such  as  formaldehyde 
that does not increase tissues levels would be capable of 
initiating the sequence of events leading to the develop-
ment of leukemia, can also be seen in another recent 
US  EPA  document  (Lymphohematopoietic  Cancers 
Induced  by  Chemicals  and  Other  Agents:  Overview 
and Implications for Risk Assessment) (US EPA, 2010b) 
where again, the Lu et al. (2010) data were incorrectly 
characterized, omitting reference to the absence of no 
detectible  exogenously  formed  formaldehyde-DNA 
adducts  in  the  blood  or  bone  marrow.  Because  this 
document  also  addresses  the  issue  of  formaldehyde-
induced leukemia, this omission is puzzling. The failure 
to properly characterize the findings of Lu et al. (2010)1 
in two recent US EPA documents (2010a, 2010b) on the 
subject of formaldehyde-induced leukemia raises ques-
tions about the basis for positions taken on this conten-
tious issue.
Other data are also not accurately characterized and/
or omitted, including (1) primary reliance on only one 
(i.e., Zhang et al., 2009) of several meta-data analyses for 
the conclusion that the equivocal body of epidemiology 
data are strongly supportive of an association between 
formaldehyde  exposure  and  leukemia  while  not  cit-
ing  another  meta-analysis  (Bachand  et  al.,  2009)  that 
was available and the only one to include the updated 
analysis of the NCI cohort (i.e., Beane Freeman et al., 
2009); (2) failure to note the results from a 13-week study 
(Meng et al., 2009) demonstrating a lack of increased p53 
mutations in nasal tissues following exposure to formal-
dehyde suggesting they are not an early driver for later 
tumorigenesis; only the reported cell proliferation data 
from this study were discussed and displayed in a table 
with permission from the authors; (3) uncritical reliance 
by IARC, NTP, and US EPA on a questionable study in 
Chinese workers by Zhang et al. (2010) suggesting that 
formaldehyde  exposure  produced  decreased  red  and 
white blood cell counts and elevations in monosomy 7 
and  trisomy  8  in  peripheral  cultured  stem/progenitor 
cells and that such findings were predictive of develop-
ing leukemia, even though there is no test available in 
hematology or clinical medicine that has been validated 
for this purpose. Table 3 is a comparison of some of the 
positions taken by IARC, NTP, and US EPA on a number 
of key issues pertaining to the use and interpretation of 
the available data. As shown in Table 3, not only do NTP 
and US EPA interpret the same data differently, but also 
in  some  instances  key  data  are  selectively  omitted  by 
NTP while cited by US EPA or vice versa. Table 4 is a com-
parison of the studies relied upon as the basis for IARC, 
NTP, and US EPA conclusions on formaldehyde-induced 
cancers and the process used for their determinations.
The  questionable  biological  plausibility  that  exog-
enous formaldehyde could adversely affect white blood 
cells or be transported to the bone marrow to cause leu-
kemia has been further confirmed by the results reported 
by Lu et al. (2010a), Moeller et al. (2010), and Swenberg 
et al. (2010). The lack of transport of exogenous formal-
dehyde to the bone marrow in non-human primates with 
hematopoietic  systems  virtually  identical  to  humans 
(Szilagyi et al., 2010) casts more doubt on a conclusion 
that formaldehyde is a cause of leukemia. In comparing 
and contrasting the equivocal body of epidemiology data 
with the data showing unequivocally that inhaled exog-
enous  formaldehyde-DNA  adducts  are  undetectable 
beyond the nasal epithelium, one is left with an inescap-
able conundrum—both sets of data cannot be correct. 
Consequently, although it may be appropriate for IARC, 
NTP, or US EPA to rely, at least in part, on what appear to 
be precautionary approaches or perhaps policy consid-
erations as a basis for concluding that there is a causal 
association between exposure to formaldehyde and leu-
kemia, such conclusions cannot be supported based on 
the available science and biological plausibility.
A corollary to this concerns how studies are reviewed 
and  characterized  in  some  of  the  large  supporting 
1  The  Society  of  Toxicology  Board  of  Publications  Best  Paper  in 
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documents compiled. Although ignoring key data (e.g., Lu 
et al., 2009; Meng et al., 2009) cannot be condoned, criti-
cally reviewing other study findings in light of the totality 
of data on a particular issue should be a goal, particularly 
for complex assessments. Simply stated, some studies are 
better than others and this requires a critical assessment 
of methods, potential confounders, conclusions, etc. The 
body of toxicogenomic studies on formaldehyde is a prime 
example of this, with those conducted via inhalation in a 
dose-response manner questioned on the basis of uncer-
tainty, whereas those using a single nasally instilled dose 
were accepted due to the reported finding of changes in 
DNA repair genes. Although a precautionary approach 
may be justified for assessing risks about chemicals for 
Table 3.  Comparison of IARC, NTP, and US EPA use of or reliance on data from key studies addressed in present review.
Study/ issue/findings IARC (2009)a NTP (2010) US EPA/IRIS (2010a)
Lu et al. (2009)/)—Lack of 
exogenous FA-DNA adducts 
at any sites distant to nasal 
epithelium
Study not available for 
most recent assessment; 
acknowledged as key issue by 
Smith and Goldstein (2010)b
Background document: 
Acknowledged finding of no 
exogenous FA-DNA adducts at any 
sites distal to nasal epithelium.
Expert panel report: Not mentioned.
Cited only for finding of endogenous 
FA-DNA adducts; failed to mention 
key finding of no exogenous FA-DNA 
adducts detected at any sites distal to 
nasal epithelium.
Meng et al. (2010))—No 
increase in p53 mutations in 
nasal epithelium following 
13 13-wk exposure to FA at 
up to 15 ppm
Not available Background document: Not cited 
Expert panel report: Not mentioned
Cited only for findings on cell 
proliferation (used with permission 
of authors); did not mention that p53 
mutations not increased after 13 wks 
exposure to FA at 15 ppm
Marsh et al. (2004, 2005, 
2007) —Re-analyses of 
NCI cohort data on NPC 
and leukemia; alternative 
explanation for increased 
NPC in Plant 1 and 
implications of significant 
mortality deficits on RR 
calculations.
Not available Background document: Marsh et al. 
(2007): Misrepresents key findings 
on previous exposure to metals and 
acids as plausible explanation for 
increased NPC in Plant #1 in NCI 
cohortExpert panel report: Ignored 
all Marsh et al. re-analyses of NCI 
data
Marsh 2004: Failed to cite 
reanalysis of NCI cohort data on 
leukemia;Marsh 2007: Inaccurately 
characterizes key findings, e.g., 
previous exposure to metals and 
acids as plausible explanation for 
increased NPC in NCI cohort
Beane Freeman et al. 
(2009);)—Update of NCI 
cohort; reveals >1000 
missing deaths in previous 
studies (Hauptmann et al., 
2003, 2004)
Not available Background document: Findings 
accurately characterizedExpert 
panel report: Incorrectly implied 
study as reporting significant 
increased mortality from AML
Inappropriately relied on to support 
conclusion of FA-induced increased 
risks of all forms of leukemia (AML, 
CML, ALL, CLL) and Hodgkin’s 
lymphoma; relied on statistically 
insignificant cumulative exposure 
findings for cancer risk projections
Bachand et al. (2009)—
Meta-analysis of leukemia 
and NPC epidemiology 
data, only meta-analysis 
to include Beane Freeman 
et al. (2009)
Not available Background document: Findings 
accurately characterized for NPL 
and leukemia.Expert panel report: 
Not mentioned or cited.
Not cited or discussed even though 
available; sole reliance on Zhang 
et al. (2009) cited 44 times as primary 
support for interpreting Beane 
Freeman et al. (2009) findings that 
all forms of leukemia and Hodgkin’s 
lymphoma causally associated with 
exposure to formaldehyde
Conolly et al. (2003, 2004)—
Biologically based dose 
response (BBDR) model for 
FA-induced nasal tumors
Not available Background document: Both 
studies discussedExpert panel 
report: Neither study mentioned
Appendices D, E, and F devoted to 
questioning/critiquing basis for and 
conclusions from BBDR model
Andersen et al. (2008, 
2010)—3 and 13- wk FA 
inhalation dose-response 
toxicogenomic studies; 
Thomas et al. (2007); 
benchmark dose analysis
Not available Background document: 2008 study 
mentioned.Expert panel report: 
Neither study mentioned.
Appendices G and H devoted to 
questioning/critiquing conclusions 
of dose-response toxicogenomic 
data and benchmark dose analysis; 
primary emphasis on Hester et al. 
(2003, 2005) single dose nasal 
instillation studies
Fox et al. (1985) and 
Matubayasi et al. (2007)—
Basis for explaining FA 
toxicity at distant sites due 
to methanediol dissociation 
to free FA
Fox: Summarizes FA use at 
4% (40,000 ppm) for tissue 
fixation; no explanation for 
relevance in living systems 
(2 ppm)c
Fox: Summarizes FA use at 4% 
(40,000 ppm) for tissue fixation; no 
explanation for relevance in living 
systems (2 ppm) Matubayasi: Article 




a: Complete report on 2009 meeting not yet available.
b: bGoldstein, B.D. and, Smith, M.T. (2010). Formaldehyde. Identification of research needs to resolve the carcinogenicity of high priority 
IARC carcinogens. IARC Technical Publication No. 42. Lyon, France: IARC.
c: cPreliminary IARC report.Indoor air exposure limit for formaldehyde  709
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Table 4.  Comparison of the basis for IARC, NTP, and US EPA conclusions on formaldehyde-induced cancers. 
Study/ issue/




Vote of working group: 
11 to 9 for leukemia
Vote of Expert Panel: Single 11 to 0 
vote for AML, NPC, and SNC
Key selected studies 
with little if any 
critical assessment of 
methodological issues.
Single NTP vote for all 
endpoints presumes 




and key studies 
relied on as 
primary support
Leukemia and NPC AML, NPC, and sinonasal cancer 
AML: Beane Freeman (2009), 
Hauptmann (2009), Coggin 
(2003), and Pinkerton (2004); 3 
of 4 studies found elevated risks 
of AML in individuals with high 
exposure to FA, as well as positive 
exposure-response relationships. 
NPC: Hauptmann 2004; the only 
cohort study that is individually 
informative for NPC
AML, CML, ALL, CLL, 
Hodgkin’s lymphoma, 
and NPC Beane Freeman 
(2009), Zhang (2009, 2010), 
Hauptmann (2004)
Only NTP concluded 
that sinonasal cancer an 
endpoint associated with 
FA exposure; US EPA/
IRIS uses statistically 
insignificant cumulative 
exposure data from 
Beane Freeman as basis 
for yearly incidence 




et al. (2009); 
most recent 
update of NCI 
cohort
Primary support for 
leukemia
AML not significantly elevated 
based on peak, no. of peaks, 
cumulative, duration, or average 
intensity of exposure; no significant 
trends
Does not support 
conclusion of FA-induced 
increased risks of all forms 
of leukemia (AML, CML, 
ALL, CLL) and Hodgkin’s 
lymphoma; insignificant 
cumulative exposure 
findings used for cancer 
incidence risk projections
No consideration of 
numerous issues with 
study; no mention of 
implications of >1000 
missed deaths
Coggin et al. 
(2003)
No significant increase 
in NPC or all forms 
of leukemia; myeloid 
leukemia not separately 
evaluated
No significant increase in all forms 
of leukemia; myeloid leukemia not 
separately evaluated
No significant increase in all 
forms of leukemia; myeloid 
leukemia not separately 
evaluated;
Little, if any, emphasis on 
study findings as basis for 
conclusions




20+ years after first 
exposure; test for trend 
not positive; no NPC 
cases.
Myeloid leukemia significantly 
elevated 20+ years after first 
exposure; test for trend not positive; 
no NPC cases
Myeloid leukemia 
significantly elevated 20+ 
years after first exposure; 
test for trend not positive; 
no NPC cases.
Little, if any, emphasis on 




Not cited in IARC 
(2009). Formaldehyde 
4. Mechanistic and 
other relevant data. Vol. 
100F, Monograph No. 
09-Formaldehyde,
Duration of embalming practice 
associated with significantly 
increased risk for mortality from 
myeloid leukemia; myeloid 
leukemia significantly associated 
with increasing number of years 
of embalming (p 
trend = .020) and 
with increasing peak formaldehyde 
exposure (p trend = .036).
Duration of embalming 
practice associated with 
significantly increased risk 
for mortality from myeloid 
leukemia; myeloid leukemia 
significantly associated 
with increasing number 
of years of embalming 
(ptrendP trend = .020) and 
with increasing peak 
formaldehyde exposure 
(ptrendP trend = .036).
Formaldehyde exposure 
not measured; number of 
embalming a surrogate 
for exposure; major issue 
concerns failure to test 




Primary support for 
NPC
Primary support for NPC Primary support for NPC Most reviews dismiss or 
ignore analysis by Marsh 
et al. (2007) showing 
previous exposure to 
known NPC risk factors 





findings not accurate 
due to failure to 
account for >1000 
missing deaths
Reported leukemia findings not 
accurate due to failure to account 
for >1000 missing deaths
Reported leukemia findings 
not accurate due to failure 
to account for >1000 missing 
deaths
Analyses by Marsh et al. 
(2004, 2007) demonstrate 
substantial attenuation of 
risks after accounting for 
>1000 missing deaths
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which there are sparse data, lack of data is hardly the 
case for formaldehyde. This is also why it is surprising to 
see the results of the controlled human exposure studies 
on formaldehyde-induced sensory irritation essentially 
ignored in favor of studies where reported results cannot 
be reliably attributed solely to formaldehyde. The same 
appears to be the case for the criticisms of the BBDR 
model, the conclusions of which have been accepted by 
numerous reviewing entities including NAS (2007).
As  briefly  summarized  above,  an  NRC  committee 
(NAS  2011)  recently  completed  its  evaluation  of  the 
EPA’s draft IRIS assessment of formaldehyde reaching 
many of the same conclusions as this review.  This criti-
cal assessment “…found that the draft was not prepared 
in a consistent fashion; it lacks clear links to an underlying 
conceptual framework; and it does not contain sufficient 
documentation on methods and criteria for identifying 
evidence from epidemiologic and experimental studies, 
for critically evaluating individual studies, for assessing 
the weight of evidence, and for selecting studies for deri-
vation of the RfCs and unit risk estimates.”  This was par-
ticularly the case for the studies selected and relied upon 
to derive the RfCs for sensory irritation and asthma.  The 
committee was also critical about EPA’s efforts to mar-
ginalize the BBDR model with “manipulations of model 
parameters that yield results that are logically implau-
sible” and instead concluded that “Given that the BBDR 
model  for  formaldehyde  is  one  of  the  best-developed 
BBDR  models  to  date,  the  positive  attributes  of  BBDR 
models generally, and the limitations of the human data, 
the committee recommends that EPA use the BBDR model 
for formaldehyde in its cancer assessment, compare the 
results with those described in the draft assessment, and 
discuss the strengths and weaknesses of each approach.”   
Readers are encouraged to peruse the NRC review for 
additional insights of the committee pertaining to the 
EPA/IRIS  assessment  (http://www.nap.edu/catalog.
php?record_id=13142.)
Study/ issue/
findings IARC (2009)a NTP (2010) US EPA/IRIS (2010a) Comment
Zhang et al. 
(2009); meta-
analysis
Cited in bibliography; 
no indication how used 
to reach conclusions.
“ ...more informative because it 
used data for individuals with the 
highest exposure to formaldehyde 
to calculate the summary relative 
risks.”
Cited 44 times to support 
reliance on Beane Freeman 
(2009) results for all 
leukemia and Hodgkin’s 
lymphoma
Findings at odds with 
2 other meta-analyses 
including Bachand et al. 
(2009), which is only one 
to include the Beane 
Freeman results.
Zhang et al. 
(2010); Chinese 
worker study
Support for biological 
plausibility of 
epidemiology results; 
no critical assessment 
of methods or assertion 
that FA equivalent 
to benzene in 
leukemogenic potential
Support for biological plausibility 
of epidemiology results; no critical 
assessment of methods or assertion 
that FA equivalent to benzene in 
leukemogenic potential
Support for biological 
plausibility of epidemiology 
results; no critical 
assessment of methods or 
assertion that FA equivalent 





undermine study; no 
critical assessment of 
reported conclusions.











Support for FA-induced 
hematotoxicity; reported results 
uncritically accepted.
Support for FA-induced 
hematotoxicity; reported 
results uncritically accepted.
All but one study in 
Chinese; only study 
in English does not 
support FA-induced 
hematotoxicity
Fox et al. 
(1985); basis 
for claiming 
FA toxicity at 




Cited to explain how 
methanediol could 
dissociate at distant 
sites to release free 
FA as explanation for 
leukemia
Cited to explain how methanediol 
could dissociate at distant sites to 
release free FA as explanation for 
leukemia
Not cited; still implies that 
FA or methanediol may 
reach sites distal to portal 
of entry
Article on use of 4% 
formalin for tissue 
fixation (40,000 ppm); not 
relevant for living systems 
(2 ppm)
Matubayasi et al. 
(2007); basis 
for claiming 
FA toxicity at 




Cited to explain how 
methanediol could 
dissociate at distant 
sites to release free 
FA as explanation for 
leukemia
Cited to explain how methanediol 
could dissociate at distant sites to 
release free FA as explanation for 
leukemia
Not cited; still implies that 
FA or methanediol may 




in boiling water; no 
relevance for living 
systems.
FA = formaldehyde.
aComplete report on 2009 meeting not yet available.
bGoldstein BD, Smith MT. (2010). Formaldehyde. Identification of research needs to resolve the carcinogenicity of high priority IARC 
carcinogens. IARC Technical Publication No. 42. Lyon: IARC.
cPreliminary IARC report.
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The  remainder  of  this  discussion  provides  a  broad 
overview of the data and their implications on the three 
endpoints of primary concern in this review, i.e., sensory 
irritation, NPC, and leukemia.
A.Sensory irritation
For  formaldehyde-induced  sensory  irritation,  because 
the extensive controlled human exposure data have been 
widely accepted by numerous regulatory and authorita-
tive entities, there is little dispute that these data accu-
rately and quantitatively characterize human responses, 
including expected behavior in sensitive individuals and 
people with asthma. However, these results were not the 
primary  basis  for  assessing  human  sensory  irritation 
responses to formaldehyde. For instance, the US EPA/
IRIS (2010a) formaldehyde assessment established the 
reference  concentrations  (RfCs)  for  sensory  irritation 
based on three “co-critical” residential and mobile home 
exposure studies (Ritchie and Lennen, 1987; Hanrahan 
et al., 1984; Liu et al., 1991) while marginalizing the con-
trolled  human  volunteer  chamber  studies.  They  argue 
that  the  controlled  human  chamber  studies  are  acute 
in nature, use few individuals, and include only healthy 
volunteers.  However,  deficiencies  of  the  studies  relied 
upon are not discussed. Because indoor air is a complex 
mixture of numerous chemicals (e.g., VOCs) and biologi-
cal  substances  (e.g.,  fungal  spores),  which  themselves 
produce irritant effects, any conclusions attributing such 
effects solely to formaldehyde in these types of environ-
ments are suspect.
With respect to the assertion that the controlled stud-
ies are acute in nature (even though several span several 
weeks), ignore the results derived from human chamber 
studies that show that once symptoms are produced at a 
certain concentration, they are not enhanced with addi-
tional exposure duration. Notably, the issue of Haber’s 
Law  and  the  line  of  analysis  upon  which  NAS  (2007) 
relied to establish chronic exposure levels based on the 
controlled  human  exposure  data  is  not  mentioned  in 
the Draft US EPA/IRIS Assessment. Importantly, Haber’s 
Law is not relevant for formaldehyde-induced irritation 
effects,  an  observation  confirmed  by  Andersen  et  al. 
(2008, 2010) with toxicogenomic data demonstrating that 
continuing exposure at doses <2 ppm do not result in a 
progression of responses. The minimal response concen-
tration of a family of seven sensitive response genes was 
essentially identical for 1, 4, and 13 weeks of exposure.
The fact that the large body of controlled human expo-
sure data has been reviewed and/or relied upon numer-
ous  times  for  establishing  formaldehyde  air  levels  to 
prevent the symptoms of sensory irritation by regulatory 
and authoritative bodies worldwide (e.g., US EPA, NAS, 
Canada’s Health Canada, Australia’s NICNAS, Germany’s 
BFR, OECD, WHO), attests to their validity and useful-
ness. Consequently, the indoor air value established in 
this review of 0.1 ppm can be considered to be protective 
from the symptoms of sensory irritation for all individu-
als, including children, asthmatics, and the elderly, for 
a lifetime of exposure. Since the data relied upon were 
derived  exclusively  from  controlled  human  exposure 
studies, there is no justification for further “adjustments” 
by the use of uncertainty factors. In contrast, the US EPA/
IRIS RfCs for sensory irritation ranged from 9.5 to 23 ppb 
or 32 to 70 ppb incorporating an uncertainty factor (UF) 
of 3 or 1, respectively. As discussed in this review, because 
the studies investigating formaldehyde and sensory irri-
tation in either residential or occupational environments 
involve  numerous  confounding  co-exposures,  there  is 
substantial certainty that they are not a valid basis for 
reaching conclusions on the effects of exposure to form-
aldehyde alone.
B.Nasopharyngeal cancer (NPC)
The  epidemiology  data  causally  linking  formaldehyde 
exposure  to  the  development  NPC  are  equivocal  with 
the findings from the NCI 10-plant study by Hauptmann 
et  al.  (2004)  as  the  primary  evidence  for  this  associa-
tion. The distribution of NPC cases over the 10 plants 
studied with five cases at 1 plant and the other four cases 
randomly  distributed  among  the  remaining  9  plants 
is  inconsistent  with  a  causal  relationship  to  exposure. 
The lack of any increase in NPC in an additional 25,000 
occupationally  exposed  workers,  many  of  whom  were 
exposed to higher formaldehyde levels than in the NCI 
cohort, also do not support a causal association (Coggon 
et al., 2003; Pinkerton et al., 2004). The multiple analyses 
of Plant 1 and the NCI cohort data by Marsh et al. (2002, 
2005, 2007a, 2007b) also cast doubt on this association. 
Characterizations of these analyses in the US EPA/IRIS 
document  are  of  interest.  While  noting  the  numerous 
analyses by Marsh and colleagues of Plant 1, US EPA/IRIS 
concludes that “…no convincing and consistent alterna-
tive hypothesis of causation has been identified” (US EPA, 
2010a, pp. 6–18). Marsh et al. (2007) showed that previous 
employment in metalworking industries was highly likely 
and could readily explain the NPC cases in Plant 1. Since 
all of the NPC cases in Plant 1 occurred after a relatively 
short time of employment at this facility, such a scenario 
is inconsistent with a causal relationship between NPC 
and  formaldehyde.  The  US  EPA/IRIS  assessment  cor-
rectly  notes  a  discrepancy  between  the  Marsh  et  al. 
(2007) abstract and text in the OR for “silversmithing and 
other metal work.”2 Additionally, it is implied that mul-
tiple comparisons in Marsh et al. (2007) may have led to 
the reported observation with silversmithing. This inter-
pretation is incorrect, since this study was not an explor-
atory “fishing expedition” type of analysis. The issue of 
previous employment was an a priori hypothesis that was 
tested with a limited number of comparisons.
The proposed causal link between formaldehyde and 
NPC in humans is also inconsistent with the mechanistic 
2 The OR of 14.41 in the abstract was incorrectly listed for “silversmithing” 
alone and should have been 7.31 as in the text for “silversmithing and 
other metal work” with the same 95% CI of 1.08–82.1 as shown in Table 4 
of Marsh et al. (2007) (G. Marsh, personal communication).712  R. Golden
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research  with  rodents.  The  remarkable  concordance 
between cytotoxicity and regenerative proliferation has 
been augmented with toxicogenomic data showing clear 
evidence of dose-dependent transitions in genes most 
likely associated with tumor formation (including DNA 
repair genes) only at ≥6 ppm has several implications.
First,  in  discussing  the  MOA  for  formaldehyde-
induced nasal tumors, the US EPA/IRIS (2010a) assess-
ment takes the position that mutations play a necessary 
early  etiological  role  in  nasal  tumorigenesis,  which  is 
consistent with a presumption that a linear, no-threshold 
model must be used to assess potential risks. If this is cor-
rect, one would expect to see toxicogenomic evidence of 
effects on DNA repair genes at the lowest formaldehyde 
doses tested (i.e., 0.7 and 2 ppm) over the course of up 
to 13 weeks of exposure, but this has not been reported 
(Andersen et al., 2008, 2010). The apparent reliance on 
single-dose nasal instillation studies (e.g., Hester et al., 
2003, 2005) that report effects on DNA repair genes as the 
basis for presuming that early mutations play an etiologi-
cal role in nasal tumorigenesis ignores the fact that the 
single  formaldehyde  dose  by  instillation  up-regulated 
3 times more genes that an inhalation dose of 15 ppm 
(Andersen et al., 2008).
Second,  the  US  EPA/IRIS  assessment  goes  to  great 
lengths  (Appendices  D,  E,  F,  G,  and  H)  to  question  the 
validity  and/or  utility  of  the  substantial  data  pertaining 
to rat nasal tumorigenesis, including the toxicogenomic 
data (Andersen et al., 2008, 2010), and derived benchmark 
dose analyses (Thomas et al., 2008) of these data as well as 
the BBDR model (Conolly et al., 2003, 2004). Much of the 
analyses address the issue of uncertainty as this concept is 
now used. However, the body of available data is now able 
to explain with considerable certainty the MOA and dose-
dependent sequence of events leading to nasal tumorigen-
esis. The US EPA (2010a) analysis also fails to consider the 
inhaled concentrations required to enhance tissue formal-
dehyde even in the proximal tissues of the nose.
Third, it is worthwhile to point out that the formalde-
hyde  concentrations  that  produce  tumors  in  rats  (i.e., 
≥6 ppm) are so irritating to human nasal tissue that they 
simply  cannot  be  tolerated  for  a  prolonged  period  of 
time. Due to this irritant potential, it is unlikely that any 
human could remain in the presence of formaldehyde 
at  sustained  concentrations  (≥6 ppm).  The  lack  of  any 
nasal tissue histopathology (i.e., squamous metaplasia/
hyperplasia) in rats or monkeys following chronic inha-
lation exposure to formaldehyde at <3 ppm also attest to 
the likely lack of such effects in humans exposed at the 
same concentrations. Indeed, the threshold limit value 
(TLV) of 5 ppm as a time-weighted average (TWA), which 
was in place from 1948 to 1962, was changed in 1963 to 
a ceiling (i.e., maximum instantaneous concentrations) 
and subsequently lowered to 2 ppm (ceiling) and eventu-
ally to a ceiling of 0.3 ppm (Paustenbach et al., 1997). It 
is now well established that formaldehyde levels in the 
range of ≈5 ppm can produce the cytotoxicity and cellu-
lar proliferation that are the obligatory precursor events 
in nasal carcinogenesis. This is supported by the INDEX 
(2005) report, which concluded, “A large body of data 
suggests an association between the cytotoxic, genotoxic, 
and carcinogenic effects of formaldehyde. The crucial role 
of tissue damage followed by hyperplasia and metaplasia 
of the nasal respiratory epithelium in formaldehyde car-
cinogenesis has been demonstrated in a convincing way. 
Thus, formaldehyde in non-cytotoxic concentrations most 
probably cannot act as a complete carcinogen.”
Substantial evidence on epidemiology, toxicology, and 
mode of action with formaldehyde calls into question the 
default that serves as the basis for US EPA’s current cancer 
10−6 risk potency value for formaldehyde (0.08 ppb), a calcu-
lation that assumes there is no threshold for nasal tumori-
genesis and thus no safe level of exposure (IRIS, 1991). The 
most recent US EPA/IRIS (2010a) evaluation of formalde-
hyde lowered the 10−6 risk value to 0.008 ppb (8 ppt), a level 
well below the range of formaldehyde measured in human 
breath (i.e., <0.5–2 ppb) or air concentrations in pristine 
rural locations. In fact, based on this value (i.e., 0.008 ppb), 
the range of exhaled formaldehyde in human breath would 
pose unacceptable cancer risks (i.e., >10−4). For all practi-
cal purposes, this exposure recommendation suggests that 
talking to one another carries a potential cancer risk from 
exhaled formaldehyde in the breath. According to US EPA’s 
cancer risk assessment guidelines, the default assumption 
is meant to be used when there are no data establishing a 
mode of action inconsistent with low-dose linearity or the 
absence of a threshold (US EPA, 2005). The amount and 
consistency of the data that have been developed charac-
terizing the MOA for formaldehyde-induced nasal tumors 
would appear to support departing from the no-threshold 
default assumption and applying a mode of action–based 
risk value. This position has been taken by numerous regu-
latory or authoritative bodies in concluding that the form-
aldehyde  exposure  concentration  protective  for  sensory 
irritation is also protective for nasal cancer.
Additional new data further challenge the current pre-
sumption of no threshold for formaldehyde-induced nasal 
tumors in rodents and derivation of cancer risk values based 
on linear extrapolations from either animal or epidemiol-
ogy data. A recent study by Moeller et al. (2010) determined 
the  presence  of  endogenous  and  exogenous  formalde-
hyde-DNA adducts from nasal mucosa and bone marrow 
of cynomolgus macaques exposed to 1.9 and 6.1 ppm of 
13CD2-formaldehyde for 6 hours a day for 2 consecutive 
days.  Both  exogenous  and  endogenous  formaldehyde-
DNA adducts were readily detected and quantified in the 
nasal tissues of both exposure groups, with an exposure-
dependent  increase  in  exogenous  formaldehyde-DNA 
adducts  observed.  In  the  nasal  tissue  DNA,  exogenous 
formaldehyde-DNA adducts were present at 0.26 ± 0.04 and 
0.41 ± 0.41 adducts/107 dG (N2-hydroxymethyl-dG) follow-
ing the 1.9 and 6.1 ppm exposures, respectively, whereas 
endogenous adducts were present in the nasal DNA of all 
animals, with an average of 2.24 ± 0.50 adducts/107 dG. It 
is unlikely that any mechanism exists in which exogenous 
formaldehyde-DNA  adducts  formed  following  1.9  or Indoor air exposure limit for formaldehyde  713
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6.1 ppm exposures, which contribute less than the stan-
dard  deviation  of  identical  endogenous  formaldehyde-
DNA adducts, could drive the biology that leads to nasal 
carcinogenesis in a non-threshold manner. Consequently, 
a formaldehyde vapor concentration of 0.1 ppm, which is 
protective for sensory irritation of the eyes, will also be far 
below the level that would initiate the sequence of events 
leading to nasal cancer, even in the most exposed tissues in 
the proximal epithelium of the nasal tract.
C.Leukemia
With respect to formaldehyde-induced leukemia, there 
remain substantial uncertainties concerning this associa-
tion, in particular the questionable biological plausibility 
for this endpoint. As discussed, the epidemiology findings 
for leukemia are equivocal, with the significant mortality 
deficits for this endpoint in non- and low-exposed workers 
in the NCI cohort studies that are used for purposes of the 
internal comparisons substantially driving the reported 
results. Although the NCI cohort studies by Hauptmann 
et  al.  (2003)  and  the  update  by  Beane  Freeman  et  al. 
(2009) are discussed and substantially relied upon in the 
various evaluations, none of these critical reviews address 
the obvious problems and implications of the leukemia 
mortality deficits. As reported by Marsh et al. (2004) who 
reanalyzed the NCI cohort data (although this study was 
not cited in the US EPA/IRIS assessment), when the leu-
kemia  mortality  in  exposed  workers  was  compared  to 
local rates, there was no increase.
Although the Zhang et al. (2010) study results in Chinese 
workers were clearly in conflict with the established chem-
istry, biochemistry, and toxicokinetics of formaldehyde, 
they were uncritically accepted by IARC, NTP, and US EPA 
in their evaluations. In particular, the characterizations in 
the assessments by IARC and NTP of the biochemical data 
concerning  methanediol  with  the  implication  that  this 
formaldehyde hydration product might be a way that free 
formaldehyde could be transported and released at dis-
tant sites were inappropriate. In addition, the assertion by 
Zhang et al. (2010) that a reported finding of aneuploidy, 
as demonstrated by increased monosomy 7 and trisomy 8 
in healthy workers, was an early indication of future leu-
kemia should have raised a flag, since there is no test in 
hematology or clinical medicine that is predictive of this 
disease.  Furthermore,  the  literature  on  formaldehyde-
induced mutations, both in vitro and in vivo, has not dem-
onstrated that aneuploidy is a consequence of exposure. 
Instead, without considering any of the numerous meth-
odological and interpretative issues as discussed in this 
review, this study was uncritically accepted as support for 
the equivocal epidemiology findings.
Relevant data from the Zhang et al. (2010) study were 
recently obtained pursuant to a Freedom of Information Act 
(FOIA) request to NCI. A critical assessment of these data 
will be addressed in a separate publication. One aspect of 
the information obtained that requires minimum analysis 
concerns the number of cells that were counted as the basis 
for the key reported finding. Determination of monosomy 
7 and trisomy 8 in exposed workers (N = 10) and controls 
(N = 12) was examined in cultured CFU-GM colony cells 
using  fluorescence  in  situ  hybridization  (FISH)  and  as 
described by Zhang et al. (2010),  “…all scorable metaphase 
spreads on each slide were analyzed, and a minimum of 150 
cells per subject were counted.” Based on this analysis, it was 
reported that the frequency of monosomy 7 and trisomy 8 
in exposed workers were significantly elevated compared 
to controls. From this it was concluded that formaldehyde 
exposure was “…associated with an increase in leukemia-
specific chromosomal aneuploidy in the hematopoietic pro-
genitor cells of the exposed workers.” However, the raw data 
obtained from NCI clearly has shown that far fewer cells 
were actually analyzed in the majority of cases than the 
minimum of 150 cells per subject, as stated. For monosomy 
7, there were only 1 exposed and 4 control cases in which 
150 cells were scored and for the remaining cases, the total 
number of cells counted ranged from 18 to 140. For trisomy 
8, there were only 3 exposed and 3 controls in which 150 
cells were scored, with the remaining cases reported cells 
counts ranging from 21 to 149. This deficiency has a sub-
stantial effect on the reported differences between exposed 
and controls, since FISH assays are subject to correction 
for background and sensitivity errors and due to statistical 
limitations inherent in scoring of FISH assays, a minimum 
of 200 cells are typically required in order to report a valid 
result in a clinical setting. For example, although statisti-
cally  significant  differences  were  reported  for  trisomy  8 
(1.21%  and  0.32%  for  exposed  and  unexposed  subjects, 
respectively), if the analysis is limited to cases where >100 
cells (but <150) are counted, the percentage with trisomy 
8 is nearly identical (i.e., 1.04% and 0.94% for exposed and 
controls, respectively. This preliminary analysis of one of 
the major reported findings from the Zhang et al. (2010) 
study suggests that caution be used in relying on such data 
as the basis for any conclusions about the likelihood of 
formaldehyde-induced leukemia.
Consequently, given the substantial uncertainties in 
the epidemiology data as well as the highly question-
able  biological  plausibility  that  inhaled  formaldehyde 
was capable of inducing leukemia, no attempt was made 
here to derive a formaldehyde exposure level that would 
be protective for leukemia. Unless other empirical data 
appear that would offset what is now known about the 
likelihood of formaldehyde-induced leukemia, it can be 
concluded that a formaldehyde concentration of 0.1 ppm 
would be protective for leukemia or cancer at any other 
site within the body.
D.Chance as a potential source of uncertainty in 
epidemiology studies
Because  there  appears  to  be  a  reasonable  likelihood 
that both of the key epidemiology results reported (i.e., 
increased NPC and leukemia) could be false positives, 
it is illustrative to note a recent commentary by Boffetta 
et  al.  (2008)  on  false-positive  results  in  cancer  epide-
miology studies. According to these authors (and using 
as  examples  some  of  the  generic  issues  raised  in  this 714  R. Golden
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review), Table 5 illustrates some examples that could “…
lead to the occurrence and reporting of false positives.”
The  issues  summarized  in  Table  5  suggest  that  the 
NCI studies should have been more critically assessed by 
reviewing agencies instead of simply accepting the reported 
results. The numerous analyses (some of which have not 
been cited in review documents) of the NCI data set by 
Marsh and colleagues on both NPC and leukemia as iden-
tified in Table 5 raise a number of relevant issues. The read-
ers are left to assess the validity and biological plausibility 
of the purported causal association between formaldehyde 
exposure and the development of either NPC or leukemia.
E.US EPA’s projected cancer risks from inhaled 
formaldehyde
Based  primarily  on  the  NCI  cohort  studies  on  25,000 
exposed workers, the US EPA/IRIS (2010a) assessment con-
cluded that exposure to formaldehyde caused all four types 
of leukemia (AML, CML, ALL, CLL), Hodgkin’s lymphoma, 
and NPC. Recognizing that it was not possible to extrapo-
late potential risks based on the peak exposure metric, for 
leukemia and lymphoma, risk estimates were based on the 
RRs using the cumulative exposure metric (none of which 
were  statistically  significant)  for  both  endpoints.  Using 
data from the Surveillance, Epidemiology, and End Results 
(SEER)  registry,  crude  upper  bound  projections  of  the 
number of people who would develop these cancers each 
year in the United States from exposure to formaldehyde 
were developed. Based on the SEER data, each year in the 
United States there are approximately 44,800 cases of leu-
kemia (all types), 8500 cases of Hodgkin’s lymphoma, and 
about 2100 cases of NPC. Table 6 illustrates the US EPA/
IRIS cancer projections based on assumed exposures of 5 
ppb and 20 ppb of formaldehyde (a common level found in 
indoor air) and the fraction of total yearly cases attributed 
to  formaldehyde  at  these  exposure  levels.  In  addition, 
since the relationship between exposure to formaldehyde 
and disease is approximately proportional, the cases that 
might result from exposure to the ACGIH (i.e., 300 ppb) 
or OSHA (750 ppb) standards, which are 15 and 38 times 
more,  respectively  than  20  ppb,  are  included.  In  addi-
tion, because formaldehyde is exhaled in the breath at an 
upper limit of ≈2 ppb, US EPA’s cancer projections would 
suggest that such levels could be the cause of 758/44,800, 
136/8500, and 88/2100 yearly cases of leukemia, Hodgkin’s 
lymphoma, and NPC, respectively, in the United States.
The cancer projections illustrated in Table 6 were criti-
cized by scientists from one of the government agencies 
that reviewed the draft US EPA/IRIS prior to its release, 
i.e., “Given this large uncertainty [i.e., problems pertain-
ing to the use of the peak exposure metric], and the lack 
of significance with any other metric, it seems premature 
at this time to use this [cumulative exposure] as a basis 
of cause and effect, and then to take the non-significant 
exposure trend for cumulative exposure and base an esti-
mate of risk on it” (US CPSC, 2010).
Because of the highly uncertain nature of any associations 
between inhalation exposure to formaldehyde and either 
NPC or leukemia, no credible evaluation is possible for esti-
mating likely incidence. This conclusion is particularly the 
case for leukemia, since the plausibility for this association 
appears to depend on a biologically implausible mode of 
action as well as ignoring the unequivocal demonstration 
that no inhaled formaldehyde is transported beyond the 
nasal epithelium to reach any distal sites in the body.
VI.Conclusions
If  ever  there  were  a  compelling  case  for  an  evidence-
based assessment of an extraordinarily large body of data, 
Table 5.  Possible contributors leading to false positive results in NCI cohort studies.
Generic issue Suggested examples
Chance Statistically significant deficits in leukemia mortality in internal non- and low-exposed comparison groups 
that substantially influence RR calculations. This single issue alone, if properly addressed and accounted for, 
would appear to undermine any conclusion about a causal association between formaldehyde exposure and 
leukemia.
Systematic errors in design 
of study
Questionable reliance on an unconventional measure of exposure, (i.e., peak); all significant associations 
with leukemia mortality disappeared when assessed using cumulative number of peaks ≥4 ppm as a more 
appropriate metric of potential exposure.
Analysis of study Failure to consider using an external comparison group in light of significant mortality deficits in internal 
groups; as shown by the Marsh et al. (2004) analysis, significant effects disappeared when this was done. In 
addition, the implications of >1000 deaths missed in the 1994 follow-up, and the substantial effects of these 
missed deaths on the RRs as shown in Table 2, should have been addressed.
Inadequate accounting for 
confounding variables
Previous employment in occupations with exposure to known risk factors for NPC.





Projected cases at various formaldehyde exposures
5 ppb 20 ppb 300 ppb 750 ppb
Leukemia 44,800 1900 7580 Everyone? Everyone?
Hodgkin’s lymphoma 8500 564 1360 Everyone? Everyone?
NPC 2100 220 880 Everyone? Everyone?Indoor air exposure limit for formaldehyde  715
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formaldehyde would appear to provide the perfect candi-
date. As a highly reactive, naturally occurring endogenous 
compound, with efficient metabolic mechanisms in place 
to protect against increases in concentrations in any tis-
sues, there is a detailed understanding of formaldehyde-
induced toxicity. Despite numerous epidemiology studies 
that have raised a specter of formaldehyde-induced NPC 
and leukemia, both endpoints now appear more likely to 
be false positives, as these findings are inconsistent with 
an ever-increasing body of data demonstrating that such 
effects simply cannot occur under any real-world expo-
sure scenario. Why else would NAS, WHO, SCOEL, BfR, 
OECD, Health Canada, NICNAS, and for sensory irritation 
even US EPA (2005) reach conclusions essentially identi-
cal to those reached in the present review?
When ATSDR (2000) reviewed the carcinogenicity of 
polychlorinated biphenyls (PCBs), it took a common sense 
approach for assessing a large body of data by adopting a 
methodology in which the observed and expected mor-
tality from each type of cancer in multiple occupational 
cohort mortality studies involving thousands of workers 
were compared to determine if there was a significant dif-
ference. In essence, this approach asks the straightforward 
question—is there a discernable signal from a large body 
of  data  in  highly  exposed  workers  from  many  different 
plants of an increase in a particular type of cancer? When 
this approach is applied to what are clearly the three larg-
est and longest followed formaldehyde-exposed occupa-
tional cohorts where this method can be used (i.e., Beane 
Freeman et al., 2009; Coggon et al., 2003; and Pinkerton 
et al., 2004), encompassing more than 50,000 workers, the 
results are illuminating. For leukemia (Table 7), a total of 
152 cases have been observed with 153 expected, whereas 
for NPC a total of 9 cases have been observed with 5 cases 
expected. Coggin et al. (2003) also assessed a subcohort 
of  4000  men  with  high  exposure  (>2 ppm);  no  cases  of 
NPC  were  observed.  Notably,  the  excess  of  NPC  cases 
in the NCI cohort (Plant 1) quite reasonably attributable 
to other exposures now stand out even more starkly as 
unlikely related to formaldehyde. It is difficult to envision 
a scenario in which the 6 cases of NPC in the approxi-
mately 7000 workers in Plant 1 were due to formaldehyde 
but not a single case of NPC occurred in the other 43,000 
occupationally exposed workers. As shown in Table 7, the 
observed and expected mortality data for leukemia and 
NPC in more than 50,000 formaldehyde-exposed workers, 
followed in some cases for more than 60 years, illustrate 
quite clearly that even occupational exposure to formal-
dehyde is not a cause of leukemia or NPC. This is further 
confirmation that an indoor air formaldehyde concentra-
tion of 0.1 ppm, which is protective for the symptoms of 
sensory irritation, will also be protective for both leukemia 
and NPC, a conclusion consistent with other reviews.
Rhomberg et al. (2011) recently completed a some-
what  different  type  of  evaluation  of  essentially  the 
same body of data as in the present review pertaining 
specifically  to  the  issue  of  whether  formaldehyde  was 
capable of causing leukemia as suggested primarily by 
the epidemiology studies. This evaluation involved the 
application of an explicit hypothesis-based weight-of-ev-
idence approach to evaluating the large body of evidence 
regarding  formaldehyde-induced  leukemia,  including 
all  human,  animal,  and  relevant  mode-of-action  data 
and how this large body of evidence informs an overall 
conclusion. Importantly, this approach explicitly consid-
ered an often-overlooked aspect of weight-of-evidence 
evaluation by also addressing when causal explanations 
have been devised to account for results already in hand 
or when post hoc additions or modifications to hypoth-
eses are constructed to explain what might otherwise be 
considered as contradictory findings. As concluded by 
Rhomberg et al., “Upon comparison of alternative propos-
als regarding what causal processes may have led to the 
array of observations as we see them, we conclude that the 
case for a causal association is weak and strains biological 
  plausibility. Instead, apparent association between form-
aldehyde inhalation and leukemia in some human studies 
is better interpreted as due to chance or confounding.”
Finally, the conclusions of the present review, those by 
Rhomberg et al. (2011) and now NAS (2011) are remark-
ably congruent despite somewhat different approaches 
and  goals.    A  central  theme  of  these  reviews  revolves 
around  how  best  to  assess  and  weigh  a  substantial 
amount of evidence in order to reach valid conclusions.   
The final summary from the NRC committee addresses 
these  overarching  issues  “…when  the  review  of  stud-
ies used in the draft IRIS assessment of formaldehyde is 
compared with the current standard for evidence-based 
reviews  and  causal  inference,  limitations  in  each  step 
used to generate the draft IRIS assessment are evident. For 
example, the methods are not clearly described, the review 
approaches are not transparent, and there is no indication 
that evidence-grading strategies were uniformly applied. 
In addition, the selection approach to identifying studies 
for RfC calculation appears ad hoc.”
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Observed Expectedb Observed Expected
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b: When only observed mortality was reported, the expected 
mortality was calculated by dividing the observed mortality by 
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